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We must not forget that when radium was discovered no one knew that it would prove useful in 
hospitals. The work was one of pure science. And this is a proof that scientific work must not be 
considered from the point of view of the direct usefulness of it. It must be done for itself, for the 
beauty of science, and then there is always the chance that a scientific discovery may become 
like the radium a benefit for humanity. 
– Marie Curie 
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Figure 4.14. 1H-1H ROESY spectrum (selected region) of the [Pt(N(SO2Me)1,1′-Me2dma)(9-
MeG)Cl]+ adduct (25 °C, DMSO-d6, shifts in ppm)……………………………………………138 
Figure 4.15. Selected region of the 1H NMR spectra (bottom, 25 °C, DMSO-d6, shifts in ppm) of 
the reaction mixture forming the [Pt(N(SO2Me)1,1′-Me2dma)(Guo)Cl]
+ adduct recorded 10 min, 
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The overall goal of this dissertation research is to design, synthesize, and study new Pt(II) 
and Re(I) complexes relevant to biomedical applications. One of the projects involves the 
assessment of the interactions of bulky tridentate carrier ligands with a bound guanine nucleobase 
derivative (G) in platinum complexes, with a goal of developing chemistry potentially relevant to 
active anti-cancer Pt drugs. In another project, the fac-[ReI(CO)3]
+ core is used to prepare novel 
Re(I) complexes with the purpose of developing new linking chemistry relevant to 99mTc and 187Re 
radiopharmaceuticals. This research explores the use of three different types of linear carrier-
ligands in approaches directed toward achieving the stated goals.   
The first type of linear tridentate carrier ligand employed (N(R)1,1′-Me2dma, when R = H, 
bis(1-methyl-2-methylimidazolyl)amine) is terminated by imidazolyl rings and has a central N-
donor with an NH or an N−C bond. High in-plane steric bulk in monofunctional Pt(II) complexes 
is a feature associated with increased anti-cancer activity. Therefore, understanding carrier-ligand 
steric effects is crucial in designing new platinum drugs. For that purpose, the new N(R)1,1′-
Me2dma ligands were utilized to synthesize [Pt(II)(N(R)1,1′-Me2dma)Cl]Cl complexes. The 
chemical behavior of adducts of simple purine derivatives (G) made with these monofunctional 
Pt(II) complexes was studied. The ligands and complexes were characterized using NMR 
spectroscopy, single-crystal X-ray crystallography and ESI mass spectrometry. Solution NMR 
spectroscopy was used as the primary tool to study the Pt(II)(N(R)1,1′-Me2dma)G adducts. During 
this work, the 3′-GMP mono adduct of [Pt(N(H)1,1′-Me2dma)Cl]Cl complex was crystallized, 




The other two types of linear tridentate ligands have the central N donor in a sulfonamide 
linkage. New ligands terminated with either two pyridyl rings (second type, N(SO2R)3,3′,5,5′-
Me4dpa and N(SO2R)6,6′-Me2dpa, derivatives of 2-dipicolylamine) or with two imidazolyl rings 
(third type, N(SO2R)1,1′-Me2dma) were prepared. Pt(II) and Re(I) complexes of these new ligands 
were synthesized and their chemical properties studied. 
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CHAPTER 1. INTRODUCTION 
Transition metal complexes play an important role in modern medicine.1-2 Anticancer 
activity in Pt(II) complexes,3 radio-diagnostic properties of 99mTc complexes,4 radio-therapeutic 
properties of 187Re complexes,4 anti-metastatic activity of Ru(III) complexes1 and antiarthritic 
properties of Au(I) complexes1 are some common examples illustrating the involvement of metal 
compounds in therapeutic and diagnostic pharmaceuticals. In metal-mediated pharmaceuticals, the 
metal atom is often chelated by a carrier ligand. In addition to coordinating to the metal atom, a 
carrier-ligand can introduce new properties to the pharmaceutical agent. As an example, by linking 
a targeting moiety onto the carrier ligand, a drug molecule can be delivered to a specific destination 
in the body such as a tumor (Figure 1.1).  
 
Figure 1.1. Schematic representation of a target-specific metal-mediated therapeutic or diagnostic 
drug molecule. 
Therefore, developing new linking strategies relevant to the chelating ligands is crucial in 
designing new metal-mediated pharmaceuticals with specific chemical properties. Furthermore, 
steric factors of the carrier ligands can be directly associated with the structure-activity relationship 
of certain drug molecules. In such cases, understanding carrier ligand steric effects is important in 
designing new drugs; one such example is the anticancer activity in platinum(II) complexes.5-7 
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1.1 Carrier-Ligand Bulk and Anticancer Activity in Platinum(II) Complexes 
Platinum complexes exclusively bind at the N7 atom in purine bases (preferably guanine) 
of DNA. There are two major types of platinum−DNA adducts: intrastrand cross-links and 
monofunctional adducts (Figure 1.2).8-10 Predominantly, the 1,2 intrastrand G*G* cross-link lesion 
is considered as the active lesion responsible for the anticancer activity of cisplatin.11-17 G* 
represents G residues in DNA or oligomers with a Pt(II) bound to N7. 
 
Figure 1.2. Chart showing common Pt−DNA binding modes and the distorted G*G* and Lippard’s 
base pair steps in intrastrand cross-link lesions. 
 
Studies of an HMG-bound 16-mer duplex studied by X-ray methods18 and a 9-mer duplex 
studied by NMR methods in solution19 reveal that the DNA distortion induced by cisplatin (G*G* 
cross-link lesion) extends over two base pair (bp) steps (Figure 1.2), the cross-link bp step 
(between the 5′-G*·C bp and the 3′-G*·C bp) and the adjacent bp step (also referred to as the 
Lippard bp step,20 between the 5′-G*·C bp and the next bp in the 5′-direction along the duplex). 
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Both bp steps are highly distorted. Both solid-state and solution studies have revealed that the 
Lippard bp step has a large shift and a large slide.18-19,21 Therefore, the Lippard bp step could 
possibly play a more important role in anticancer activity than the G*G* cross-link bp step.19-22 
1.2 Monofunctional Platinum Complexes and Pt(Ltri)G Adducts  
Monofunctional platinum complexes were considered as inactive in early days.23-24 
Because the monofunctional agents studied previously contained small carrier ligands (such as 
[Pt(diethylenetriamine)Cl]Cl and [Pt(NH3)3Cl]Cl),
18,25-27 the small distortion to the DNA structure 
created by these compounds is insufficient to inhibit cancer cell growth. Later, certain 
monofunctional platinum complexes containing bulky carrier ligands were found to be anticancer 
active (pyriplatin and phenanthriplatin);28 this finding increased interest in developing 
monofunctional platinum anticancer agents. A distortion very similar to that found in the Lippard 
bp step of DNA having the cisplatin lesion was later also observed in an X-ray structure of an 
oligomer adduct of the bulky monofunctional platinum anticancer agent, cis-
[Pt(NH3)2(pyridine)Cl]
+ (pyriplatin).29-30 This finding indicates that the monofunctional platinum 
agents can be anticancer active, if enough bulk is present at one cis position to induce distortion in 
the adjacent bp step in DNA. Therefore, studying carrier-ligand steric effects is key in designing 
such new monofunctional platinum drugs and in understanding their mechanism of action. 
Studying DNA duplexes bearing Pt drug lesions can be very complicated. Work from this 
laboratory19 showed many mistakes were made in such studies and the nature of the distortion 
reported in several papers was not correct. Historically, simple models (adducts with small 
oligomers, or with single stranded DNA, etc.) are often employed to execute preliminary studies 
of new platinum complexes.18-19,31-34 Adducts of platinum complexes with unlinked 
guanine/hypoxanthine derivatives (G) are the simplest models;31,35-36 hence, they provide an 
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accurate starting point to study the chemical and physical properties of new platinum agents. Also, 
such simple models allow one to employ invaluable characterization techniques such as NMR 
spectroscopy or X-ray crystallography.5-7,16,37 In the studies presented here, we assess the 
interactions of G with newly designed platinum(II) complexes (bifunctional and monofunctional), 
specifically the influence of carrier-ligand bulk on the properties of the formed G adducts. 
The nucleobase (G) in Pt(Ltri)G type adducts (Ltri = a tridentate, one bidentate and one 
monodentate, or three monodentate ligands) orients roughly perpendicular to the coordination 
plane defined by Pt and the four ligating atoms N, N′, N′′, and Cl or N7(G). The nucleobase can 
rotate around the Pt−N7 single bond and acquire two possible orientations (Figure 1.3, arrow up 
and arrow down). When N, N′, and N′′ are symmetric with respect to the coordination plane and 
N equals N′′, both orientations lead to one rotamer, if R′ is not chiral. If N is not equal to N′′, the 
two orientations represent two rotamers. If N′ is not symmetric with respect to the coordination 
plane, two rotamers are possible regardless of whether or not N is equal to N′′. 
 
Figure 1.3. The two possible orientations of G in Pt(Ltri)G type adducts. Note that the nucleobase 
is represented by an arrow with the tip at the H8 of the purine. 
If the rotation of G around the Pt−N7 bond is too fast relative to the NMR time scale, only 
one set of signals for the two rotamers of the Pt(Ltri)G adduct can be observed. However, if the Ltri 
carrier ligand is bulky enough to impede the nucleobase rotation, two separate sets of signals for 
each rotamer can be observed. NMR spectroscopy can thus be used effectively to assess whether 
a Ltri ligand is bulky enough to interact with G (and interfere with its free rotation) in a Pt(Ltri)G 
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type adduct. Such information can provide insight into how that monofunctional platinum complex 
would influence the structure of Pt−DNA adducts on the cellular level. 
1.3 Rhenium Complexes as Models for Diagnostic and Therapeutic Radiopharmaceuticals 
Nuclear medicine is a powerful, non-invasive tool, which can be used for diagnostic and 
therapeutic medical processes for many diseases. Technetium-99m (99mTc) is one of the most 
widely used radio-imaging agents.4,38-39 The radioactive isotope of rhenium, 187Re, has also 
received much attention owing to its useful therapeutic properties.4,38-39 Rhenium and technetium 
are members of the same group in the periodic table and share similar chemical and physical 
properties. Therefore, non-radioactive Re(I) complexes (185Re) are commonly used as models in 
developing new radiopharmaceuticals of 99mTc and 187Re.38-39 In such developments, fac-
[MI(CO)3]
+ core plays a major role because of its many ideal properties relevant to medicinal 
applications (such as high in vivo robustness, stable association of the low oxidation numbered 
metal atom, water-soluble precursor complex, fac-[MI(CO)3(H2O)3]
+, etc.).4,40 Many carrier-ligand 
systems coordinated to the fac-[MI(CO)3]
+ core have been studied.4,38-39,41 However, developing 
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CHAPTER 2. A VERY RARE EXAMPLE OF A STRUCTURALLY CHARACTERIZED 
3'-GMP METAL COMPLEX. NMR AND SYNTHESTIC ASSESSMENT OF ADDUCTS 
FORMED BY GUANINE DERIVATIVES WITH [Pt(Ltri)Cl]Cl COMPLEXES WITH AN 
N,N',N" TRIDENTATE LIGAND (Ltri) TERMINATED BY IMIDAZOLE RINGS* 
 
2.1 Introduction 
High carrier-ligand bulk leads to decreases in anticancer activity and increases in toxicity 
of bifunctional platinum(II) anticancer agents,42-46 whereas for monofunctional platinum(II) agents 
we believe5-6,12,47 that high carrier-ligand bulk correlates with increased anticancer 
activity.12,25,29,48-50 Bifunctional agents, such as cisplatin, form G*G* intrastrand cross-link lesions 
and cause large distortions in DNA structure, manifest in large changes in CD51 and NMR26-27 
spectra. (G residues in DNA or oligomers with a Pt(II) center bound to N7 are designated as G*). 
In contrast, small monofunctional platinum agents, such as [Pt(dien)Cl]Cl (dien = 
diethylenetriamine) and [Pt(NH3)3Cl]Cl, cause minimal changes in the DNA CD
14,18 and NMR26-
27 spectra, indicating that monofunctional agents with small carrier ligands are unable to distort 
the DNA structure greatly upon adduct formation.5 Studies of oligomer duplexes having one G*G* 
cross-link lesion (an HMG-bound 16-mer duplex studied by X-ray methods18 and a 9-mer duplex 
studied by NMR methods in solution19) reveal that the DNA distortion induced by bifunctional 
Pt(II) agents extends over two base pair (bp) steps. The cross-link bp step (between the 5′-G*•C 
bp and the 3′-G*•C bp) and the adjacent bp step (between the 5′-G*•C bp and the next bp in the 





*Reproduced with permission from American Chemical Society: Ranasinghe, Kokila.; Marzilli, 
Patricia A.; Pakhomova, Svetlana.; Marzilli, Luigi G. “A Very Rare Example of a Structurally 
Characterized 3'-GMP Metal Complex. NMR and Synthetic Assessment of Adducts Formed by 
Guanine Derivatives with [Pt(Ltri)Cl]Cl Complexes with an N,N',N" Tridentate Ligand (Ltri) 
Terminated by Imidazole Rings.” Inorg. Chem. (2017), 56(14), 8462-8477. Copyright 2017 
American Chemical Society. 




Both solid-state and solution structural studies have revealed that the adjacent bp step has 
a large shift and a large slide.18-19,21 Therefore, we considered the possibility that this highly 
distorted bp step could play an important role in anticancer activity.19-20A very similar distortion 
as found in this adjacent bp step was later observed in an X-ray structure of an oligomer adduct of 
a bulky monofunctional platinum anticancer agent.29-30 Such findings indicate that a 
monofunctional agent with bulky carrier ligands could manifest anticancer activity by forming 
DNA adducts with a highly distorted bp step similar to that found in DNA adducts formed by non 
bulky bifunctional agents such as cisplatin. Understanding carrier-ligand steric effects is thus key 
in designing new platinum drugs. Adducts formed between the Pt agents and G ligands (bold G = 
monodentate N9-substituted guanine or hypoxanthine derivative, Figure 2.1) have been studied by 
NMR methods in order to assess carrier-ligand bulk.22,47,52  
 
Figure 2.1. Top: Numbering scheme for [Pt(N(R)1,1′-Me2dma)Cl]
+ complexes containing carrier 
ligands based on di-(2-methylimidazolyl)amine, N(H)dma (R = H, Z = H). To our knowledge, no 
complexes of N(H)dma with Pt are known. Bottom: Numbering scheme for the guanine nucleobase 
and for 3′-GMP and 5′-GMP. Ino and 5′-IMP contain hypoxanthine, having a hydrogen instead of 
the amino group at position 2 of the purine ring. The atom-numbering schemes depicted here are 
employed in the NMR discussion. 
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In order to gain a fundamental understanding of the steric effects within monofunctional 
Pt(II) G adducts, this laboratory has used NMR techniques to assess the properties of Pt(Ltri)G 
adducts (Ltri = an N,N',N" tridentate carrier ligand) formed by monofunctional platinum agents 
with Ltri ligands based on di-(2-picolyl)amine [N(H)dpa] or dien.5-7,53-54 The present study focuses 
on the preparation of water-soluble [Pt(II)(Ltri)Cl]Y complexes of tridentate imidazolyl ligands 
and on identifying the adducts that these complexes form in solution with various purine 
derivatives. We utilize both di-(1-methyl-2-methylimidazolyl)amine [N(H)1,1′-Me2dma (1)] and 
a ligand new to the literature, N-(methyl)-di-(1-methyl-2-methylimidazolyl)amine [N(Me)1,1′-
Me2dma (2)]; we designate these ligands as N(R)1,1′-Me2dma (Figure 2.1, R = H, Me). The 
tridentate ligand, N(H)1,1′-Me2dma, and its derivatives (with a substituent on the central N; e.g., 
‒CH2CH2OH) have been used to synthesize complexes of various metals (e.g., Re, Cu, Tc, Fe) 
usually intended for biomedical applications.55-62 
We describe the synthesis of [Pt(N(H)1,1′-Me2dma)Cl]Y (3) and [Pt(N(Me)1,1′-
Me2dma)Cl]Y (4) [Y = Cl
- (3a and 4a) and BF4
-
 (3b and 4b)] and the structural characterization 
of their cations by 1H NMR spectroscopy and single-crystal X-ray diffraction. We then use 1H 
NMR spectroscopy to examine Pt(N(R)1,1′-Me2dma)G adducts formed from [Pt(N(R)1,1′-
Me2dma)Cl]Cl complexes and compare the results to those of other Pt(L
tri)G adducts. In the 
present study, the crystallization of one product, [Pt(N(H)1,1′-Me2dma)(3′-GMPH)]NO3•5H2O 
(5), allowed characterization by single-crystal X-ray diffraction. 
Structures of metal 3'-GMP complexes are particularly rare. Only two molecular structures 
of complexes with 3'-GMP are described in the literature, and both are Cu(II) complexes. One, 
[Cu(3'-GMP)(phen)(H2O)]2•7H2O,
63 lacks M─N7 bonding, and the other, ([Cu3(3'-GMP)2(3'-
GMPH)2(H2O)5]•7H2O)n,
64 is a polymeric compound exhibiting nucleotide metal coordination 
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through both the N7 atoms and the phosphate groups. Thus, to our knowledge 5 is the first 
crystallographically characterized complex with any metal in which 3′-GMP is bound through only 







67 and  
cis-[Pt(NH3)2(N
2,N2-dimethyl-9-methylguanine)Cl]PF6.
68 In contrast, there are many reported 
structures of complexes with two cis Pt─N7 bonds to G ligands, quite often 5′-GMP.35,44,69-78 
In studies of Pt(N(H)dpa)G adducts, no quality crystals for single-crystal X-ray structures 
could be obtained to support the conclusions reached by using NMR methods.5-7,53 The structure 
of [Pt(N(H)1,1′-Me2dma)(3′-GMPH)]NO3•5H2O (5) gives us deeper insights into previous 
findings on Pt(N(H)dpa)G adducts, in addition to confirming and supporting our previous analysis 
of solution results for Pt(N(H)dpa)G adducts. 
2.2 Experimental Section     
Starting Materials. Sodium salts of G nucleotides [5'-guanosine monophosphate (5'-
GMP), 5'-guanosine diphosphate (5′-GDP), 5'-guanosine triphosphate (5'-GTP), 5'-inosine 
monophosphate (5'-IMP), and 3'-guanosine monophosphate (3'-GMP)], neutral purine derivatives 
[inosine (Ino), 1-methylguanosine (1-MeGuo), and 9-ethylguanine (9-EtG)], K2[PtCl4], 1-methyl-




methylimidazole hydrochloride80 were prepared by known methods. Because the protonation state 
and hence the charge of the Pt(N(R)1,1′-Me2dma)G adducts in which G = a nucleotide are not well 
defined, we omit charges for the adducts. However, charges are specified for structurally 
characterized isolated complexes. 
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NMR Measurements. NMR spectra were recorded on an Avance-III Prodigy 500 MHz 
Bruker spectrometer. Peak positions are relative to TMSP-d4 in D2O or to solvent residual peak 
with TMS as reference. A presaturation pulse to suppress the water peak was employed when 
necessary. All NMR data were processed with TopSpin and MestReNova 10.0.0 software. The pH 
values of D2O or 65:35 D2O:DMSO-d6 solutions examined by NMR spectroscopy are stated as 
measured and not corrected for D2O. The pH (uncorrected) of all solutions, including reaction 
mixtures, was adjusted when necessary with DNO3 or NaOD (0.5 M) D2O solutions. 
Mass Spectrometric Measurements. High resolution mass spectra were recorded on an 
Agilent 6210 ESI TOF LCMS mass spectrometer. 
X-ray Data Collection and Structure Determination. Diffraction data were collected on 
a Bruker Kappa Apex-II DUO CCD diffractometer with Mo K radiation (λ = 0.71073 Å), 
equipped with an Oxford Cryosystems Cryostream. All X-ray structures were determined by direct 
methods and difference Fourier techniques and refined by full-matrix least-squares by using 
SHELXL201481 with H atoms in idealized positions.  
N-(methyl)-di-(1-methyl-2-methylimidazolyl)amine [N(Me)1,1′-Me2dma, 2]. A 
solution of 2-(chloromethyl)-1-methylimidazole hydrochloride (1.00 g, 6 mmol), K2CO3 (1.7 g, 12 
mmol), and MeNH3Cl (0.16 g, 2.4 mmol) in acetonitrile (100 mL) was heated at reflux under 
nitrogen for 18 h. After the mixture was allowed to cool to room temperature and filtered, the 
solvent was removed under reduced pressure. The resulting pale yellow residue was dissolved in 
eluent A [acetone:5.0 M NH4OH (80:20)] and purified by chromatography on a silica column with 
eluent A. The fractions collected were spotted and analyzed on TLC plates by using eluent A. The 
cleanest fractions, as assessed by 1H NMR spectroscopy, were combined and taken to dryness by 
rotary evaporation to afford a colorless oil (0.21 g, 40% yield). 1H NMR signals (ppm) in D2O (pH 
13 
 
8.3): 7.09 (s, 2H, H5/5'), 6.96 (s, 2H, H4/4'), 3.68 (s, 4H, CH2), 3.56 (s, 6H, CH3), 2.25 (s, 3H, 
CH3). 1H NMR signals (ppm) in DMSO-d6: 7.07 (s, 2H, H5/5'), 6.76 (s, 2H, H4/4'), 3.52 (s, 4H, 
CH2), 3.48 (s, 6H, CH3), 2.06 (s, 3H, CH3). ESI-MS (m/z): [M + H]
+  calcd for C11H17N5, 220.1557; 
found, 220.1558. 
[Pt(N(H)1,1′-Me2dma)Cl]Y (3a and 3b). A solution of N(H)1,1′-Me2dma (21 mg, 0.1 
mmol) in methanol (1 mL) was added to a methanol solution of cis-Pt(DMSO)2Cl2 (42 mg, 0.1 
mmol, in 5 mL) and the mixture was heated at 50 °C overnight. The pale yellow [Pt(N(H)1,1′-
Me2dma)Cl]Cl (3a) solid (24 mg, 55% yield) formed was collected by filtration, washed with cold 
methanol, then with ether, and air dried. 1H NMR signals (ppm) in D2O (pH 4): 7.03 (d, J = 1.5 
Hz, 2H), 6.85 (d, J = 1.6 Hz, 2H, H4/4'), 4.63 (d, J = 15.4 Hz, 2H, CH2), 3.67 (s, 6H, CH3); one of 
the methylene signals is masked by the solvent peak. 1H NMR signals (ppm) in DMSO-d6: 8.31 
(bs, 1H, NH), 7.38 (s, 2H, H5/5'), 6.93 (s, 2H, H4/4'), 4.56 (d, J = 15.3 Hz, 2H, CH2), 4.53 (d, J = 
15.0 Hz, 2H, CH2), 3.73 (s, 6H, CH3).
  ESI-MS (m/z): [M + H]+  calcd for C10H15ClN5Pt, 436.0737; 
found, 436.0639. An aqueous solution of [Pt(N(H)1,1′-Me2dma)Cl]Cl (3a) (80 mg, 2 mL) was 
treated with an excess of NaBF4 (30 mg) to yield a yellow solid. A solution of this solid in acetone 
(50 mg, 2 mL) was allowed to stand at room temperature, and slow evaporation produced pale 
yellow, X-ray quality crystals of [Pt(N(H)1,1′-Me2dma)Cl]BF4 (3b) formed after 4 d. 
1H NMR 
signals (ppm) in DMSO-d6: 8.12 (bs, 1H, NH), 7.38 (2H, H5/5'), 6.93 (2H, H4/4'), 4.55 (d, J = 
15.3 Hz, 2H, CH2), 4.53 (d, J = 15.3 Hz, 2H, CH2), 3.73 (s, 6H, CH3).
    
[Pt(N(Me)1,1′-Me2dma)Cl]Y (4a and 4b). A solution of N(Me)1,1′-Me2dma (22 mg, 0.1 
mmol) in methanol (1 mL) was added to a methanol solution of cis-Pt(DMSO)2Cl2 (42 mg, 0.1 
mmol, in 5 mL), and the mixture was heated at 50 °C overnight. The pale yellow solid (29 mg, 
61% yield) that formed was collected by filtration, washed with cold methanol, then with ether, 
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and air dried. X-ray quality crystals of [Pt(N(Me)1,1′-Me2dma)Cl]Cl (4a) were obtained by mixing 
equal volumes (1 mL) of acetonitrile solutions of cis-Pt(DMSO)2Cl2 (10 mg, 12.5 mM) and the 
ligand (5 mg, 12.5 mM) and allowing the resulting solution to stand at room temperature. Pale 
yellow, needle-like crystals that separated overnight were characterized by single-crystal X-ray 
crystallography. 1H NMR signals (ppm) in D2O (pH 4, uncorrected for D2O): 7.15 (d, J = 1.5 Hz, 
2H, H5/5'), 7.01 (d, J = 1.6 Hz, 2H, H4/4'), 4.97 (d, J = 15.4 Hz, 2H, CH2), 4.64 (d, J = 15.4 Hz, 
2H, CH2), 3.73 (s, 6H, CH3), 3.12 (s, 3H, CH3).
  1H NMR signals (ppm) in DMSO-d6: 7.43 (d, J = 
1.6 Hz, 2H, H5/5'), 6.97 (d, J = 1.6 Hz, 2H, H4/4'), 4.87 (d, J = 15.1 Hz, 2H, CH2), 4.72 (d, J = 
15.4 Hz, 2H, CH2), 3.77 (s, 6H, CH3), 2.99 (s, 3H, CH3).
 An aqueous solution of 4a (87 mg, 2 mL) 
was treated with an excess of NaBF4 (30 mg) to yield a yellow solid. When a solution of this solid 
in acetone (50 mg, 2 mL) was allowed to stand at room temperature, slow evaporation afforded X-
ray quality, pale yellow crystals of [Pt(N(Me)1,1′-Me2dma)Cl]BF4 (4b) after 2 d. 
1H NMR signals 
(ppm) in DMSO-d6: 7.43 (d, J = 1.7 Hz, 2H, H5/5'), 6.96 (d, J = 1.7 Hz, 2H, H4/4'), 4.86 (d, J = 
15.3 Hz, 2H, CH2), 4.71 (d, J = 15.3 Hz, 2H, CH2), 3.77 (s, 6H, CH3), 2.99 (s, 3H, CH3).
  
G Adduct Formation with [Pt(N(R)1,1′-Me2dma)Cl]Cl. A 10 mM solution of 
[Pt(N(R)1,1′-Me2dma)Cl]Cl (R = H or Me) in D2O at pH 4 (uncorrected) was treated with 2.5 
molar equiv of G (G = 5'-GMP, 5'-GTP, 3'-GMP, 5'-IMP and Ino for R =  H or Me, and with G = 
5'-GDP, 1-MeGuo and 9-EtG for R = H). The solution was maintained at 25 °C and at pH 4 and 
monitored by 1H NMR spectroscopy until the [Pt(N(R)1,1′-Me2dma)Cl]Cl signals completely 
disappeared. The signals of the reactants are shifted by stacking interactions between free G and 
the [Pt(N(R)1,1′-Me2dma)Cl]
+ cation. As the adduct formed (decreasing the concentrations of the 
reactants), the resulting decrease in the extent of stacking interactions between the reactants caused 
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the slight shift changes. Similar results were found in studies of Pt(N(H)dpa)G adducts, and a more 
complete explanation can be found in the published report.5 
In order to compare properties for the [Pt(N(H)1,1′-Me2dma)Cl]
+ cation and Pt(N(H)1,1′-
Me2dma)G adducts with those reported in a D2O:DMSO-d6 (65:35) solvent mixture for the 
[Pt(N(H)dpa))Cl]+ cation and Pt(N(H)dpa)G  adducts,5 the formation of selected Pt(N(H)1,1′-
Me2dma)G adducts (G = 5'-GMP and 5'-GTP) from [Pt(N(H)1,1′-Me2dma)Cl]
+ was studied in this 
solvent mixture at pH 4 (uncorrected) (Supporting Information, Table A.2).  
Crystallization of [Pt(N(H)1,1′-Me2dma)(3′-GMPH)]NO3•5H2O (5). In order to obtain 
X-ray quality crystals of the Pt(N(H)1,1′-Me2dma)(3'-GMP) adduct, 12.2 mg of 3'-GMP (2.5 
molar equiv) was added to a 20 mM solution (5.2 mg/600 µL) of [Pt(N(H)1,1′-Me2dma)Cl]Cl in 
D2O, and the pH was adjusted to 4. The solution was allowed to stand at room temperature. Pale 
yellow, needle-like crystals were collected after two weeks. 
2.3 Results and Discussion 
Synthesis of N(R)1,1′-Me2dma and [Pt(N(R)1,1′-Me2dma)Cl]Y (Y = Cl or BF4). 
N(H)1,1′-Me2dma (1) was synthesized by hydrogenation of the 1-methyl-2-
imidazolecarboxaldehyde oxime as reported in the literature.58 Several procedures are known57,59,82 
for coupling the appropriate amine derivative with two equiv of 1-methyl-2-
imidazolecarboxaldehyde in the presence of sodium triacetoxyborohydride in order to synthesize 
tridentate imidazolyl ligands having different substituents at the central nitrogen. However, the 
attempt to synthesize the N(Me)1,1′-Me2dma (2) ligand by this method was unsuccessful.  
Therefore, we employed a coupling method known to produce tridentate pyridyl derivatives, which 
involves coupling the appropriate amine with 2-(chloromethyl)pyridine.83 Correspondingly, the 
coupling of methylamine with two equiv of 2-(chloromethyl)-1-methylimidazole under basic 
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conditions produced N(Me)1,1′-Me2dma (2) in acceptable yield. Several platinum precursors, such 
as cis-Pt(DMSO)2Cl2, K2[PtCl4] and Pt(1,5-cyclooctadiene)Cl2, have been used in synthesizing 
platinum complexes of pyridyl or imidazolyl ligands.84-88 The procedures with the latter two 
precursors use water as the solvent. Because our complexes are highly soluble in water, we 
employed cis-Pt(DMSO)2Cl2 in methanol and obtained [Pt(N(R)1,1′-Me2dma)Cl]Cl (3a and 4a) in 
55−61% yields.   
Structural Results. Crystal data and details of the structural refinement for [Pt(N(H)1,1′-
Me2dma)Cl]BF4 (3b), [Pt(N(Me)1,1′-Me2dma)Cl]Cl•H2O (4a), [Pt(N(Me)1,1′-Me2dma)Cl]BF4 
(4b), and [Pt(N(H)1,1′-Me2dma)(3′-GMPH)]NO3•5H2O (5)  are summarized in Table 2.1. Selected 
bond lengths and angles are reported in Table 2.2, along with data for [Pt(N(H)dpa)Cl]Cl89 and 
[Pt(N(Me)dpa)Cl]Cl90 for comparison. The ORTEP plots for cations of [Pt(N(H)1,1′-
Me2dma)Cl]BF4 (3b), [Pt(N(Me)1,1′-Me2dma)Cl]BF4 (4b), and  [Pt(N(H)1,1′-Me2dma)(3′-
GMPH)]NO3•5H2O (5)  (Figure 2.2; the 4a structure is similar to 4b and not shown here) show the 
numbering system used to describe the solid-state data. Crystals of 3b contain two independent 
complexes in the asymmetric unit, only one (A) of which is shown in Figure 2.2 and used in the 
discussion. The N2 atom of the cation [Pt(N(H)1,1′-Me2dma)Cl]
+ is disordered over two almost 
equivalent positions with occupancies of 0.51:0.49 (1A:2A). Compound 4b is a non-merohedral 
twin. Compound 5 was losing solvent rapidly during crystal harvesting. The resulting crystal 
structure has a disordered nitrate anion and water molecules. Hydrogen atoms of water molecules 
and the phosphate moiety were not located in the difference Fourier map. In the discussions related 
to the 3′-GMPH group in complex 5, the standard numbering system for guanine derivatives 
(Figure 2.1) is employed to allow comparisons with known structures.  
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Table 2.1. Crystal Data and Structure Refinement for [Pt(N(H)1,1′-Me2dma)Cl]BF4 (3b), 
[Pt(N(Me)1,1′-Me2dma)Cl]Cl•H2O (4a),  [Pt(N(Me)1,1′-Me2dma)Cl]BF4 (4b),  and [Pt(N(H)1,1′-
Me2dma)(3′-GMPH)]NO3•5H2O (5) 
 









fw 522.62 503.30 536.65 913.66 
crystal system triclinic monoclinic monoclinic orthorhombic 
space group Pī P21/c C2/c  P212121 
a (Å) 7.4468(4) 10.7948(6) 22.684(3) 9.0409(6) 
b (Å) 12.5154(7) 11.5052(6) 12.5272(17) 16.7570(12) 
c (Å) 17.0151(11) 12.2870(7) 11.2101(15) 20.8873(15) 
α (deg) 110.894(2) 90 90 90 
 (deg) 92.093(3) 97.773(3) 95.074(6) 90 
γ (deg) 97.991(3) 90 90 90 
V (Å3) 1460.77(15) 1537.19(15) 3173.1(7) 3164.4(4) 
T (K) 106 90 90 90 
Z 4 4 8 4 
calc (mg/m3) 2.376 2.175 2.247 1.918 
abs coeff (mm-1) 9.83 9.48 9.06 4.58 
2max () 52.8 61.0 71.8 51.4 
R[F2 > 2σ(F2)]a 0.035 0.030 0.030 0.037 
Rwb 0.071 0.089 0.089 0.084 
res. dens. (e Å-3) 1.46, -0.90 4.90, -2.56 2.39, -1.60 1.68, -0.94 
data/parameters 5955/430 4689/190 7527/212 5877/457 
aR = (||F| - |Fc||)/|F|. 
bRw = [[w(F2 - Fc
2)2]/[w(F2)2]]1/2,  in which w = 1/[2(F2) + (dP)2 




Table 2.2. Selected Bond Distances (Å) and Angles (deg) for [Pt(N(H)1,1′-Me2dma)Cl]BF4 (3b), [Pt(N(Me)1,1′-Me2dma)Cl]Cl•H2O 
(4a), [Pt(N(Me)1,1′-Me2dma)Cl]BF4 (4b), [Pt(N(H)1,1′-Me2dma)(3′-GMPH)]NO3•5H2O (5), [Pt(N(H)dpa)Cl]Cl
a, and 
[Pt(N(Me)dpa)Cl]Clb 
 3b 4a 4b 5 [Pt(N(H)dpa)Cl]Cl [Pt(N(Me)dpa)Cl]Cl 
                                                                                             bond distances 
Pt–N1 1.992(6) 1.992(3) 1.978(4) 2.004(8) 2.008(6) 2.006(3) 
Pt–N2 2.035(13), 2.069(13) 2.042(3) 2.041(3) 2.031(9) 2.009(12) 2.017(3) 
Pt–N3 1.98(2) 1.998(3) 2.002(4) 1.995(9) 2.011(5) 2.007(3) 
Pt–Cl or N6 2.317(6) 2.3065(7) 2.2793(10) 2.007(8) 2.301(2) 2.3048(10) 
bond angles 
N1–Pt–N3 164.6(2) 164.27(14) 165.32(14) 164.5(4) 166.0(2) 166.0(2) 
N1–Pt–Cl or N6 97.08(18) 96.21(9) 96.85(11) 96.4(4) 97.2(2) 96.62(9) 
N2–Pt–Cl or N6 167.6(6), 169.9(5) 176.63(8) 176.53(9) 178.0(6) 168.7(6) 179.52(9) 
N3–Pt–Cl or N6 98.27(17) 98.63(9) 97.12(12) 98.7(4) 97.8(2) 96.82(9) 
N2–Pt–N1 83.1(4), 81.5(4) 82.67(12) 83.60(15) 81.6(3) 83.3(3) 83.35(12) 
N2–Pt–N3 81.8(4), 83.5(4) 82.80(11) 82.73(15) 83.3(3) 83.3(3) 83.4(2) 
Pt–N3–C6c 113.1(5) 111.9(2) 111.6(3) 110.6(7) 112.7(4)d 114.1(5)d 
Pt–N3–C8c 139.4(5) 141.0(3) 139.5(3) 140.9(8) 127.2(5)d 128.7(5)d 
C6–N3–C8c 107.1(6) 106.8(3) 108.8(4) 108.3(10) 120.1(6)d 117.0(6)d 
aData from ref.89 bData from ref.90 cThe angles for the other ring are similar to the values reported here. dFor [Pt(N(H)dpa)Cl]Cl and 
[Pt(N(Me)dpa)Cl]Cl the C6 and C8 numbering in the table represents the C2 and C6 atoms, respectively, in NMR discussions.
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[Pt(N(H)1,1′-Me2dma)Cl]BF4 (3b) and [Pt(N(Me)1,1′-Me2dma)Cl]Y  (4a, Y = Cl, and 
4b, Y = BF4). Cations of 3b, 4a and 4b have a pseudo square planar geometry. The four 
coordination sites are occupied by the N1, N2 and N3 atoms of the tridentate ligands and by a Cl 
atom (trans to N2).  The Pt─Cl and Pt─N bond distances and N1─Pt─N3 bite angles in 3b, 4a and 
4b are not significantly different from the values reported for their [Pt(N(H)dpa)Cl]+89 and 
[Pt(N(Me)dpa)Cl]+90 analogs (Table 2.2). In these complexes, all of the Pt─N bond distances lie 
within the ranges expected for Pt─N(sp2) bond distances (1.99─2.08 Å)7,84,91 or Pt─N(sp3) bond 
distances (2.01─2.12 Å).7,54,92-93  
 
Figure 2.2. ORTEP plots showing the cations of [Pt(N(H)1,1′-Me2dma)Cl]BF4 (3b, top left), 
[Pt(N(Me)1,1′-Me2dma)Cl]BF4 (4b, bottom left), and [Pt(N(H)1,1′-Me2dma)(3′-
GMPH)]NO3•5H2O  (5, right). Thermal ellipsoids are drawn with 50% probability. 
For the cations in 3b, 4a and 4b, the sp3 geometry of the central N atom places the two 
methylene groups on the side of the coordination plane opposite to the NH or N(Me) groups 
(Figure 2.3 and Figure A.1 in Supporting Information). As a result, the plane of the imidazolyl 
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rings (defined by the 3 C and 2 N atoms in the ring) is tilted with respect to the coordination plane 
(defined by Pt and the four ligating atoms N1, N3, N2 and Cl/(G)N7). The average tilt angles for 
rings in [Pt(N(H)1,1′-Me2dma)Cl]BF4 (3b), [Pt(N(H)dpa)Cl]Cl,
89 and [Pt(N(H)6,6′-
Me2dpa)Cl]Cl
7 structures are 7.1°, 5.4° and 5.2°, respectively. Addition of a methyl group on the 
central nitrogen appears to force the CH2 groups to be farther below the coordination plane 
(Figures A1 and A2 in Supporting Information); consequently, the average tilt angles 
approximately double to 12.4°, 12.9° and 12.3° in [Pt(N(Me)1,1′-Me2dma)Cl]Cl (4a), 
[Pt(N(Me)1,1′-Me2dma)Cl]BF4 (4b), and [Pt(N(Me)dpa)Cl]Cl,
90 respectively. The tilting of all the 
imidazolyl rings with respect to the coordination plane results in the H4/4' protons projecting 
toward the same side of the coordination plane as the NH or N(Me) groups (Figure 2.3). 
 
Figure 2.3. Orientation of the H4/4′ protons, methylene groups, and the imidazolyl rings in the 
[Pt(N(R)1,1′-Me2dma)Cl]BF4 cations [top: 3b (R = H), middle and bottom: 4b (R = Me)] viewed 
along the coordination plane. Also shown are designations of the endo-CH and the exo-CH 
protons. For clarity, the N-Me groups of the imidazolyl rings are hidden. 
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[Pt(N(H)1,1′-Me2dma)(3′-GMPH)]NO3•5H2O (5). The Pt─N1, Pt─N2, and Pt─N3 (Table 
2.2) bond distances of this pseudo square planar Pt(II) complex do not differ significantly from the 
values for 3b. Also, the N1─Pt─N3 bite angle of 5 (164.5(4)°) is comparable to the value for 
[Pt(N(H)1,1′-Me2dma)Cl]
+ in 3b (164.6(2)°, Table 2.2). Compared to the tilting observed for 3b 
(7.1°), the imidazolyl rings in 5 have a greater degree of tilting. One of the imidazolyl rings is 
tilted by 19.1° and the other ring by 10.0°. The Pt─N7(G) bond of 2.007(8) Å in 5 falls within the 
typical Pt─N7(G) bond distance ranges reported for mono adducts65-68 (1.99─2.07 Å) and for bis 
adducts35,44,69-78 (2.02─2.08 Å). The metric parameters and conformational features of the 3′-
GMPH ligand are normal and are described in the Supporting Information. 
The difference, Pt–N7–C5 bond angle minus the Pt–N7–C8 bond angle, in structures of 
Pt(II) complexes of G (G = any derivative of guanine) is defined as the 'rocking angle'.94 The 
typical range of the rocking angle, identified some years ago as being about -2° to +11°,94 indicates 
that the Pt–N7–C8 angle is normally smaller than the Pt–N7–C5 angle. Rocking angles in more 
recent structures also almost always fall in this range.67,69,71-72,74-76 Mono adducts tend to be at the 
lower end of this range. Small rocking angles usually are observed when the structure has no clear 
intramolecular interactions, as in [Pt(N(H)1,1′-Me2dma)(3′-GMPH)]
+ (5), which has a positive 
rocking angle of 1.4°. Rare examples of highly negative values for the rocking angle occur only 
when the carrier ligand has high bulk, such as for Pt(N,N,N′,N′-tetramethylethylenediamine)G2 
complexes, with values of -3.2° (G = 5′-GMP)70 and -6.8° (G = 9-MeG).44 
An analysis by Yao et al. of crystallographic data for cis-[PtL2G2] type structures available 
at the time demonstrated a linear correlation (R = 0.897) between the rocking angle and the Pt–O6 
non bonded distance.94 The linear correlation also accounts for the Pt–O6 distance in 5 (3.40 Å) 
22 
 
and in all relevant structures published after the report by Yao et al.94 and discussed here.67,69-72,74-
76  
Canting is another parameter used to compare structural features of Pt(II) complexes of 
coordinated purines. If the dihedral angle between the plane of a base and the coordination plane 
is close to 90°, the base is not canted. The smaller the dihedral angle, the greater the canting. This 
dihedral angle in 5 is 66.5°, indicating moderate canting. As previously reported,78,95 6-oxopurine 
Cu(II) complexes exhibit an interesting relationship between the dihedral angle and intramolecular 
hydrogen bonding interactions of the 6-oxo group with protons in cis-carrier ligands. If the proton 
can project out of the coordination plane, such as a proton on a ligating sp3 N cis to the purine, a 
hydrogen bond is then possible. When a hydrogen bond is present, the dihedral angle falls in a 
highly canted 40−60° range. In the absence of such an interaction, the angle is usually greater than 
65° and in the moderately canted range. Except for a few Pt(II) complexes exhibiting strong 
intramolecular base-base stacking between two adjacent cis purines,69,72-73,77 all published Pt(II) 6-
oxopurine complexes also seem to follow this relationship.44,65-68,70-71,74-76,78 Accordingly, the small 
canting value exhibited by 5 (characteristic of the absence of intramolecular hydrogen bond 
interactions) is consistent with the closest proton in the carrier ligand being a partially positive CH 
atom lying essentially in the coordination plane. 
NMR Spectroscopy. 1H NMR spectroscopy was used to characterize the N(Me)1,1′-
Me2dma ligand (in D2O and DMSO-d6), the [Pt(N(R)1,1′-Me2dma)Cl]
+ complexes (in D2O and 
DMSO-d6), and the Pt(N(R)1,1′-Me2dma)G adducts (in D2O) reported here. NMR signals were 
assigned by analyzing their chemical shifts, splitting pattern, integration, and data from 2D NMR 
experiments. Selected 1D 1H and 13C NMR data and assignments in D2O for [Pt(N(H)1,1′-
Me2dma)Cl]Cl, [Pt(N(Me)1,1′-Me2dma)Cl]Cl, and their G adducts are collected in Tables 2.3, 2.4 
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and 2.5. The atom-numbering scheme in Figure 2.1 is employed in the NMR discussion. 1H NMR 
results in D2O/DMSO-d6 (65:35) for Pt(N(H)1,1′-Me2dma)G adducts (G = 5′-GMP and 5′-GTP) 
appear in the Supporting Information. 
Table 2.3. 1H NMR Data (ppm) for the N(R)1,1′-Me2dma Carrier Ligands in Pt(N(R)1,1′-
Me2dma)G and in [Pt(N(R)1,1′-Me2dma)Cl]Cl (D2O, pH 4.0, 25 °C) 
 
R Cl or G t 
(days) 
a 
H4/4' H5/5' 1/1′-Me N-Me 
  syn anti  
H Clb  6.85 7.03 3.67 - 
H 5'-GMPc 6 6.53, 6.52 6.57, 6.55 7.07d 3.75 - 
H 5'-GTPc 6 6.52, 6.51 6.56, 6.54 7.07d 3.74 - 
H 3'-GMPc 10 6.56, 6.53 6.58, 6.57 7.09d 3.75 - 
H 5'-IMPc 6 6.50, 6.47 6.53, 6.52 7.08d 3.76 - 
H 5'-GDPc 4 6.52, 6.51 6.57, 6.55 7.07d 3.74 - 
H Inoc 10 6.51, 6.49 6.54, 6.52 7.09d 3.77 - 
H 1-MeGuoc 10 6.52, 6.51 6.55 7.09d 3.77 - 
H 9-EtGc 10 6.52 6.54 7.10d 3.77 - 
Me Cle  7.01 7.15 3.73 3.12 
Me 5'-GMPc 10 6.58, 6.57 6.65, 6.63 7.12d 3.79 3.18 
Me 5'-GTPc 10 6.58, 6.56 6.66, 6.65 7.13d 3.79 3.18 
Me 3'-GMPc 10 6.61, 6.58 6.66, 6.64 7.14d 3.80 3.20 
Me 5'-IMPc 10 6.54, 6.51 6.59, 6.58 7.12d 3.79 3.20 
Me Inoc 10 6.55, 6.53 6.59, 6.57 7.13d 3.79 3.22 
at = reaction completion time. bendo-H6/6′ signal is masked by the solvent peak and exo-H6/6′ 
signal is 4.63 ppm (15.4 Hz). cexo- and endo-H6/6′ signals are masked by the solvent peak. dsyn 
and anti signals are overlapped. eendo- and exo-H6/6′ are 4.97 and 4.64 ppm, respectively. 
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Table 2.4. Selected 1H NMR Data (ppm) for the G Ligand in Pt(N(R)1,1′-Me2dma)G Adducts 


















H 5'-GMP 8.10 8.69 9.00 5.91 6.05 6.10 0.31 1.07:1 
H 5'-GTP 8.19 8.74 9.05 5.92 6.05 6.09 0.31 1.01:1 
H 3'-GMP 8.01 8.65 8.95 5.93 6.05 6.09 0.30 1.18:1 
H 5'-IMPb 8.44 9.08 9.40 6.12 6.28 6.31 0.32 1.05:1 
H 5'-GDP 8.12 8.71 9.01 5.91 6.04 6.09 0.30 1.02:1 
H Inoc 8.34 9.04 9.35 6.09 6.23 6.27 0.31 1.22:1 
H 1-MeGuo 7.96 8.63 8.92 5.88 6.02 6.07 0.29 1.25:1 
H 9-EtGd 7.91 8.43 8.74 - - - 0.31 1.30:1 
Me 5'-GMP 8.11 8.66 8.98 5.91 6.05 6.09 0.32 1.60:1 
Me 5'-GTP 8.14 8.69 9.01 5.93 6.05 6.09 0.32 1.63:1 
Me 3'-GMP 8.01 8.61 8.97 5.94 6.04 6.10 0.36 1.57:1 
Me 5'-IMPe 8.44 9.04 9.36 6.14 6.27 6.31 0.32 1.65:1 
Me Inof 8.33 8.97 9.33 6.08 6.26 6.20 0.36 1.26:1 
aShift difference between the H8 signals of the syn and anti rotamers (cf. text). bH2: 8.21 (free), 
8.40 (syn), and 8.34 ppm (anti). cH2: 8.21 (free), 8.40 (syn), and 8.34 ppm (anti). dCH2: 4.08 (free), 
4.26 (syn), 4.21 ppm (anti); CH3: 1.41 (free), 1.48 (syn), 1.54 ppm (anti). 
eH2: 8.21 (free), 8.40 





Table 2.5. 1D 13C NMR Data (ppm) for [Pt(N(R)1,1′-Me2dma)Cl]Cl [3a (R = H) and 4a (R = 
Me)] and for Their 5'-GMP Adducts (D2O, pH 4.0, 25 °C) 
 
carbonsa 3a adduct 4a  adduct 
  syn anti   syn anti 
5'-GMP C8  139.96 140.03   139.96 140.04 
5'-GMP C1'  87.97   88.03 
  87.94   87.95 
C5/5' 122.32 122.48 122.36  122.78 
  122.40   122.70 
C4/4' 123.42 124.40 124.33  124.73 
  124.29   124.70 
  124.20   124.59 
      124.52 
C2/2' 153.92 153.80 152.87  152.46 
C6/6' 51.02 51.50 61.95  61.94 
  51.44   61.90 
  51.39   61.88 
C1/1' 34.58 34.62 34.72  34.74 
N(Me) - - 52.72  52.24 
aFree 5′-GMP: C8, 137.48 ppm; C1', 86.85 ppm. 
[Pt(N(R)1,1′-Me2dma)Cl]Cl Assignments. Complexes 3 (R = H) and 4 (R = Me) both 
have two downfield 1H NMR signals (Figure 2.4), as expected for the H4/4' and H5/5' aromatic 
protons. However, the small coupling constant of ∼1.5 Hz, combined with the effect of the nearby 
quadrupolar nitrogen atoms, causes the signals to appear as singlets in some spectra. In a ROESY 
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spectrum (Supporting Information) in D2O for [Pt(N(H)1,1′-Me2dma)Cl]Cl (3a), a strong NOE 
cross-peak from the 1/1′-Me signal at 3.67 ppm to the most downfield signal (7.03 ppm) allows 
the signal to be assigned to H5/5'. The other aromatic peak (6.85 ppm) can thus be assigned to 
H4/4', an assignment supported by the absence of any NOE cross-peak from the H4/4' signal to 
any other peak except to the H5/5' signal. 
 
Figure 2.4. 1H NMR spectra (25 °C, D2O, pH 4) of [Pt(N(H)1,1′-Me2dma)Cl]Cl (3a) (top) and 
[Pt(N(Me)1,1′-Me2dma)Cl]Cl (4a) (bottom) complexes (shifts in ppm). 
The two protons in each methylene group in the [Pt(N(R)1,1′-Me2dma)Cl]
+ cations are not 
magnetically equivalent; these are designated as endo-CH and exo-CH (Figure 2.3). The two 1H 
NMR methylene signals are doublets. Analysis of NOE cross-peaks led us to assign the upfield 
and downfield [Pt(N(R)1,1′-Me2dma)Cl]Cl doublets to the exo-CH and endo-CH signals, 
respectively. A similar relationship was found for [Pt(N(H)dpa)Cl]Cl.5 The 13C NMR shifts were 
determined from 1D NMR spectra (Table 2.5). The 13C NMR signals for the C4/4', C5/5', and 
C1/1' carbons of [Pt(N(H)1,1′-Me2dma)Cl]Cl (3a) were assigned  (Table 2.5) with the aid of cross-
peaks (in ppm) involving the H4/4' (6.85−123.4), H5/5' (7.03−122.3), and 1/1'-Me (3.67−34.6) 
signals, respectively, in an HSQC experiment (Supporting Information). Cross-peaks from the 
endo-CH and exo-CH signals assign the 13C NMR signal at 51.5 ppm to C6/6'. The only signal 
with no HSQC cross-peak (153.92 ppm) is assigned to C2/2'. As described in Supporting 
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Information, this approach for assigning the signals of 3a was also used to assign the 1H and 13C 
NMR signals (Tables 2.3 and 2.5) for [Pt(N(Me)1,1′-Me2dma)Cl]Cl (4a). 
Although the 3a and 4a structures are similar except for the different substituent on the 
central N atom, the methylene signals (in DMSO-d6) are separated by only 0.03 ppm for 3a (an AB 
pattern, endo-CH at 4.56 and exo-CH at 4.53 ppm), whereas the separation between the two 
doublets of 4a is 0.15 ppm (in DMSO-d6, endo-CH at 4.87 and exo-CH at 4.72 ppm). These 
separations of methylene signals in [Pt(N(R)1,1′-Me2dma)Cl]Cl are significantly less than the 
values reported for their [Pt(N(R)dpa)Cl]Cl analogs (in DMSO-d6, 0.32
5 and 0.6490 ppm for R = 
H and Me, respectively). However, the coupling constants for all four platinum complexes are ∼15 
Hz regardless of the carrier ligand or the substituent at the central N. 
The robustness of [Pt(N(H)1,1′-Me2dma)Cl]Cl (3a) in D2O (pH 7), in DMSO-d6, and in 
strongly acidic (0.2 M HCl) conditions was monitored by using 1H NMR spectroscopy. The spectra 
revealed no change even 10 days after addition of HCl (Supporting Information). 
Pt(N(R)1,1′-Me2dma)G Adducts. NMR Background for Determining Rotamer 
Conformation in Adducts. In simple Pt(Ltri)G adducts, the inductive effect of the Pt(II) center 
causes the H8, H2 (in hypoxanthine derivatives, cf. Figure 2.1), and ribose H1′ peaks of bound G 
to be shifted downfield compared to these signals for free G.96-97 Two G base orientations and 
hence two rotamers are possible for Pt(Ltri)G adducts having Ltri ligands that are unsymmetrical 
with respect to the coordination plane but symmetrical about a plane perpendicular to the 
coordination plane (Figure 2.5). By convention,96 the rotamer of Pt(Ltri)G adducts having the R 
group and the guanine O6 on the same side of the coordination plane is named syn, and the rotamer 
having these groups on opposite sides of this plane is named anti (Figure 2.5). The syn and anti 
rotamers interconvert by rotation about the Pt−N7 bond.19,43,97-99 Furthermore, neither rotamer has 
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a plane of symmetry in an adduct formed by G derivatives having a chiral ribose, such as 5'-GMP. 
Therefore, in each rotamer the corresponding protons in the two halves of the carrier ligand are 
not magnetically equivalent. When NMR evdience is found that Pt(Ltri)G rotamers exist, only two 
signals are found for each type of G proton but as many as four signals can be observed for each 
proton type of carrier-ligand proton. Such a situation in fact applies to the new Pt(N(R)1,1′-
Me2dma)G adducts studied here (Figure 2.6). 
 
Figure 2.5. The two possible purine orientations for Pt(Ltri)G adducts when the tridentate carrier 
ligand (Ltri) is unsymmetrical with respect to the coordination plane but symmetrical about a plane 
perpendicular to the coordination plane. Note that the nucleobase is represented by an arrow with 
the tip at the H8 of the purine. R can be any substituent such as H or Me. 
For separate sets of NMR signals of the syn and anti rotamers to be observed, the carrier 
ligand must be bulky enough to slow the rotation rate of the nucleobase on the NMR time scale.36-
37,96-102 For example, Pt(Me5dien)G adducts (Me5dien = N,N,N′,N′′,N′′′-
pentamethyldiethylenetriamine) exhibit two sharp H8 NMR signals, one for each rotamer, 
indicating that the presence of terminal dimethylamino groups provides enough bulk to hinder 
nucleobase rotation about the Pt–N7 bond.96 In contrast, because of the relatively low bulk of dien, 
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the H8 proton of the Pt(dien)G adducts shows only one sharp G H8 NMR peak, indicating fast 
rotation of the guanine base about the Pt―N7 bond.5 Recently, the N(H)dpa ligand was found to 
possess enough bulk to impede the rotation of the guanine nucleobase in Pt(N(H)dpa)G adducts.5-
6 Similarly, all new Pt(N(R)1,1′-Me2dma)G adducts examined in the present study have spectra 
with two sharp downfield H8 NMR signals (Figure 2.7 and Supporting Information), a finding 
consistent with hindered rotation of the purine base.  
 
Figure 2.6. Models of the two possible rotamers for Pt(Ltri)G complexes with tridentate ligands 
(Ltri) unsymmetrical with respect to the coordination plane but symmetrical about a plane 
perpendicular to the coordination plane, illustrated for Ltri = N(H)1,1′-Me2dma and G = 9-EtG. 
Rotation of the ethyl group around the N9–CH2 bond creates a time-averaged mirror plane, 
preserving the symmetry of the Pt(N(H)1,1′-Me2dma) moiety. However, if a chiral N-9 substituent 
is created by replacing one methylene proton (circled), then the two halves of the Pt(N(H)1,1′-
Me2dma) moiety become magnetically inequivalent.  
The main factor influencing the downfield shift of 1H NMR signals on complex formation 
is the Pt(II) inductive effect, and this effect is expected to fall off as the number of bonds between 
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the proton and the Pt(II) increases. However, the inductive effect is not expected to be different 
for the two rotamers.  Indeed, the shift difference (Δδ) between the H8 signals of the syn and anti 
rotamers is only ∼0.04 ppm for the Pt(Me5dien)(5'-GMP) adduct and Δδ = 0 for H2 in almost all 
closely related 5'-IMP adducts.96 In contrast, the aromatic rings terminating both ends of the 
tridentate ligand lead to large Δδ values for H8 of ∼0.36 ppm for the Pt(N(H)dpa)G adducts.5 The 
syn H8 signal is upfield to the anti H8 signal. These observations for Pt(N(H)dpa)G adducts were 
explained by invoking models with a relatively uncanted guanine nucleobase in both rotamers. In 
such a model, H8 is closer to the shielding region of tilted anisotropic pyridyl groups of the carrier 
ligand in the syn rotamer than in the anti rotamer, accounting for the syn rotamer having the more 
upfield H8 signal.5 As we discuss below, this explanation can be evaluated with the help of the 
structure of 5 because the H8 signals of Pt(N(R)1,1′-Me2dma)G adducts exhibit NMR features 
similar to those of Pt(N(H)dpa)G adducts.  
Pt(N(H)1,1′-Me2dma)(5'-GMP) Adduct. Spectra of the reaction mixture of [Pt(N(H)1,1′-
Me2dma)Cl]Cl (3a) and 2.5 molar equiv of 5'-GMP in D2O (pH 4) showed new 
1H NMR signals 
clearly detectable about 1 h after mixing. The signals for 3a disappeared in ∼6 days (Figure 2.7), 
indicating that the reaction was complete. Compared to the H8 signal for free 5'-GMP at 8.10 ppm, 
two sharp downfield H8 singlets characteristic of Pt(II)-bound 5'-GMP were observed. As 
discussed above, two H8 singlets (Figure 2.7) provide evidence for impeded rotation of the guanine 
nucleobase in two rotamers of the Pt(N(H)1,1′-Me2dma)(5'-GMP) adduct; for reasons given above, 
the H8 signals at 9.00 and 8.69 ppm are assigned to the anti and syn rotamers, respectively. 
Furthermore, strong EXSY cross-peaks between the syn and anti H8 signals in the ROESY 
spectrum of the Pt(N(H)1,1′-Me2dma)(5'-GMP) adduct (Figure 2.8) add further strong evidence 
that the two H8 signals arise from slow exchange between two rotamers. In contrast, ROESY 
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spectra of Pt(N(H)dpa)G adducts show no EXSY cross-peaks,5 indicating that the exchange 
between Pt(N(H)dpa)G rotamers occurs relatively more slowly than exchange between 
Pt(N(H)1,1′-Me2dma)G rotamers. 
 
Figure 2.7. Aromatic and H1' region of the 1H NMR spectra (25 °C, D2O, pH 4) of [Pt(N(H)1,1′-
Me2dma)Cl]
+(10 mM, bottom) and of the reaction mixture forming Pt(N(H)1,1′-Me2dma)(5'-
GMP) recorded 15 min, 14 h, 24 h, 76 h, and 147 h after adding 2.5 molar equiv of  5'-GMP (shifts 
in ppm). 
 
The two rotamers of the Pt(N(H)1,1′-Me2dma)(5'-GMP) adduct each have an H1' doublet 
shifted downfield similarly (∼0.2 ppm) by metal coordination. The NOE cross-peak between the 
downfield anti H8 signal and the downfield H1' doublet (6.10 ppm) in the ROESY spectrum 
(Figure 2.8) assigns this H1' doublet to the anti rotamer. The NOE cross-peak from the syn H8 
signal to the doublet at 6.05 ppm confirms its assignment as syn H1'. Because both the H1′ and H8 
protons are associated with the five-membered ring of the guanine base, the H1′ and H8 signals 
are shielded more by the tilted imidazolyl rings in the syn rotamer than in the anti rotamer. A 
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similar relationship was found to be caused by the tilted pyridyl rings in the Pt(N(H)dpa)G class 
of adducts.5 
 
Figure 2.8. 1H–1H ROESY spectrum of Pt(N(H)1,1′-Me2dma)(5′-GMP), showing syn H8-anti H8 
EXSY cross-peaks and H8–H4/4′ and H8–H1′ NOE cross-peaks (D2O, pH 4.0, 25 °C, shifts in 
ppm). 
 
The above rotamer assignments rely on shifts of the bound 5'-GMP signals as described 
previously.5 The NMR features of Pt(N(R)1,1′-Me2dma)G adducts and the molecular structure of 
5 allow the use of NOE cross-peaks between the bound G H8 and the carrier-ligand signals to 
remove any doubt about previous assignments. From its characteristic shift and the integration, the 
singlet at 3.75 ppm is unambiguously assigned to the 1/1'-Me signal of the Pt(N(H)1,1′-
Me2dma)(5'-GMP) adduct. The 1/1'-Me signal shows a strong cross-peak to an apparent singlet at 
7.07 ppm in the ROESY spectrum (Supporting Information), allowing the assignment of the 7.07 
ppm signal to H5/5'. This H5/5' singlet has a strong, broad cross-peak to four closely bunched 
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singlets near 6.57–6.52 ppm (Figure 2.8). The four singlets together integrate as having the same 
intensity as the H5/5' singlet, and thus all can be assigned to the H4/4' protons. These signals 
exhibit no cross-peaks with the 1/1'-Me signal, confirming the H4/4' assignment. As mentioned 
above, the two halves of the carrier ligand are not magnetically equivalent when the N9-substituent 
is chiral (Figure 2.6). 
In the ROESY spectra of both Pt(N(H)1,1′-Me2dma)(5'-GMP) (Figure 2.8) and 
Pt(N(Me)1,1′-Me2dma)(5'-GMP) (Supporting Information), the H8-H4/4' NOE cross-peaks are 
stronger for the anti rotamer than for the syn rotamer. To understand this difference in NOE cross-
peaks, we used the GaussView 5.0.8 software program to construct a model of the anti rotamer 
(Figure A.3 in Supporting Information) from the molecular structure of the syn rotamer in 
[Pt(N(H)1,1′-Me2dma)(3′-GMPH)]NO3•5H2O (5). The 3'-GMP ligand of the syn rotamer in 5 was 
rotated by 180° about the Pt−N7 bond and the C8―N7―Pt angle adjusted to that of the syn 
rotamer (126.78°). The G H8 proton and carrier-ligand H4/4' protons are farther apart in the syn 
rotamer structure (~3.5 Å) than in the model of the anti rotamer (~2.8 Å). Thus, the NOE intensities 
confirm the rotamer assignments using the reasoning in previous work5 based on the effects on H8 
shifts of the anisotropy of the tilted carrier-ligand aromatic rings. 
The anisotropic guanine in Pt(N(Me)dpa)G,53 Pt(N(H)dpa)G5 and Pt(5,5'-Me2bipy)G2
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(5,5'-Me2bipy = 5,5'-dimethyl-2,2'-bipyridine) adducts caused large upfield shifts (∼1.1 ppm) of 
the signals of the carrier-ligand protons closest (H6/6') to the coordinated G. Similarly, in the G 
adducts of 3a and 4a, the signals of the protons closest (H4/4') to the coordinated G are affected 
the most (upfield shifts of ∼0.3 to 0.4 ppm as compared to the H4/4' signal for 3a) by adduct 
formation. The non bonded distance from the chloride atom to the H4/4' protons in 3b is ~0.4 Å 
longer than the corresponding distance to the H6/6' protons in [Pt(N(H)dpa)Cl]Cl.89  Therefore, 
34 
 
the coordinated guanine must be closer to the H6/6' protons in Pt(N(H)dpa)G adducts as compared 
to the H4/4' protons in Pt(N(H)1,1′-Me2dma)G adducts (Figure 2.9). Hence, the guanine 
nucleobase will undoubtedly cause more upfield shifting of the H6/6' signals than the H4/4' 
signals, as observed.  
 
Figure 2.9. Overlap of stick drawings of [Pt(N(H)1,1′-Me2dma)Cl]
+ (purple) and [Pt(N(H)dpa)Cl]+ 
(gold) cations (by superimposing the Pt, N1, N2 and N3 atoms). By using GaussView 5.0.8 
software, 9-methylguanine (9-MeG) adduct models were constructed from the X-ray data by 
replacing the coordinated Cl atoms with a 9-MeG having a Pt―N7 distance of 2.007 Å (the 
distance in 5) in the plane bisecting the two halves of the cations. These two halves are almost but 
not exactly equivalent (Table 2.2). For simplicity, the illustration replaces the purine with a blue 
arrow. The syn orientation is shown. Cones qualitatively indicate that the H4/4' and H6/6' atoms 
lie within the shielding region of the purine base. The thin green arrows span the distances to the 
center of the purine six-membered ring from the H4 and the H6 atoms in one half of the carrier 
ligand. The average of distances (Å) of the H4/4' and H6/6' atoms to the center of the 9-MeG rings 
measured using Mercury 3.7 software follow: for the [Pt(N(H)1,1′-Me2dma)(9-MeG)]
2+ models 
(6-membered ring, syn 4.51 and anti 4.54; 5-membered ring, syn 3.63 and anti 3.63) and for the 
[Pt(N(H)dpa)(9-MeG)]2+ models (6-membered ring, syn 4.13 and anti 4.13; 5-membered ring, syn 
3.14 and  anti 3.14). Thus, for a given adduct and a given ring, the distances are virtually identical 




As described above, the chiral ribose in 5'-GMP makes the two halves of the carrier ligand 
of each Pt(N(H)1,1′-Me2dma)(5'-GMP) rotamer inequivalent. The effect of chirality is small. 
Likewise, the difference in orientation of the nucleobase leads to only small differences in shifts 
of carrier-ligand signals. As stated in Figure 2.9, the distances from H4/4' to the center of the 
guanine rings in the syn rotamer are almost all identical to the respective distances in the anti 
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rotamer. Thus, resolution of the four possible signals can be observed only for signals of nuclei 
close to the anisotropic nucleobase of the chiral G. The two rotamers of Pt(N(H)1,1′-Me2dma)(5'-
GMP) exhibit four closely spaced H4/4' signals. NOE cross-peaks (Figure 2.8) from the anti H8 
and syn H8 singlets to the two most downfield and the two most upfield H4/4' signals, respectively, 
assign the H4/4' signals (Table 2.3). The H5/5' protons in Pt(N(H)1,1′-Me2dma)(5'-GMP) are far 
from the coordinated 5'-GMP and exhibit an apparent singlet with a very small downfield shift 
change (0.04 ppm) compared to the H5/5' signal for 3a.  
The 13C NMR shifts were determined from 1D NMR spectra (Table 2.5). All of the carrier-
ligand carbons are farther from the anisotropic nucleobase than are the H4/4' protons; thus, there 
are usually fewer than the four possible detectable 13C NMR signals arising from the two chiral 
rotamers of the Pt(N(H)1,1′-Me2dma)(5'-GMP) adduct. For example, only three peaks are 
assignable to C4/4' in an HSQC experiment for Pt(N(H)1,1′-Me2dma)(5'-GMP) (Supporting 
Information) in which four clustered H4/4' signals exhibit one strong cross-peak to the 13C NMR 
peaks at 124.4, 124.3, and 124.2 ppm. Similarly, the H5/5' signal has a strong cross-peak to only 
two closely associated peaks at 122.5 and 122.4 ppm for C5/5'. In addition, the 1/1'-Me 1H NMR 
signal shows a cross-peak to the C1/1' signal at 34.6 ppm (Table 2.5).  
The HSQC spectrum of the Pt(N(H)1,1′-Me2dma)(5'-GMP) adduct (Supporting 
Information) is in turn useful in locating the methylene endo-CH signals, which fall close to the 
HOD solvent peak and are  suppressed by presaturation of the HOD signal. The two strong cross-
peaks observed involve the C6/6′ signal (at 51 ppm, a characteristic shift for such methylene 
carbons5,7,58) and the cluster of peaks at 4.60 ppm and the suppressed signals near 4.73 ppm 
(Supporting Information). We can confidently assign these 1H NMR clusters respectively to the 
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exo-CH and endo-CH protons because endo-CH signals are invariably downfield, as discussed 
above.  
Other Pt(N(H)1,1′-Me2dma)G Adducts. With the progression of the reaction between 
[Pt(N(H)1,1′-Me2dma)Cl]
+ and 3′-GMP (molar ratio = 1:2.5) in D2O at pH 4, the adduct separated 
as pale yellow crystals. The carrier-ligand signals in the Pt(N(H)1,1′-Me2dma)(3′-GMP) adduct 
have shifts similar to those observed for the 5′-GMP, 5′-GDP and 5′-GTP adducts (Table 2.3). 
These observations suggest that the location of the phosphate groups at the 3′ or 5′ position of the 
sugar groups does not appear to have a major effect on the properties of the adducts. 
For the Pt(N(H)1,1′-Me2dma)(5′-IMP) adduct, the H8 singlets are at 9.40 (anti) and 9.08 
ppm (syn), and the H2 signals are at 8.40 (syn) and 8.34 (anti) ppm (Figure 2.10, Table 2.4). The 
opposite order of shifts of the H2 and H8 signals in the anti vs the syn rotamer arises because the 
imidazolyl anisotropy affects mainly the six-membered ring signals in the anti rotamer and mainly 
the five-membered ring signals in the syn rotamer. A similar opposite directional influence on the 
H2 and H8 signals by a nearby anisotropic ring was found for other 5′-IMP adducts.5,100 Because 
the rotamer abundance for the Pt(N(H)1,1′-Me2dma)(5′-IMP) adduct is very close to 1:1 (Figure 
2.10), the relative intensities of the two H1' signals of the adduct were not useful for assigning the 
H1' signals. The Pt(N(Me)1,1′-Me2dma)(5′-IMP) adduct has a syn:anti intensity ratio of 1.65:1, 
and the relative intensities of the peaks show that the syn H1' signal is upfield and the anti H1' 
signal is downfield (Supporting Information); this is the expected shift relationship because H1' is 
on the five-membered ring. By analogy, the more upfield H1' signal for Pt(N(H)1,1′-Me2dma)(5′-
IMP) is assigned to the syn rotamer. For these two Pt(N(R)1,1′-Me2dma)(5′-IMP) adducts, the 
order of shifts of the H2 signal compared to the H8 and H1' signals is opposite in the anti vs the 
syn rotamer. The effect of ring anisotropy is largest on H8 shifts and smallest on H1' shifts. All 
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these shift relationships were found also for Pt(N(H)dpa)(5′-IMP) (in a solvent mixture),5 but the 
shift difference between rotamers for all three types of signals is greatest for Pt(N(H)dpa)(5′-IMP), 
consistent with our conclusion below that the anisotropy of the pyridyl ring is greater than that of 
the imidazolyl ring in these adducts.  
 
Figure 2.10. 1H NMR spectra (25 °C, D2O, pH 4) of the mixture of [Pt(N(H)1,1′-Me2dma)Cl]
+ and 
5′-IMP at 15 min after mixing (bottom) and of the Pt(N(H)1,1′-Me2dma)(5′-IMP) adduct 6 days 





2+ adducts were studied to assess the influence of the phosphate group on the 
formation and properties of the adducts. Complete formation of Pt(N(H)1,1′-Me2dma)G adducts 
by reaction of 3a with neutral nucleobases/nucleosides required ∼10 days, a longer time than for 
nucleotides (Table 2.3); the relatively shorter reaction times observed for the 3a cation with anionic 
nucleotides can be attributed to the electrostatic attraction between the reactants.  
The 1H NMR chemical shifts, Δδ values, and syn:anti ratios for these three [Pt(N(H)1,1′-
Me2dma)G]
2+ adducts are similar to those of the adducts with nucleotides (Tables 2.3 and 2.4 and 
Supporting Information), indicating that phosphate and ribose groups have at best a small influence 
on Δδ and on impeding nucleobase rotation. The absence of the chiral sugar group in the 
[Pt(N(H)1,1′-Me2dma)(9-EtG)]
2+ adduct results in only one H4/4' signal for each rotamer, giving 
a total of two H4/4' signals, not four as found with adducts in which G has a ribose group. 
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Furthermore, correlating the abundance of the two sets of CH2 and CH3 signals with that of the H8 
signals establishes that the anti rotamer has the more downfield signals for all of the protons 
associated with the five-membered guanine ring (Table 2.4).  
Comparison between Pt(N(H)dpa)G and Pt(N(H)1,1′-Me2dma)G Adducts. In order to 
compare the properties of the new adducts with those found previously for the Pt(N(H)dpa)G 
adducts,5 we conducted a few studies of Pt(N(H)1,1′-Me2dma)G adducts (G = 5'-GMP and 5'-
GTP) in the solvent mixture (65:35 D2O:DMSO-d6 at pH 4) used previously for the Pt(N(H)dpa)G 
adducts.5 The results for both classes of adducts, such as the syn:anti ratios, are comparable 
(Supporting Information). Also, the Δδ values (in 65:35 D2O:DMSO-d6) for G = 5'-GMP and 5'-
GTP are ~0.4 ppm for Pt(N(H)dpa)G adducts and are ~0.3 ppm for Pt(N(H)1,1′-Me2dma)G 
adducts. The non bonded distances between the bound Cl and the center of the aromatic rings 
found in the molecular structures are shorter to the imidazolyl rings (~4.2 Å) of the [Pt(N(R)1,1′-
Me2dma)Cl]
+ cations than to the pyridyl rings (~4.4 Å) of the [Pt(N(R)dpa)Cl]+  cations.89-90 The 
difference in these distances suggests that H8 in adducts is farther from the center of the pyridyl 
rings than from the center of the imidazolyl rings. Together with the Δδ values for these adducts 
in the solvent mixture, the difference in these distances leaves little doubt that the anisotropy of 
the pyridyl ring is greater than that of the imidazolyl ring.  
Upon adduct formation, the downfield shift changes of the H8 and H1′ NMR signals 
(relative to free G) are comparatively smaller for Pt(N(H)1,1′-Me2dma)G than for Pt(N(H)dpa)G 
adducts. As an example, from data in Supporting Information, the H8 shift changes upon adduct 
formation are 0.62 and 0.91 ppm for the syn and anti rotamers of Pt(N(H)1,1′-Me2dma)(5'-GMP), 
respectively, vs. 0.76 and 1.12 ppm5 for the corresponding rotamers of Pt(N(H)dpa)(5'-GMP). 
Because the anisotropic effect of the pyridyl rings on H8 is greater than that of the imidazolyl 
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rings, the conclusion is clear that the Pt(II) center exerts a stronger electron-withdrawing effect on 
the nucleobase in the Pt(N(H)dpa)G than in the Pt(N(H)1,1′-Me2dma)G adducts. The strength of 
this Pt(II) inductive effect provides a rough estimate of the relative electron-donating ability of the 
bound aromatic rings. Thus, the imidazolyl rings have a relatively higher donating ability than the 
pyridyl rings, as might be expected. This difference, which undoubtedly occurs also in the chlorido 
complexes, may be the reason that complete formation of the Pt(N(H)dpa)(5'-GMP) adduct 
requires less time (~2 d) than that needed for the Pt(N(H)1,1′-Me2dma)(5'-GMP) adduct (≥4 d) in 
either D2O (100%) or D2O:DMSO-d6 (65:35).  
Pt(N(Me)1,1′-Me2dma)G Adducts. To examine the influence of increased bulk at the 
central nitrogen of the carrier ligand, we evaluated the properties of the Pt(N(Me)1,1′-Me2dma)G 
adducts (Table 2.4). The Pt(N(Me)1,1′-Me2dma)(5'-GMP) adduct showed sharp H8 singlets for 
the syn (upfield H8 signal at 8.66 ppm) and the anti (downfield H8 signal at 8.98 ppm) rotamers 
(Supporting Information, Table 2.4). The Δδ for the two H8 signals (0.32 ppm) is comparable to 
that of Pt(N(H)1,1′-Me2dma)(5'-GMP) (0.31 ppm). The chemical shifts for H1′ doublets of the syn 
and anti rotamers of the Pt(N(Me)1,1′-Me2dma)(5'-GMP) adduct are similar to what is observed 
for the Pt(N(H)1,1′-Me2dma)(5'-GMP) adduct (Table 2.4). Similarly, the Pt(N(Me)1,1′-
Me2dma)(5′-GTP), Pt(N(Me)1,1′-Me2dma)(3′-GMP), Pt(N(Me)1,1′-Me2dma)(5′-IMP), and 
Pt(N(Me)1,1′-Me2dma)(Ino)  adducts have shifts (Tables 2.3 and 2.4 and Supporting Information) 
very similar to those of the corresponding Pt(N(H)1,1′-Me2dma)G
 adducts. However, the EXSY 
cross-peaks connecting the syn and anti H8 signals in a ROESY spectrum of the Pt(N(Me)1,1′-
Me2dma)(5'-GMP) adduct (Supporting Information) are relatively smaller than those of the 




Another difference between the Pt(N(Me)1,1′-Me2dma)G adducts and the Pt(N(H)1,1′-
Me2dma)G adducts was the relative abundance of the rotamers in D2O when G = 5'-GMP, 5'-GTP, 
3'-GMP, and 5'-IMP. The Pt(N(Me)1,1′-Me2dma)G adducts have a high syn:anti ratio (≥1.5:1), 
whereas the Pt(N(H)1,1′-Me2dma)G adducts have rotamers of nearly equal abundance (Table 2.4). 
Comparison of the model of the anti rotamer (Figure A.3 in Supporting Information) with the 
molecular structure of the syn rotamer in [Pt(N(H)1,1′-Me2dma)(3′-GMPH)]NO3•5H2O (5) did not 
show any steric interactions that would favor either rotamer, consistent with the similar abundance 
of the rotamers. Finally, it is interesting to note 1) that the imidazole ring has a greater degree of 
tilting in 5 than in the chlorido complexes and 2) that a methyl group on the central nitrogen 
increases tilting. Thus, the greater abundance of the syn rotamer typically found for Pt(N(Me)1,1′-
Me2dma)G adducts than for Pt(N(H)1,1′-Me2dma)G adducts may arise in part because the tilting 
is already greater in the starting [Pt(N(Me)1,1′-Me2dma)Cl]Cl complex. 
Relationship of the Phosphate Group to Pt(II) and N7 in GMP Complexes. The 
molecular structure of [Pt(N(H)1,1′-Me2dma)(3′-GMPH)]NO3•5H2O (5) allows us to compare the 
proximity of the phosphate group to Pt(II) and N7 to such distances in structurally characterized 
5′-GMP complexes, all of which are bis adducts.69-72,77 Non-bonded distances were obtained from 
crystallographically determined molecular structures by using Mercury 3.7 software. For our 
purposes, we use the central P atom to gauge the distance of the phosphate group to the other 
atoms. The Pt-to-P non bonded distance (9.7 Å) in the 3′-GMP complex (5) is much longer than 
in the 5′-GMP complexes (5.0-6.2 Å). The NMR and structural data for such bis 5′-GMP adducts, 
especially for the ΔHT conformation (head-to-tail orientation of the two bases and right-handed 
chirality), suggest that the phosphate group of 5′-GMP interacts electrostatically with the Pt(II) 
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center or the carrier ligand.70-71 Thus, the most abundant conformers often differ between bis 
adducts formed by 5′-GMP and those formed by 3′-GMP.102  
The spatial position of the 3′-phosphate group in 3′-GMP bound via N7 to a metal center 
separates the centers of charge. This separation may explain why so few 3′-GMP complexes have 
been crystallized. The large number of known structures of 5′-GMP complexes of many metals 
may indicate that charge neutralization resulting from the close proximity of the 5′-phosphate 
group to the metal center facilitates crystallization.  
Furthermore, the inability of 3′-GMP to form such electrostatic interactions explains why 
formation of the Pt(N(R)1,1′-Me2dma)(3′-GMP) adduct requires 10 d vs the 6 d or less needed to 
form the 5′-GMP, 5′-GDP, 5′-GTP, and 5′-IMP adducts, in which a phosphate group is closer to 
the Pt(II) center. The N7-to-P non bonded distance in 5 is 8.0 Å. The attraction of the negative 3′-
phosphate to the positive Pt(II) center during adduct formation positions the N7 of 3′-GMP too far 
from Pt(II) to facilitate N7-to-Pt bond formation. In contrast, the N7-to-P non bonded distances in 
5′-GMP adducts range from 5.1 to 6.3 Å.69-72,77 The attraction of the negative 5′-phosphate group 
to the positive Pt(II) center positions the N7 of GMP closer to Pt(II) during adduct formation by 
5′-GMP than during adduct formation by 3′-GMP. This positioning probably accounts for the 
shorter times observed for reactions of 5′-GMP than of 3′-GMP. 
2.4 Conclusions 
The presence of EXSY cross-peaks in the ROESY spectra of Pt(N(R)1,1′-Me2dma)(5′-
GMP) adducts but not in the ROESY spectrum of the Pt(N(H)dpa)(5′-GMP) adduct5 revealed that 
rotamer interchange is more facile for Pt(N(H)1,1′-Me2dma)G adducts than for Pt(N(H)dpa)G 
adducts; we conclude that this finding establishes that the N(R)1,1′-Me2dma carrier-ligand steric 
effect is relatively lower than the N(H)dpa carrier-ligand steric effect. We believe that this lower 
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steric effect is a consequence of the greater distance of the H4/4′ protons from the G nucleobase 
in Pt(N(H)1,1′-Me2dma)G adducts as compared to the distance of the corresponding H6/6′ protons 
in Pt(N(H)dpa)G adducts.  
The structural data for [Pt(N(H)1,1′-Me2dma)(3′-GMPH)]NO3•5H2O (5) confirm that the 
3′-phosphate group is too far from the carrier ligand or the positive Pt(II) center to influence the 
properties of the complex. This finding nicely complements a study with Pt(Me5dien)(5'/3'-GMP) 
adducts, which exhibited properties independent of the 3′ or 5′ position of the phosphate group on 
the ribose.96 The Me5dien carrier ligand has considerable steric bulk projecting out of the 
coordination plane, and the 5′-phosphate group cannot easily approach the positive Pt(II) center. 
In analogs of Pt(Me5dien)(5'/3'-GMP) adducts in which protons occupied the positions of some of 
the carrier-ligand N-Me groups,96-97 the rotamer distribution greatly favored the rotamer in which 
the 5′-phosphate group could form a hydrogen bond to the carrier-ligand NH proton. The solid-
state structure of 5 in the present study thus fully supports previous less direct evidence regarding 
the role of the phosphate group in influencing rotamer abundance when the carrier ligand has NH 
groups in the cis position. 
Finally, the structure of [Pt(N(H)1,1′-Me2dma)(3′-GMPH)]NO3•5H2O (5) establishes the 
validity of features deduced from NMR results for Pt(N(H)dpa)G adducts5 that have a related 
tridentate ligand. In particular, the structure of 5 shows that the G nucleobase has low canting and 
that the carrier-ligand aromatic rings in a G adduct are tilted, as found in the parent chlorido 
complexes. In studies of Pt(N(H)dpa)G adducts,5 the tilting of the pyridyl rings served to assign 
signals to the syn or anti rotamer. The structure of 5 provides a basis for creating models of the 
syn and anti rotamers. These models indicate that the H8-to-H4/4′ distance is longer in the syn 
than in the anti rotamer. The relevant cross-peak intensity is larger for the anti than for the syn 
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signals, a finding that provides strong support for the validity of previous rotamer assignments5 
based on the effect of carrier-ligand anisotropic groups on H8 chemical shifts.  
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CHAPTER 3. NNN-TRIDENTATE LIGANDS WITH CENTRAL SULFONAMIDE AND 
TERMINAL PYRIDYL RING N-DONORS. COMPARISON OF FACTORS AFFECTING 
LIGAND COORDINATION MODE AND BINDING STRENGTH TO fac-[Re(I)(CO)3]+ 




New properties can be introduced into metal complexes by linking dangling groups with 
targeting moieties or fluorophores onto carrier ligands. Typically, the most useful linking 
chemistry avoids creating new asymmetric centers in the complexes, especially when the ultimate 
goal is to identify a diagnostic or therapeutic agent. One common approach is to attach the dangling 
group to the central N atom of N,N',N''-donor tridentate ligands (Figure 3.1).1-15 Various metal 
complexes of tridentately bound ligand derivatives of 2-dipicolylamine (N(H)dpa) (Figure 3.2), 
di-(2-methylimidazolyl)amine (N(H)dma), or diethylenetriamine (dien) with a suitable group 
attached to the central N possess useful properties, such as enhanced targeting ability,2,7-8 
fluorescence,3,10,13 high anticancer/antitumor activity,9,11-12 or new bioconjugation chemistry.4-6 In 
almost all cases, the dangling group is attached to the chelate ligand via an N–C bond. As one 
example, naphthalimide derivatives (R) are attached via an N–C bond to the central N atom of the 
N(R)dpa ligand in  fac-[Re(CO)3(N(R)dpa)]BF4 complexes, which have promising cell-imaging 
properties.3 In particular, complexes of Pt(II) with chelate ligands having dangling groups9-17 have 
been widely explored because such complexes often exhibit anticancer or antiviral activity.9,11-12,17 
Recent studies from our laboratory have shown that N(SO2R)dpa (Figure 3.2) or 
N(SO2R)dien type ligands, in which the central N-donor atom is part of a tertiary sulfonamide 
group, function as a new class of tridentate ligands and form Re(I) complexes,  fac-
[Re(CO)3(N(SO2R)dpa)]PF6
4 and fac-[Re(CO)3(N(SO2R)dien)]PF6
5 (R = Me and Tol (p-tolyl)). 
Such ligands, in which the dangling group is attached via an N–S bond to the central N atom, 
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expand the scope of dangling-group properties that can be employed. The relevance of such Re(I) 
compounds to the development of 99mTc(I) and Re(I) radiopharmaceutical diagnostic and 
therapeutic agents has been discussed.4-5 
 
Figure 3.1. Components of a biological targeting therapeutic or diagnostic metal-containing agent. 
*Component with no geometrical or optical isomers. #Non-chiral linking component attached to 




+ cations are the first 
examples of any metal complex with the sulfonamide as part of a noncyclic linear tridentate ligand 
having a normal metal-to-sulfonamide nitrogen bond length (~2.2 Å).4-5 More recently, closely 
related complexes of Mn(I) have been described.18-19 Resonance stabilization within the 
sulfonamide group results in the sulfonamide nitrogen lacking a readily available lone pair of 
electrons for metal coordination. For a M–N bond to form, the bond must be energetically 
favorable enough to convert the hybridization of the sulfonamide N from sp2 (resonance stabilized) 
to sp3 (stabilized by the M–N bond). A key factor favoring coordination of the tertiary sulfonamide 
N of N(SO2R)dpa- and N(SO2R)dien-type ligands to Re(I) is the formation of two adjacent 5-
membered chelate rings, the most favorable ring size for chelate formation. In this study, we 
investigate whether the normally highly favorable Pt–N bond could also form when the N atom is 
within the sulfonamide group in N(SO2R)dpa-type ligands; in such a case, new types of dangling 
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groups could be employed with Pt(II) complexes that possess a metal center forming agents known 
to have widespread use in biomedicine.  
 
Figure 3.2. Line drawing and numbering scheme for N(SO2R)Mendpa ligands based on the parent 
(P) ligand framework, N(SO2R)dpa: N,N-di(3,5-dimethyl-2-picolyl)methanesulfonamide, 
N(SO2Me)3,3',5,5'-Me4dpa (1); N,N-di(3,5-dimethyl-2-picolyl)-p-tolylsulfonamide, 
N(SO2Tol)3,3',5,5'-Me4dpa (2); N,N-di(6-methyl-2-picolyl)methanesulfonamide, N(SO2Me)6,6'-
Me2dpa (3); and N,N-di(6-methyl-2-picolyl)-p-tolylsulfonamide, N(SO2Tol)6,6'-Me2dpa (4). Note 
that the p-tolyl group numbering is italicized to prevent confusion with the pyridyl ring numbering. 
 
Unlike the situation with the Re(I) complexes, for which adduct formation with biological 
molecules is usually not a key feature for biological applications, Pt(II) complexes typically act by 
forming adducts and require one or two leaving groups for functionality. Because aromatic protons 
have 1H NMR signals complicating such studies, we chose to prepare and study N(SO2R)dpa-type 
ligands with methyl groups replacing some of the aromatic protons characteristic of known 
ligands. Furthermore, methyl groups can increase the steric bulk on the carrier ligand, a factor 
influencing anticancer activity of Pt(II) compounds.20-25 Therefore, we prepared Pt(II) complexes 
utilizing four new N(SO2R)Mendpa ligands (Figures 3.2 and 3.3, R = Me or Tol and with n 
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indicating different methyl substitution patterns on the pyridyl ring). fac-
[Re(CO)3(N(SO2R)Mendpa)]PF6 complexes of these new ligands were synthesized to confirm that 
they are capable of binding tridentately to Re(I), despite the presence of methyl substituents on the 
pyridyl ring, especially for N(SO2R)6,6'-Me2dpa. All of the fac-[Re(CO)3(chelate)]PF6 complexes 
discussed below have facial geometry, and thus from this point onward we omit the fac- 
designation when discussing specific compounds. 
 
Figure 3.3. Synthetic routes for the ligands, N(SO2R)dpa (Route 1) and N(SO2R)Mendpa (Route 
2). (i) dioxane, RT, 24 h. (ii) K2CO3, acetonitrile at reflux, N2, 18 h. 
Previous studies from this laboratory have shown that the N(R)dpa and N(R)1,1'-Me2dma 
ligands (R = H or Me) readily bind to the Pt(II) metal center in a tridentate fashion to form 
[Pt(Ltri)Cl]+ (Ltri = N,N',N''-donor tridentate carrier ligand) complexes.26-27 However, the new 
N(SO2R)Mendpa ligands form Pt(II) complexes with bidentate N(SO2R)Mendpa ligands having an 
8-membered chelate ring with the  tertiary sulfonamide nitrogen not bound directly to Pt(II) but 
serving as an atom in the chain of the chelate ring. Structural characterizations of Pt(II) complexes 
with bidentate ligands having 8-membered chelate rings such as those found here are very few in 
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number, as compared to bifunctional Pt(II) complexes with smaller 5-, 6-, and 7-membered chelate 
rings of bidentate pyridyl/imidazolyl ligands28-50 or with two pyridyl/imidazolyl monodentate 
ligands.51-55 The rarity and unusual properties of the new bifunctional Pt(II) compounds with a 
large 8-membered chelate ring in the current work led us to compare their structural features with 
these features in related bifunctional Pt(II) complexes. The relevance of binding at G residues in 
DNA by anticancer-active Pt(II) compounds28,33,43-44,55 has led to many studies of adduct formation 
of guanine derivatives with mono- and bi-functional Pt(II) complexes bearing carrier ligands with 
5- and 6-membered chelate rings.26-27,56 In rare cases the guanine derivatives disrupt and open the 
chelate ring.57 We found that the chelate rings in the new complexes open relatively easily but that 
this process is not facilitated in the presence of guanine derivatives.  
3.2 Experimental Section 
Starting Materials. Methanesulfonamide (MeSO2NH2), p-tolylsulfonamide 
(TolSO2NH2), 2,3,5-collidine, 6-methyl-2-pyridinemethanol, tetraethylammonium chloride 
([Et4N]Cl), and K2PtCl4 were used as received from Aldrich. cis-Pt(DMSO)2Cl2,
58 aqueous 
[Re(CO)3(H2O)3]OTf (OTf = trifluoromethanesulfonate),
59 2-(chloromethyl)-6-methylpyridine,60 
and 2-(chloromethyl)-3,5-dimethylpyridine61 were prepared by known methods. 
NMR Measurements. 1H NMR spectra were recorded on a 400 MHz or on an Avance-III 
Prodigy 500 MHz Bruker spectrometer. Peak positions are relative to TMS or solvent residual 
peak with TMS as reference. All NMR data were processed with TopSpin and MestReNova 
software. A presaturation pulse to suppress the water peak was employed when necessary. 
Mass Spectrometric Measurements. High resolution mass spectra were recorded on an 
Agilent 6210 ESI TOF LCMS mass spectrometer. 
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X-ray Data Collection and Structure Determination. Diffraction data were collected on 
a Bruker Kappa Apex-II DUO CCD diffractometer with Mo K radiation (λ = 0.71073 Å), 
equipped with an Oxford Cryosystems Cryostream. All X-ray structures were determined by direct 
methods and difference Fourier techniques and refined by full-matrix least-squares by using 
SHELXL201462 with H-atoms in idealized positions. 
General Synthesis of Ligands. A solution of the desired 2-chloromethyl pyridine 
derivative (~6 mmol), K2CO3 (~1.7 g, 12 mmol), and the appropriate sulfonamide (~2.5 mmol) in 
acetonitrile (95 mL) was heated at reflux under nitrogen for 18 h. After removal of acetonitrile 
under reduced pressure, the residue was dissolved in water (45 mL) and the solution extracted with 
CH2Cl2 (3 x 45 mL). The organic layers were combined, washed with saturated aqueous sodium 
chloride solution, dried over sodium sulfate, and taken to dryness under reduced pressure. The 
residue was dissolved in ethyl acetate:hexane (80:20) and purified by chromatography on a silica 
column with the same eluent. Fractions were collected and spotted on TLC plates by using the 
same eluent. The cleanest fractions, as assessed by 1H NMR spectroscopy, were combined and 
taken to dryness by rotary evaporation to afford the desired ligand in sufficient purity to use in the 
synthesis of the corresponding Pt(II) complex. 
N(SO2Me)3,3',5,5'-Me4dpa (1). The general ligand synthesis described above carried out 
with 2-(chloromethyl)-3,5-dimethylpyridine (0.98 g, 6.2 mmol) and MeSO2NH2 (0.23 g, 2.4 
mmol) produced an orange residue, which was purified by using column chromatography to afford 
N(SO2Me)3,3',5,5'-Me4dpa as a white solid (0.54 g, 67% yield). 
1H NMR signals (ppm) in CDCl3: 
8.19 (s, 2H, H6/6'), 7.23 (s, 1H, H4/4'), 4.60 (s, 4H, CH2), 3.15 (s, 3H, CH3), 2.28 (s, 6H, CH3), 
2.21 (s, 6H, CH3). 
1H NMR signals (ppm) in DMSO-d6: 8.17 (s, 2H, H6/6'), 7.33 (s, 2H, H4/4'), 
54 
 
4.45 (s, 4H, CH2), 3.13 (s, 3H, CH3), 2.23 (s, 6H, CH3), 2.12 (s, 6H, CH3). ESI-MS (m/z): [M + 
H]+  = 334.1596. Calcd for [M + H]+  = 334.1584. 
N(SO2Tol)3,3',5,5'-Me4dpa (2). The general ligand synthesis with 2-(chloromethyl)-3,5-
dimethylpyridine (1.04 g, 6.6 mmol) and TolSO2NH2 (0.46 g, 2.6 mmol) yielded an orange residue, 
which was purified by using column chromatography to afford N(SO2Tol)3,3',5,5'-Me4dpa as a 
pale yellow solid (0.88 g, 79% yield). 1H NMR signals (ppm) in CDCl3: 7.98 (s, 2H, H6/6'), 7.70 
(d, J = 8.1 Hz, 2H, H2/6), 7.26 (masked by the solvent peak, 2H, H3/5), 7.07 (s, 2H, H4/4'), 4.48 
(s, 4H, CH2), 2.43 (s, 3H, CH3), 2.25 (s, 6H, CH3), 2.19 (s, 6H, CH3). 1H NMR signals (ppm) in 
DMSO-d6: 7.94 (s, 2H, H6/6'), 7.62 (d, J = 7.8 Hz, 2H, H2/6), 7.32 (d, J = 7.9 Hz, 2H, H3/5), 7.21 
(s, 2H, H4/4'), 4.41 (s, 4H, CH2), 2.39 (s, 3H, CH3), 2.16 (s, 6H, CH3), 2.13 (s, 6H, CH3). ESI-MS 
(m/z): [M + H]+  = 410.1876. Calcd for [M + H]+ = 410.1897. 
N(SO2Me)6,6'-Me2dpa) (3). The general ligand synthesis with 2-(chloromethyl)-6-
methylpyridine (0.90 g, 6.4 mmol) and MeSO2NH2 (0.24 g, 2.5 mmol) yielded an orange residue, 
which was purified by using column chromatography to afford N(SO2Me)6,6'-Me2dpa as a 
colorless oil (0.68 g, 88% yield). 1H NMR signals (ppm) in CDCl3: 7.55 (t, J = 7.7 Hz, 2H, H4/4'), 
7.18 (d, J = 7.7 Hz, 2H, H5/5'), 7.05 (d, J = 7.7 Hz, 2H, H3/3'), 4.54 (s, 4H, CH2), 3.15 (s, 3H, 
CH3), 2.51 (s, 6H, CH3). 
1H NMR signals (ppm) in DMSO-d6: 7.63 (t, J = 7.7 Hz, 2H, H4/4'), 
7.12 (d, J = 7.8 Hz, 4H, H3/3' and H5/5'), 4.42 (s, 4H, CH2), 3.14 (s, 3H, CH3), 2.41 (s, 6H, CH3). 
ESI-MS (m/z): [M + H]+ = 306.1269. Calcd for [M + H]+ = 306.1271. 
N(SO2Tol)6,6'-Me2dpa (4). The general ligand synthesis with 2-(chloromethyl)-6-
methylpyridine (1.00 g, 7.1 mmol) and TolSO2NH2 (0.58 g, 3.4 mmol) yielded an orange residue, 
which was purified by using column chromatography to afford N(SO2Tol)6,6'-Me2dpa as a yellow 
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oil (1.14 g, 89% yield). 1H NMR signals (ppm) in CDCl3: 7.71 (d, J = 8.1 Hz, 2H, H2/6), 7.43 (t, 
J = 7.7 Hz, 2H, H4/4'), 7.24 (d, J = 8.1 Hz, 2H, H3/5), 7.14 (d, J = 7.8 Hz, 2H, H3/3'), 6.92 (d, J 
= 7.7 Hz, 2H, H5/5'), 4.56 (s, 4H, CH2), 2.42 (s, 3H, CH3), 2.37 (s, 6H, CH3). 1H NMR signals 
(ppm) in DMSO-d6: 7.67 (d, J = 8.2 Hz, 2H, H2/6), 7.53 (t, J = 7.7 Hz, 2H, H4/4'), 7.33 (d, J = 8.0 
Hz, 2H, H3/5), 7.04 (quasi t, 4H, H3/3' and H5/5'), 4.43 (s, 4H, CH2), 2.37 (s, 3H, CH3), 2.28 (s, 
6H, CH3). ESI-MS (m/z): [M + H]
+ = 382.1591. Calcd for [M + H]+ = 382.1584. 
General Synthesis of Platinum Complexes. A stirred solution of the ligand (0.1 mmol) 
and cis-Pt(DMSO)2Cl2 (0.1 mmol) in methanol (5 mL) was heated at reflux overnight (~16 h). The 
yellow precipitate that formed overnight was collected by filtration, washed with methanol and 
ether, and air-dried (Method A). X-ray quality crystals were obtained by mixing equal volumes (1 
mL) of solutions of cis-Pt(DMSO)2Cl2 (12.5 mM) and the ligand (12.5 mM) in acetonitrile and 
allowing the mixture to stand at room temperature. Needle-like crystals were obtained within 2 
days to 2 weeks (Method B). The 1H NMR data are identical for the products obtained by Methods 
A and B. 
Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5). With N(SO2Me)3,3',5,5'-Me4dpa (1, 33 mg, 0.1 
mmol) and cis-Pt(DMSO)2Cl2 (42 mg, 0.1 mmol), Method A afforded a pale yellow solid (26 mg, 
44% yield). Yellow crystals obtained by Method B were characterized by single-crystal X-ray 
crystallography. 1H NMR signals (ppm) in DMSO-d6: 8.98 (s, 2H, H6/6'), 7.56 (s, 2H, H4/4'), 5.99 
(d, J = 14.7 Hz, 2H, CH2), 5.37 (d, J = 14.9 Hz, 2H, CH2), 3.35 (s, 3H, CH3), 2.37 (s, 6H, CH3), 
2.23 (s, 6H, CH3). ESI-MS (m/z): [M-H]
- = 597.0450. Calcd for [M-H]-  =  597.0463. 
Pt(N(SO2Tol)3,3',5,5'-Me4dpa)Cl2 (6). With N(SO2Tol)3,3',5,5'-Me4dpa (2, 41 mg, 0.1 
mmol) and cis-Pt(DMSO)2Cl2 (42 mg, 0.1 mmol), Method A afforded a pale yellow solid (25 mg, 
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37% yield). Yellow crystals obtained by Method B were characterized by single-crystal X-ray 
crystallography. 1H NMR signals (ppm) in DMSO-d6: 8.90 (s, 2H, H6/6'), 8.03 (d, J = 8.2 Hz, 2H, 
H2/6), 7.60 (d, J = 8.1 Hz, 2H, H3/5), 7.56 (s, 2H, H4/4'), 5.55 (d, J = 14.3 Hz, 2H, CH2), 5.47 (d, 
J = 14.3 Hz, 2H, CH2), 2.45 (s, 6H, CH3), 2.21 (s, 6H, CH3); the phenyl methyl signal is masked 
by the solvent peak. ESI-MS (m/z): [M + H]+ = 676.0926. Calcd for [M + H]+ = 676.0913. 
 [trans-Pt(DMSO)Cl2]2(N(SO2Me)6,6'-Me2dpa) (7). With N(SO2Me)-6,6'-Me2dpa (3, 30 
mg, 0.1 mmol) and cis-Pt(DMSO)2Cl2 (42 mg, 0.1 mmol), Method A afforded a pale yellow solid 
(16 mg, 28% yield). 1H NMR signals (ppm) in DMSO-d6: 7.85 (t, J = 7.8 Hz, 2H, H4/4'), 7.68 (d, 
J = 7.9 Hz, 2H, H3/3'), 7.46 (d, J = 7.8 Hz, 2H, H5/5'), 5.55 (s, 4H, CH2), 3.33 (s, 3H, CH3), 3.12 
(s, 6H, CH3). ESI-MS (m/z): [M + H]
+ = 993.9522. Calcd for [M + H]+ =  993.9569. 
 [trans-Pt(DMSO)Cl2]2(N(SO2Tol)6,6'-Me2dpa) (8). With N(SO2Tol)6,6'-Me2dpa (4, 38 
mg, 0.1 mmol) and cis-Pt(DMSO)2Cl2 (42 mg, 0.1 mmol), Method A afforded a pale yellow solid 
(14 mg, 22% yield). Yellow needle-shaped crystals obtained by Method B were characterized by 
single-crystal X-ray crystallography. 1H NMR signals (ppm) in DMSO-d6: 7.91 (d, J = 8.0 Hz, 2H, 
H2/6), 7.76 (t, J = 7.9 Hz, 2H, H4/4'), 7.57 (d, J = 8.0 Hz, 2H, H3/3'), 7.52 (d, J = 8.0 Hz, 2H, 
H3/5), 7.43 (d, J = 7.9 Hz, 2H, H5/5'), 5.46 (s, 4H, CH2), 3.11 (s, 6H, CH3), 2.43 (s, 3H, CH3). 
ESI-MS (m/z): [M + H]+ = 1069.9921 Calcd for [M + H]+ =  1069.9884. The solvent of the resultant 
clear, pale yellow filtrate (Method A) was removed under reduced pressure, leaving a residue. The 
1H NMR spectrum of this residue in DMSO-d6 shows peaks for free ligand 4 and for ligand 4 
bound to Pt(II) in an unsymmetric monodentate fashion.  
Isolation of trans-[Pt(DMSO)Cl2](N(SO2Tol)6,6'-Me2dpa) Crystals (8a). In a 
preparation that led to the isolation of the new complex detected in the residue just mentioned, an 
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aqueous solution of K2PtCl4 (0.208 g, 0.5 mmol in 10 mL) was heated to 70
 °C and treated with 
70 µL (1 mmol) of DMSO followed after 10 min by N(SO2Tol)-6,6'-Me2dpa (4, 191 mg, 0.5 
mmol). The mixture was heated and stirred for 1 h at 95 °C. The yellow solid (78 mg, 15%) that 
precipitated was collected by filtration, washed with methanol and ether, and identified as complex 
8 by its 1H NMR spectrum. Yellow X-ray quality crystals of 8a (53 mg, 15%) deposited overnight 
from the clear yellow filtrate. The 1H NMR signals (in DMSO-d6) of the 8a crystals are identical 
to those for the complex in the residue obtained with Method A (see above). 1H NMR signals 
(ppm) in DMSO-d6: 7.88 (t, J = 8.0 Hz, 1H, H4bound), 7.78 (d, J = 8.0 Hz, 2H, H2/6), 7.54 (t, J = 
7.9 Hz, 1H, H4dangling), 7.49 (d, J = 8.0 Hz, 1H, H3bound), 7.42 (d, J = 8.0 Hz, 3H, H3/5 & H5bound), 
7.14 (d, J = 7.9 Hz, 1H, H3dangling), 7.04 (d, J = 7.9 Hz, 1H, H5dangling), 5.40 (s, 2H, CH2bound),  4.50 
(s, 2H, CH2dangling),  3.09 (s, 3H, CH3bound), 2.42 (s, 3H, CH3), 2.27 (s, 3H, CH3dangling). MALDI-
TOF (m/z): [M + Na]+ = 748.096. Calcd for [M + Na]+ =  748.052.  
General Synthesis of [Re(CO)3(N(SO2R)Mendpa)]PF6 Complexes. Ligands 1-4 were 
employed to synthesize [Re(CO)3(N(SO2R)Mendpa)]PF6 complexes according to the following 
general procedure: a methanol solution of the ligand (30−41 mg, 0.1 mmol in 2 mL) was treated 
with aqueous [Re(CO)3(H2O)3]OTf (0.1 mmol in 2 mL).
59 Methanol (2─3 mL) was added to 
dissolve any precipitate that formed, and the clear reaction mixture was heated at reflux for 16 h. 
An excess of NaPF6 (0.16 g, 1 mmol) was added to the cooled clear solution, and the resulting 
precipitate was collected on a filter, washed with water, and air-dried. A concentrated covered 
solution of each compound in acetone was kept at room temperature to allow the solvent to 
evaporate slowly and crystals to form. Two solutions produced X-ray quality crystals, and two 
yielded powders.  
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[Re(CO)3(N(SO2Me)3,3',5,5'-Me4dpa)]PF6 (9). With N(SO2Me)3,3',5,5'-Me4dpa (1, 33 
mg 0.1 mmol), and [Re(CO)3(H2O)3]OTf (0.1 mmol), the general preparation described above 
produced [Re(CO)3(N(SO2Me)3,3',5,5'-Me4dpa)]PF6 as a white solid (34 mg, 42% yield) after the 
addition of NaPF6 (∼0.16 g). Slow evaporation of a concentrated solution of this compound in 
acetone produced yellow needle-like crystals that were characterized by single-crystal X-ray 
crystallography.  1H NMR signals (ppm) in DMSO-d6: 8.60 (s, 2H, H6/6'), 7.75 (s, 2H, H4/4'), 
5.29 (d, J = 17.2 Hz, 2H, CH2), 5.07 (d, J = 17.0 Hz, 2H, CH2), 3.96 (s, 3H, CH3), 2.34 (s, 6H, 
CH3), 2.29 (s, 6H, CH3).  
[Re(CO)3(N(SO2Tol)3,3',5,5'-Me4dpa)]PF6 (10). With N(SO2Me)3,3',5,5'-Me4dpa (2, 41 
mg 0.1 mmol), and [Re(CO)3(H2O)3]OTf (0.1 mmol), the general preparation described above 
produced [Re(CO)3(N(SO2Tol)3,3',5,5'-Me4dpa)]PF6 as a white solid (38 mg, 57% yield) after the 
addition of NaPF6 (∼0.16 g). 1H NMR signals (ppm) in DMSO-d6: 8.63 (s, 2H, H6/6'), 8.33 (d, J 
= 8.2 Hz, 2H, H2/6), 7.75 (d, J = 8.5 Hz, 2H, H3/5), 7.72 (s, 2H, H4/4'), 5.48 (d, J = 17.0 Hz, 2H, 
CH2), 4.55 (d, J = 17.0 Hz, 2H, CH2), 2.56 (s, 3H, CH3), 2.28 (s, 6H, CH3), 2.20 (s, 6H, CH3). ESI-
MS (m/z): [M]+ = 678.1210. Calcd for [M]+ =  678.1195. 
[Re(CO)3(N(SO2Me)6,6'-Me2dpa)]PF6 (11). With N(SO2Me)3,3',5,5'-Me4dpa (3, 30 mg 
0.1 mmol), and [Re(CO)3(H2O)3]OTf (0.1 mmol), the general preparation described above 
produced [Re(CO)3(N(SO2Me)3,3',5,5'-Me4dpa)]PF6 as a white solid (25 mg, 34% yield) after the 
addition of NaPF6 (∼0.16 g). 1H NMR signals (ppm) in DMSO-d6: 8.06 (t, J = 7.7 Hz, 2H, H4/4'), 
7.65 (d, J = 7.8 Hz, 2H, H3/3'), 7.47 (d, J = 7.7 Hz, 2H, H5/5'), 5.36 (d, J = 16.9 Hz, 2H, CH2), 
5.03 (d, J = 17.0 Hz, 2H, CH2), 3.90 (s, 3H, CH3), 2.88 (s, 6H, CH3). ESI-MS (m/z): [M]
+ = 
574.0583. Calcd for [M]+ =  574.0569. 
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[Re(CO)3(N(SO2Tol)6,6'-Me2dpa)]PF6 (12). With N(SO2Tol)6,6'-Me2dpa (4, 38 mg, 0.1 
mmol) and [Re(CO)3(H2O)3]
+ (0.1 mmol), the general preparation described above produced 
[Re(CO)3(N(SO2Tol)6,6'-Me2dpa)]PF6 as a pale yellow solid (41 mg, 51% yield) after the addition 
of NaPF6 (∼0.16 g). Slow evaporation of a concentrated solution of this compound in acetone 
produced pale yellow, needle-like crystals that were characterized by single-crystal X-ray 
crystallography. 1H NMR signals (ppm) in DMSO-d6: 8.21 (d, J = 8.0 Hz, 2H, H2/6), 8.02 (t, J = 
7.8 Hz, 2H, H4/4'), 7.75 (d, J = 7.7 Hz, 2H, H3/5), 7.63 (d, J = 8.0 Hz, 2H, H3/3'), 7.52 (d, J = 7.6 
Hz, 2H, H5/5'), 5.23 (d, J = 16.8 Hz, 2H, CH2), 4.52 (d, J = 16.6 Hz, 2H, CH2), 2.90 (s, 6H, CH3), 
2.57 (s, 3H, CH3).  
Solution Studies of Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5). A solution of 5 (10 mM) in 
DMSO-d6 (Solution 1), at 25 °C was monitored by 
1H NMR spectroscopy for at least 21 d. Another 
10 mM solution of 5 in DMSO-d6 was treated with 10 molar equiv of [Et4N]Cl (10 mg) after 1 d 
(Solution 2). In another experiment, 5 (3.6 mg) was added to a solution of [Et4N]Cl (100 mM) in 
DMSO-d6 to make the solution 10 mM in 5 (Solution 3). In a similar experiment, a sufficient 
amount of ligand 1 (1.3 mg) was added to a solution containing cis-Pt(DMSO)2Cl2 (10 mM) and 
[Et4N]Cl (100 mM) in DMSO-d6 to make the solution 10 mM in ligand 1 (Solution 4). Another 10 
mM solution of 1 in DMSO-d6 was treated with 1 molar equiv of cis-Pt(DMSO)2Cl2 (1.7 mg, 
Solution 5). Solutions 2, 3, 4, and 5 were monitored with time by 1H NMR spectroscopy. Solutions 
of 6 (4.0 mg, 10 mM) in DMSO-d6 or in DMF-d7 (partially dissolved) were kept at 25 °C and 
monitored by 1H NMR spectroscopy. Furthermore, 10 mM solutions of 7, 8, and Re(I) complexes, 
9–12, in DMSO-d6 were kept at 25 °C and monitored over time by 





3.3 Results and Discussion  
Synthesis of N(SO2R)Mendpa Derivatives and Their Pt(II) and Re(I) Complexes. Our 
previous synthesis of N(SO2R)dpa
4 ligands utilized the commercially available parent ligand, 
N(H)dpa (Figure 3.2), which was coupled with the appropriate sulfonyl chloride (Route 1, Figure 
3.3). However, the N(H)Mendpa parent ligands needed in this study, N(H)3,3',5,5'-Me4dpa and 
N(H)6,6'-Me2dpa, are not commercially available. Thus, the new N(SO2R)Mendpa (1-4) ligands 
were synthesized by a different route, in which the desired 2-chloromethyl pyridyl derivative (2 
equiv) was coupled with the appropriate sulfonamide under basic conditions (Route 2, Figure 3.3). 
This route gave the expected ligand as the main product, and the side-products were readily 
removed by column chromatography. These isolated ligands were treated with cis-Pt(DMSO)2Cl2 
in methanol at reflux to obtain the neutral Pt(II) complexes in this study, 5–8 (Figure 3.4). Using 
a synthesis similar to that reported for [Re(CO)3(N(SO2R)dpa)]PF6,
4 we obtained 
[Re(CO)3(N(SO2R)Mendpa)]PF6 complexes 9–12 (Figure 3.5).  
 
Figure 3.4. General reaction conditions for forming complexes 5-8. 
X-ray Structural Results. Crystal data and details of the structural refinement for Pt (5, 
6, 8 and 8a) and Re (9 and 12) complexes are summarized in Table 3.1. The ORTEP plots 5, 6, 8, 
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and 8a and cations of 9 and 12 (Figures 3.6 and 3.7) show the numbering system used to describe 
the solid-state data. Selected bond lengths and angles are reported in Tables 3.2 and 3.3. Crystals 
of 6 contain two independent molecules in the asymmetric unit, only one of which (B) is shown in 
Figure 3.6 and used in the discussion. Structural metrics of the two halves of complex 8 are slightly 
different in the solid state and are reported separately in Table 3.2 as Pt1 and Pt2.  
The molecular structures (Figure 3.6) and other properties of the pseudo octahedral 
complexes, [Re(CO)3(N(SO2Me)3,3',5,5'-Me4dpa)]PF6 (9) and [Re(CO)3(N(SO2Tol)6,6'-
Me2dpa)]PF6 (12), are compared to features of the new Pt(II) complexes below. In 9 and 12, all 
three nitrogen atoms of the tridentate ligands (1 and 4, respectively) occupy one face, and the three 
carbonyl ligands occupy the other face. The lengths of the Re−N(sulfonamide) bonds (Table 3.3) 
in both complexes are in the typical range (∼2.23−2.29 Å) reported for Re−N(sp3) bonds.63-64 The 
Re−N1 and Re−N3 bond distances in 9 are in the typical range (2.14−2.18 Å) for Re−N(sp2) 
bonds.4,63,65-66 However, 12 has significantly longer Re−N1 and Re−N3 bonds [2.228(3) Å]), an 
observation we attribute to the steric effect of the ortho methyl groups of ligand 4, as discussed 
later. 
 




Table 3.1. Crystal Data and Structure Refinement for Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5), Pt(N(SO2Tol)3,3',5,5'-Me4dpa)Cl2 (6), 
[trans-Pt(DMSO)Cl2]2(N(SO2Tol)6,6'-Me2dpa) (8), [trans-Pt(DMSO)Cl2](N(SO2Tol)6,6'-Me2dpa) (8a), 
[Re(CO)3(N(SO2Me)3,3',5,5'-Me4dpa)]PF6 (9), and [Re(CO)3(N(SO2Tol)6,6'-Me2dpa)]PF6 (12) 















fw 599.43 675.52 1069.72 725.60 748.64 837.74 
crystal system triclinic triclinic triclinic monoclinic monoclinic triclinic 
space group Pī Pī Pī P21/n P21/c Pī 
a (Å) 9.3872(5) 9.6341(13) 11.1641(13) 13.4349(2) 18.3654(18) 7.9263(7)  
b (Å) 10.7446(6) 15.4229(18) 13.1322(16) 10.4611(2) 10.1944(10) 13.2608(12)  
c (Å) 11.0369(6) 17.847(2) 13.7223(16) 20.4190(4) 13.5371(13) 14.6563(12)  
α (deg) 85.528(3) 66.561(5) 68.349(7) 90 90 90.652(5) 
 (deg) 84.236(3) 82.411(7) 70.784(7) 108.118(1) 105.056(5) 91.950(5) 
γ (deg) 79.345(3) 80.900(5) 68.683(7) 90 90 106.425(5) 
V (Å3) 1086.47(10) 2395.3(5) 1697.2(4) 2727.48(9) 2447.5(4) 1476.4(2) 
T (K) 110 105 99 102 111 100 
Z 2 4 2 4 4 2 
calc (g/m3) 1.832 1.873 2.093 1.767 2.032 1.884 
abs coeff (mm-1) 6.82 6.19 8.77 5.52 5.20 4.32 
(Table 3.1. continued)      
63 
 
 5 6 8 8a 9 12 
2max () 78.4 61.0 66.6 80.6 52.8 61.0 
R[F2>2σ(F2)] 0.025 0.028 0.062 0.020 0.022 0.031 
Rw 0.068 0.060 0.180 0.047 0.046 0.079 
res. dens. (e Å-3) 2.85, -1.45 0.92, -1.16 7.91, -4.42 1.51, -1.30 0.97, -0.63 2.74, -2.08 
data/parameters 12704/240 14452/587 12716/377 17149/312 4987/339 8815/401 
a R = (||F| - |Fc||)/|F|. 
b Rw = [[w(F2 - Fc





















Figure 3.6. ORTEP plots of complexes Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5) and 
Pt(N(SO2Tol)3,3',5,5'-Me4dpa)Cl2 (6) and cations of [Re(CO)3(N(SO2Me)3,3',5,5'-Me4dpa)]PF6 
(9) and [Re(CO)3(N(SO2Tol)6,6'-Me2dpa)]PF6 (12). Thermal ellipsoids are drawn with 50% 
probability. 
In contrast to the findings with the [Re(CO)3(N(SO2R)Mendpa)]PF6 complexes 9–12, 
molecular structures of the pseudo square planar Pt(II) complexes of ligands 1, 2 and 4 reveal that 
the sulfonamide N does not form a Pt−N bond in any of the complexes (5, 6, 8 and 8a, Figures 3.6 
and 3.7). The only Pt−N bonds found involve a pyridyl group, and all Pt−N bonds have lengths 
(Table 3.2) falling in the range typically reported for Pt−N(sp2) bonds (1.99−2.08 Å).27,67 The 
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bidentate coordination mode in Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2 complexes (5, R = Me and 6, R = 
Tol, Figure 3.6) creates a relatively large and uncommon 8-membered chelate ring. The 
N(SO2R)6,6'-Me2dpa ligands, 3 and 4, do not bind to Pt(II) as chelate ligands, and the complexes 
formed are discussed later. 
 
Figure 3.7. ORTEP plots of complexes [trans-Pt(DMSO)Cl2]2(N(SO2Tol)6,6'-Me2dpa) (8) and 
[trans-Pt(DMSO)Cl2](N(SO2Tol)6,6'-Me2dpa) (8a). Thermal ellipsoids are drawn with 50% 
probability. 
 
Structural Features Arising from the Different Chelate Binding Modes of Re(I) and 
Pt(II) Complexes. The angles around the sulfonamide N in the Re(I) complexes, 9 and 12, are 
close to tetrahedral values (Table 3.3), indicating that the sulfonamide N hybridization changed 
from sp2 to sp3. When a tertiary sulfonamide N is bound to Re(I)4-5 or to other metals [e.g., Mn(I), 
Cu(II), Ni(II), Co(II)],1,18-19,68-69 the angles around the sulfonamide N atom are consistent with sp3 
hybridization. In contrast, the angles around the tertiary sulfonamide N in 5 and 6 (Table 3.2) are 
closer to 120° than to 109.5° (tetrahedral geometry), indicating that sp2 hybridization for the 




Table 3.2. Selected Bond Distances (Å) and Angles (deg) for Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 
(5), Pt(N(SO2Tol)3,3',5,5'-Me4dpa)Cl2 (6), [trans-Pt(DMSO)Cl2]2(N(SO2Tol)6,6'-Me2dpa) (8), 
and [trans-Pt(DMSO)Cl2](N(SO2Tol)6,6'-Me2dpa) (8a) 
 
  5 6 (B) 8 8a 
   Pt1 Pt2  
Pt–N1 2.023(2) 2.027(3) 2.062(9) - 2.0757(9) 
Pt−N2a 3.693(2) 3.317(3) 3.744(8) 4.51(1) 4.5556(9) 
Pt–N3 2.031(2) 2.032(3) - 2.066(8) - 
Pt–Cl1/3 2.2939(6) 2.2888(8) 2.303(2) 2.297(2) 2.2922(3) 
Pt–Cl2/4 2.2990(6) 2.3009(8) 2.304(2) 2.320(3) 2.3030(3) 




S1–O2 1.435(3) 1.434(3) 1.4327(9) 
N2–S1 1.6565(19) 1.630(3) 1.6390(10) 
Pt–S2/3 - - 2.217(3) 2.219(3) 2.2218(3) 
      
N1–Pt–N3 87.98(8) 95.21(10) - - 




S1–N2–C7 113.83(17) 117.0(2) 118.66(7) 
C6–N2–C7 114.78(17) 121.30(2) 116.15(9) 
N1–Pt–Cl2/4 176.99(6) 176.62(8) 89.4(2) - 89.70(3) 
N1−Pt−Cl1/3 89.51(6) 86.18(8) 86.9(2) - 87.15(3) 
N3–Pt–Cl1/3 175.88(6) 178.51(7) - 86.2(2) - 
N3−Pt−Cl2/4 90.22(6) 86.92(8) - 89.4(2) - 
Cl1/3–Pt–Cl2/4 92.15(2) 90.66(3) 176.05(9) 175.57(9) 175.68(12) 
dihedral angleb 77.18, 82.61 86.47, 87.17 75.13 82.91 85.23 
Pt−N−centroid 174.82, 174.23 169.84, 166.56 173.49 179.52 174.16 
N1−N3a 2.816(3) 2.998(4) 5.15(1) 4.632(1) 
aNon-bonded distance between the two atoms. bAngle between the coordination plane (defined 





Table 3.3. Selected Bond Distances (Å) and Angles (deg) for [Re(CO)3(N(SO2Me)3,3',5,5'-
Me4dpa)]PF6 (9), and [Re(CO)3(N(SO2Tol)6,6'-Me2dpa)]PF6 (12) 
  9 12 
Re–N1 2.180(3) 2.228(3) 
Re–N2 2.253(3) 2.263(3) 
Re–N3 2.176(3) 2.228(3) 
Re–C1 1.926(4) 1.933(3) 
Re–C2 1.899(4) 1.917(3) 
Re–C3 1.919(3) 1.919(3) 
S1–O4 1.431(2) 1.428(3) 
S1–O5 1.425(2) 1.428(3) 
N2–S1 1.749(3) 1.752(3) 
   
N1–Re–N2 74.21(10) 74.38(10) 
N1–Re–N3 89.37(9) 90.49(10) 
N2–Re–N3 77.26(9) 77.19(10) 
S1–N2–C9 111.34(19) 111.2(2) 
S1–N2–C10 110.4(2) 110.9(2) 
C9–N2–C10 109.9(2) 109.0(2) 
Re–N2–S1 109.34(13) 111.31(13) 
Re–N2–C9 105.51(18) 104.27(18) 
Re–N2–C10 110.26(18) 109.93(19) 
N1–Re–C2 96.13(13) 100.28(12) 
N1–Re–C3 90.02(12) 87.33(12) 
N3–Re–C2 98.31(12) 103.07(13) 
N3–Re–C1 91.59(12) 90.49(10) 
dihedral anglea 74.23, 77.72 72.18, 79.53 
Re−N−centroid 173.88, 173.92 171.33, 171.64 
N1−N3b 3.063(4) 3.164(4) 
aAngle between the coordination plane (defined by the Re, N1, N3, O1 and O3 atoms) and 
the pyridyl ring planes. bNon-bonded distance between the two atoms. 
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The N−S bond distances are generally longer (1.73−1.78 Å)1,4,18-19,68-69 in metal complexes 
with an N-coordinated tertiary sulfonamide than in complexes with an uncoordinated sulfonamide 
N (1.62−1.64 Å).1,4,68,70 Accordingly, the N−S bond distances in the Pt(II) complexes reported here 
are shorter than those for Re(I) complexes (Tables 3.2 and 3.3). Shorter N−S bond distances in an 
uncoordinated sulfonamide group indicate a considerable amount of double-bond character of the 
N−S bond owing to the delocalization of the lone pair of the N atom.1,4,71  
Coordination geometry could be another factor leading to the different chelate ligand 
binding modes in the new Pt(II) and Re(I) complexes. The N(SO2R)dpa-type ligands (including 1-




+).4,18-19 In these 
complexes, the metal atom and the three donor N atoms (sulfonamide N and the two N atoms of 
the adjacent pyridyl rings) do not define a common plane: the three N-donor atoms are facially 
coordinated. Similarly, in almost all of the metal complexes in which the metal is bound to a 
tertiary sulfonamide nitrogen, the three N-donor atoms occupy the face of an octahedron or have 
a similar arrangement in complexes with other geometries (such as distorted trigonal bipyramidal 
or square pyramidal).4,18,72 In square-planar Pt(II) complexes, the central donor atom of a tridentate 
ligand forming two 5-membered chelate rings must be able to accommodate the meridional 
coordination mode. A clear case in which a tertiary sulfonamide group anchors two chelate rings 
having a meridional disposition has been reported for a square planar Cu(II) complex of a 
derivative of cyclam (a cyclic tetradentate macrocyclic N-donor ligand with alternating 5- and 6-
membered chelate rings).72  One of the four donor nitrogens in the derivative bears a tosyl 
group. The angles and other parameters involving the sulfonamide N are normal for a coordinated 
sulfonamide. Even in this case with 5- and 6-membered chelate rings anchored by the sulfonamide 
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N, the complex is distorted relative to the complex of the parent cyclam lacking the tosyl group.  In 
the complex having the tosyl group, the Cu(II) atom deviates by ~0.2 Å from the planes defined 
either by all four ligating N atoms or by any three ligating N atoms. However, in the cyclam 
complex, the Cu(II) atom lies in all such planes (deviation ~0.002 Å). We believe that our analysis 
of this reported data makes a strong case that there is a steric requirement that the N of a tertiary 
sulfonamide group with two adjacent 5-membered chelate rings must anchor a facially coordinated 
rather than a meridionally coordinated tridentate ligand. 
Hence, ligands 1 and 2 coordinate bidentately in Pt(II) complexes 5 and 6, respectively. 
Comparison of Structural Features of the New Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2 
Complexes with Other Bifunctional Pt(II) Complexes. The 8-membered chelate ring in 
the Pt(N(SO2R)Mendpa)Cl2  complexes is a rare and hence interesting feature. Indeed, only limited 
types of Pt(II) complexes containing 8-membered chelate rings have molecular structures reported 
in the Cambridge Crystallographic Data Centre (CCDC). Most examples have very closely related 
bidentate ligand derivatives with Pt(II) bound to the pyridyl N of a fused bicyclic 7-azaindo-1-yl 
group.45-46,49 Only one Pt(II) complex contains a linear ligand terminated with two simple aromatic 
rings (pyridyl). Other complexes commonly have macrocyclic N-donor (mostly sp3) ligands 
bound in a bidentate mode.47-48 We found that there are only three Pt(II) complexes of 8-membered 
chelate rings containing two aromatic ring nitrogens (pyridyl/imidazolyl) and two halides as the 
other ligating atoms listed in the CCDC data base;48-50 in contrast, there are seven, seventeen and 
one hundred eight for 7-, 6-, and 5-membered chelate rings, respectively.28-44 Data for fifty-
three complexes (all of the complexes containing 8-, 7- and 6-membered chelate rings, plus 
twenty-six randomly chosen complexes of 5-membered chelate rings) were utilized in the 
following structural comparisons with the structural data for 5 and 6.  
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In bifunctional Pt(II) complexes with two cis aromatic planar N-donor rings (one bidentate 
or two monodentate), the tilting of each ring can be gauged by the dihedral angle between the plane 
of the aromatic ring (defined by the C and N atoms in the ring) and the coordination plane (defined 
by Pt and the four ligating atoms). If the dihedral angle is close to 90°, the aromatic ring is 
described as not being tilted. As the angle decreases, the ring is said to become more tilted. The 
two pyridyl rings in 5 and 6 are only slightly tilted, with the dihedral angles ranging from 77° to 
87° (Table 3.2); thus, the 8-membered ring allows the pyridyl rings to be oriented roughly 
perpendicular to the coordination plane. In contrast, other known bifunctional Pt(II) complexes 
with a bidentate ligand terminated by pyridyl or imidazolyl rings [and the remaining coordination 
site(s) occupied by halide(s)] and forming 5-, 6-, or 7-membered chelate rings28-44 have relatively 
smaller average dihedral angles (Figure 3.8). However, the three known Pt(II) complexes with 8-
membered chelate rings48-50 used in the plot have high dihedral angles (73−89°), values close to  
 
Figure 3.8. Relationship between the average dihedral angle (blue line, left axis, degrees) and the 
chelate ring size plotted for the reported molecular structures of bifunctional platinum(II) 
complexes with linear bidentate ligands terminated by pyridyl or imidazolyl donor rings (the 
remaining two coordination sites are occupied by halide ligands). The orange line shows the 
number of donor rings utilized for each chelate ring size. The red dot shows the average (83.4°) of 
the dihedral angles for 5 and 6. Note: All published data in this figure and in Figure 3.9 are from 
the Cambridge Crystallographic Data Centre, ConQuest 1.19. Of the 108 structures available for 
complexes with a 5-membered chelate ring, data from 26 randomly selected structures were used 
to prepare the plot. 
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the dihedral angles observed in the complexes reported here (Figure 3.8). Furthermore, the dihedral 
angles of the known bifunctional Pt(II) complexes increase almost linearly with increasing chelate 
ring size (Figure 3.8). Therefore, the low degree of tilting in 5 and 6 reflects the structural freedom 
allowed by the relatively large 8-membered chelate ring.  
The N1−Pt−N3 bite angle of 5 (87.98°) is at the high end of the range (78° to 91°) in reports 
for Pt complexes with mono- or bidentately coordinated ligands terminated by pyridyl or 
imidazolyl rings.28-55 Known Pt complexes containing 8-membered chelate rings have higher bite 
angles (average 89.5°) than the average bite angle values of the Pt complexes containing smaller 
chelate rings (Figure 3.9).28-50 In fact, the bite angles of the complexes with 8-membered chelate 
rings are quite close to the corresponding angles observed in monodentate complexes (average 
89.4°).51-55 We attribute this finding to the greater spatial freedom provided by the large chelate 
ring; this freedom allows the rings to be located in the same relative position as monodentate 
ligands. Complex 6 has a high bite angle (95.21°) but this may be a solid-state effect because the 
solution behavior of 6 is close to that of 5, see below.  
 
Figure 3.9. Relationship of the average N−Pt−N bite angle (degrees, from reported molecular 
structures) to the chelate ring size of bifunctional Pt(II) complexes of bidentate ligands terminated 
by pyridyl or imidazolyl donor rings (with the remaining coordination sites occupied by halide 
ligands). Note: of the 108 structures available for complexes with a 5-membered chelate ring, data 
from 26 randomly selected structures were used to prepare the plot. The average (89.4°) of the bite 
angles for 8 cis bifunctional Pt(II) complexes of monodentately bound pyridyl or imidazolyl rings 
is shown by the red dot in the figure for comparison. 
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In an ideal situation, the lone pair of the N atom in the ring of an aromatic N donor ligand 
is positioned directly toward the Pt(II) center to allow excellent overlap of bonding orbitals, 
thereby creating a strong bond. The angle between the N-donor aromatic ring plane and the Pt 
atom is a good structural parameter for assessing how close the Pt is to being in this plane. This 
angle can be defined as Pt−N−centroid angle (N = N1 or N3, centroid = aromatic ring center). 
When this angle is ~180°, the Pt atom lies in the plane of the aromatic ring.  The Pt−N−centroid 
angle ranges from 164−180° for known Pt(II) complexes of imidazolyl or pyridyl ligands bound 
monodentately, bidentately, or tridentately;27-57,73-80 for 5 this angle is >174° (Table 3.2). This 
finding is another indication that the large chelate rings permit the pyridine rings to adopt a location 
for binding with the same freedom as that of monodentate ligands (Supporting Information). 
NMR Spectroscopy. All of the complexes (in DMSO-d6) and ligands (in CDCl3 and 
DMSO-d6) reported here were characterized by 
1H NMR spectroscopy. In freshly prepared 
DMSO-d6 solutions, all of the new complexes gave one set of signals, consistent with the presence 
of one time-averaged symmetrical complex and agreeing with the solid-state molecular structure, 
when it was available.  The atom-numbering scheme in Figure 3.2 was used for NMR data. Signals 
were assigned by analyzing their chemical shifts, splitting pattern, integration, and data from 1H-
1H ROESY NMR experiments (the ROESY spectra of selected complexes are presented in 
Supporting Information). 1H NMR data and assignments appear in the Experimental Section; see 
also Table 3.4 for selected data. 
Effects of Coordination Binding Mode on the Methylene 1H NMR Signals of 1 to 4. Inversion 
at the sulfonamide N of ligands 1 to 4 leads to time averaging and makes the methylene protons 
magnetically equivalent, and the methylene 1H NMR signal is a singlet. When the ligand is 
coordinated bidentately (as in the Pt(II) complexes 5 and 6) or tridentately (as in the Re(I) 
73 
 
complexes 9−12), the methylene protons are no longer made equivalent by a time-averaging 
process. The protons projecting toward and away from the Cl or CO ligands are designated as 
endo-CH and exo-CH protons, respectively (Figure 3.10). The endo-CH and exo-CH protons in 
the complexes produce either an AB pattern or two doublets in 1H NMR spectra (Figure 3.11 and 
Supporting Information). Similar methylene group NMR features have been reported for Pd(II),70 
Pt(II),26-27,56 and Re(I)4-5 complexes. Whereas an AB pattern or two doublets for the methylene 
signals is a good indication that the bound ligand is symmetrical, the observation of an AB pattern 
or two doublets cannot be used to distinguish between a bidentate or tridentate coordination mode. 
The assignment of the AB features/doublets as endo-CH or exo-CH for 5 and 6 (explained in 
Supporting Information) can be found in Figure 3.11 and in Table 3.4. The 1H NMR assignments 
of the methylene signals of  [Re(CO)3(N(SO2R)Mendpa)]PF6 (9−12, Table 3.4) were based on 
ROESY spectra, and the approach to the assignments followed the rationale used for 5, 6, and for 
the previously reported [Re(CO)3(N(SO2R)dpa)]PF6 complexes.
4  
 
Figure 3.10. Designation of the methylene endo-CH and exo-CH protons, illustrated for the 
structure of Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5).  
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Table 3.4. Selected 1H NMR Chemical Shifts for the N(SO2R)Mendpa Free Ligands (1-4) and for Their Pt(II) (5-8a) and Re(I) (9-12) 
Complexes (ppm, DMSO-d6, 25 °C) 
complex/ 





1 8.17 - 7.33 - 4.45 - 2.12 2.23 3.13 
5 8.98 - 7.56 - 5.99a, 5.37b - 2.23 2.37 3.35 
9 8.60 - 7.75 - 5.29a, 5.07b - 2.29 2.34 3.96 
      -    
2 7.94 - 7.21 - 4.41  2.13 2.16 - 
6 8.90 - 7.56 - 5.55b, 5.47a - 2.21 2.45 - 
10 8.63 - 7.72 - 5.48a, 4.55b - 2.20 2.28 - 
      -    
3 - 7.12 7.63 7.12 4.42 2.41 - - 3.14 
7 - 7.46 7.85 7.68 5.55 3.12 - - 3.33 
7a - 7.49c, 7.16d 7.97c, 7.60d 7.57c, 7.18d 5.44c, 4.52d 3.23c, 2.44d - - 3.22 
11 - 7.47 8.06 7.65 5.36a, 5.03b 2.88 - - 3.90 
          
4 - 7.04 7.53 7.04 4.43 2.28 - - - 
8 - 7.43 7.76 7.57 5.46 3.11 - - - 
8a - 7.42c, 7.04d 7.88c, 7.54d 7.49c, 7.14d 5.40c, 4.50d 3.09c, 2.27d - - - 





From the NMR data for 5 and 9−12 and for the previously reported 
[Re(CO)3(N(SO2R)dpa)]PF6,
4 [Pt(N(H)dpa)]Cl,26 and [Pt(N(H)6,6'-Me2dpa)]Cl
56-57 complexes, 
the endo-CH signal is normally clearly downfield of the exo-CH signal for both Pt(II) and Re(I) 
complexes. The only exception is the endo-CH signal (5.47 ppm) of 6, which is slightly upfield of 
the exo-CH signal (5.55 ppm) at 25 °C. These signals appear in an overlapped AB pattern, and the 
assignments were aided by a study of temperature dependence of the chemical shifts (Supporting 
Information). 
 
Figure 3.11. Selected region of 1H NMR spectra in DMSO-d6 at 25 °C (shifts in ppm) of (a) 
N(SO2Me)3,3',5,5'-Me4dpa (1); (b) Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5); (c) 
[Re(CO)3(N(SO2Me)3,3',5,5'-Me4dpa)]PF6 (9); (d) N(SO2Tol)3,3',5,5'-Me4dpa (2); (e) 
Pt(N(SO2Tol)3,3',5,5'-Me4dpa)Cl2 (6); and (f) Re(CO)3(N(SO2Tol)3,3',5,5'-Me4dpa)]PF6 (10). 
The structures of [trans-Pt(DMSO)Cl2]2(N(SO2Tol)6,6'-Me2dpa) (8) and [trans-
Pt(DMSO)Cl2](N(SO2Tol)6,6'-Me2dpa) (8a) (Figure 3.7) and the NMR data for complexes 7, 7a, 
8, and 8a establish that, unlike 1 and 2, the N(SO2R)6,6'-Me2dpa ligands (3, R = Me and 4, R = 
Tol) coordinate monodentately (not bidentately) to the Pt(II) center to form binuclear or 





quality crystals of 8 or of 8a in DMSO-d6 are consistent with symmetric binuclear and 
unsymmetric mononuclear complexes, respectively. Also, the signal corresponding to the 
methylene protons is a singlet (Figure 3.12), indicating that ligand 4 coordinates monodentately to 
Pt(II) (Figure 3.7). The methylene signal remains a singlet, as occurs in the free ligands, because 
inversion at the sulfonamide N (N2) is not inhibited when the ligand is bound monodentately. 
Similar NMR features were observed for 7 (Table 3.4, Figure 3.12), thus confirming that ligand 3 
(N(SO2Me)6,6'-Me2dpa) forms a binuclear complex similar to 8.  
 
Figure 3.12. Selected region of 1H NMR spectra in DMSO-d6 at 25 °C (shifts in ppm) of (a) 
N(SO2Me)6,6'-Me2dpa (3), (b) [trans-Pt(DMSO)Cl2]2(N(SO2Me)6,6'-Me2dpa) (7), (c) 
N(SO2Tol)6,6'-Me2dpa (4), (d) [trans-Pt(DMSO)Cl2]2(N(SO2Tol)6,6'-Me2dpa) (8) and (e) [trans-
Pt(DMSO)Cl2](N(SO2Tol)6,6'-Me2dpa) (8a). Line drawing of 8a shown on the right. 
The methylene singlets at 4.42 ppm in 3 and 4.43 ppm in 4 have shifted downfield upon 
Pt(II) metal binding to 5.55 ppm in 7 and to 5.46 ppm in 8 (Figure 3.12). Furthermore, in the 
mononuclear Pt(II) compound (8a) with ligand 4 bound monodentately and unsymmetrically 
(Figure 3.7), the methylene protons produce two singlets (Figure 3.12). From the characteristic 
shift, the more downfield singlet (5.40 ppm) is assigned to CH2bound (the methylene group attached 





has a shift close to that of the free ligand methylene signal (4.42 ppm) and thus is assigned to 
CH2dangling. Even though the compound 7a was not isolated, it is undoubtedly the analog of 8a, 
from the methylene singlets at 5.44 (CH2bound) and 4.52 ppm (CH2dangling). 
Other 1H NMR Signal Assignments for Pt and Re Complexes. The 1H NMR 
assignments of [Re(CO)3(N(SO2R)Mendpa)]PF6 (9−12) were based on ROESY spectra 
(Supporting Information) and arguments similar to those used for the previously reported 
[Re(CO)3(N(SO2R)dpa)]PF6 complexes;
4 this assignment approach is also illustrated next for the 
Pt(II) chelate complexes, 5 and  6.  
The observation of one set of 1H NMR signals within 10 min of dissolution of 
Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5, 10 mM) in DMSO-d6 (Figure 3.11) indicates that 5 dissolves 
as one species. The signals are consistent with a symmetrical complex, such as the dichloro 
complex. For example, there is one aromatic singlet at 8.98 ppm with a shift and intensity of two 
protons consistent with assignment of the peak to H6/6' of 5. This assignment is confirmed by an 
NOE cross-peak to one of the two pyridyl ring methyl singlets (at 2.23 ppm, integrating to 6 
protons) in a ROESY spectrum of 5 in DMSO-d6 (Supporting Information). This pyridyl ring 
methyl singlet can be assigned to 5/5'-Me because it is the only methyl group near the H6/6' 
protons, and thus the other pyridyl ring methyl singlet (2.37 ppm) can be assigned to the 3/3'-Me. 
The more upfield aromatic singlet at 7.56 ppm has NOE cross-peaks to both 3/3'-Me and 5/5'-Me 
singlets and thus can be assigned to the H4/4' protons. The 1H NMR signals for 
Pt(N(SO2Tol)3,3',5,5'-Me4dpa)Cl2 (6) likewise occur as one set, indicating that fresh solutions 
contain the symmetrical dichloro complex. The 1H NMR signals for 6 were assigned as for 5, by 
using a ROESY spectrum of 6 in DMSO-d6 (Supporting Information). (The p-tolyl group 





H2/6 signal was identified as the doublet at 8.03 ppm from an NOE cross-peak to the methylene 
AB feature.  
Assignments of the methylene signals of 7, 8, 7a, and 8a in DMSO-d6 were discussed 
above. Other signals were assigned by using ROESY spectra (Supporting Information). All 
spectral features of fresh solutions are consistent with a single complex that has the molecular 
structure expected from the solid-state data (Figure 3.7). The only triplet in the 1H NMR spectrum 
of 7 is assigned to the H4/4' protons (Figure 3.12). Singlets at 3.12, 3.33 and 5.55 ppm are 
respectively assigned to the 6/6'-Me, the sulfonamide methyl (SO2Me), and the methylene groups, 
based on the integration (6, 3, and 4 protons, respectively). In the ROESY spectrum 
of 7 (Supporting Information), the more upfield (7.46 ppm) of the two aromatic doublets has NOE 
cross-peaks to the 6/6'-Me signal and the H4/4' signal and can thus be assigned to H5/5'. The other 
aromatic doublet (7.68 ppm) is therefore assigned to H3/3', an assignment further supported by the 
observed NOE cross-peaks from this signal to the H4/4', the SO2Me, and the methylene 
signals. The 1H NMR ROESY spectrum of 8 (Supporting Information) was used for assignments 
in a similar way as for 7. 
The atom-numbering scheme for 8a shown in Figure 3.12 is used to discuss the NMR data. 
In the ROESY spectrum of 8a (Supporting Information), a doublet at 7.14 ppm shows NOE cross-
peaks to the two methylene singlets (the NOE cross-peak to the CH2dangling is stronger than the NOE 
peak to the CH2bound) and is assigned to H3dangling. This doublet has an NOE cross-peak to the triplet 
at 7.54 ppm, which can be assigned to H4dangling, because only the H4 protons are close to the H3 
protons and can produce triplet peaks. Therefore, the other triplet in the spectrum (at 7.88 ppm) 
can be assigned to H4bound. The H4dangling peak has an NOE cross-peak to the doublet at 7.04 ppm, 





(H5dangling) has an NOE cross-peak to a singlet at 2.27 ppm (integrating to 3 protons), which can 
be assigned to 6-Medangling. There are two more singlets with similar integrations in the aliphatic 
region at 3.09 and 2.41 ppm. The singlet at 3.09 ppm can be assigned to 6-Mebound, because it has 
a similar shift to the 6/6'-Me singlet of 8. Therefore, the other singlet at 2.41 ppm can be assigned 
to the tolyl Me group. The H4bound triplet has two NOE cross-peaks to two doublets at 7.49 and 
7.42 ppm. The doublet at 7.49 ppm (integrating to one proton) has an NOE cross-peak to the 
CH2bound singlet, thus can be assigned to H3bound. The doublet at 7.42 ppm integrates for three 
protons, indicating that it consists of overlapping aromatic signals. This doublet has NOE cross-
peaks to the 6-Mebound and to the tolyl-Me signals, indicating that the doublet is a combination of 
the H5bound and H3/5 signals. Furthermore, this doublet has another NOE cross-peak to a doublet 
at 7.78 ppm (with an integration of 2 protons), which can be assigned to H2/6 in the tolyl group.  
Because all of the 1H NMR peaks of 7a have chemical shifts similar to those of 8a and are 
consistent with the unsymmetrically bound ligand 3 (Table 3.4), the 7a signals were assigned as 
for 8a. As an example, two triplets corresponding to the H4/4' protons in 7a are observed at 7.97 
(for H4bound) and at 7.60 ppm (for H4dangling). Note that because of rapid inversion at the 
sulfonamide N in the dangling group, 7a and 8a have time-averaged symmetry. 
Solution Studies of 1H NMR Spectral Features and Robustness of Pt(II) and Re(I) 
Complexes of N(SO2R)3,3',5,5'-Me4dpa Ligands 1 and 2. All of the corresponding 1H NMR 
signals of ligands 1 and 2 are shifted downfield in Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2 (5 and 6) and 
[Re(CO)3(N(SO2R)3,3',5,5'-Me4dpa)]PF6 (9 and 10) (Table 3.4). The 
1H NMR spectra of the 
complexes 5 and 9 of ligand 1 (having R = Me) are less complicated than the spectra of the 
complexes 6 and 10 of ligand 2 (having R = Tol). Hence, the data for 5 and 9 are utilized here for 





upon formation of Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5) and by 0.41 ppm upon formation of 
[Re(CO)3(N(SO2Me)3,3',5,5'-Me4dpa)]PF6 (9). The greater downfield shift of the H6/6' singlet 
of 5 compared to the shift of 9 is a result of the greater electron-withdrawing inductive effect of 
Pt(II) when compared to Re(I).4 The J coupling constants (15−17 Hz) of the methylene doublets 
are similar for the Pt(II) and Re(I) complexes. Regardless of the coordination mode, the chemical 
shifts of the methylene proton signals for a given carrier ligand are more downfield when bound 
to Pt(II) than when bound to Re(I) (Table 3.4). For example, the chemical shifts of the endo-CH 
and exo-CH signals are at 5.99 and 5.37 ppm in 5 at 5.29 and 5.07 ppm in 9. 
The downfield shift change of the sulfonamide methyl (SO2Me) singlet observed for ligand 
1 upon metal coordination is 0.83 ppm for [Re(CO)3(N(SO2Me)3,3',5,5'-Me4dpa)]PF6 (9) and 0.22 
ppm for Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5). This difference can be attributed to the inductive 
effect acting through the direct Re−N(sulfonamide) bond in 9, compared to the transmission of the 
inductive effect of Pt(II) through several bonds in 5. This SO2Me signal is thus diagnostic of 
sulfonamide metal binding. Although complexes of ligand 2 have more complicated NMR spectra 
owing to the Tol group, the observations noted for ligand 1 complexes apply also to ligand 2 
complexes. These results show that the pyridyl groups of ligands 1 and 2 can adopt a position very 
favorable for bonding to Pt(II) and that such interactions lead to good electron donation from the 
pyridyl groups to Pt(II) in complexes 5 and 6. 
1H NMR spectra of 10 mM solutions of [Re(CO)3(N(SO2Me)3,3',5,5'-Me4dpa)]PF6 (9) and 
[Re(CO)3(N(SO2Tol)3,3',5,5'-Me4dpa)]PF6 (10) in DMSO-d6 show no change even after more than 
3 years, indicating that the Re(I) complexes of ligands 1 and 2 are very robust. The Pt(II) 
complexes Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2 (5 and 6) of these ligands in DMSO-d6, however, are 





because 5 has fewer and simpler NMR signals than 6. One hour after "Solution 1" 
[Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5), 10 mM in DMSO-d6] was prepared, its spectrum showed, 
in addition to the peaks for 5, a small but detectable new set of 1H NMR peaks; these new peaks 
gradually increased with time (Figure 3.13). The intensity of the H6/6' singlet of 5 at 8.98 ppm 
gradually decreased. The presence of two new equally intense singlets arising at 9.17 and 8.76 
ppm indicates that the new product contains geometrically inequivalent pyridyl groups, both still 
bound to Pt(II). These new aromatic H6 and H6' signals are consistent with formation of the 
solvolysis product, [Pt(N(SO2Me)3,3',5,5'-Me4dpa)(DMSO-d6)Cl]
+ (5sol). Unlike the H6/6' 
protons, the H4/4' protons of 5sol appear as one overlapped signal (7.74 ppm) with an intensity 
twice that of the H6 or H6' signals. The H4/4' protons are located farther from the Pt(II) center 
than are the H6/6' protons, accounting for the presence of an overlapped H4/4' signal. A different 
solution (Solution 2) but otherwise identical to Solution 1 was allowed to sit for one day and then 
10 molar equiv of [Et4N]Cl was added. The 5sol peaks converted within 4 h almost completely to 
signals of the original dichloro complex 5 (Supporting Information). 
 
Figure 3.13. Selected region of 1H NMR spectra of Solution 1 (Pt(N(SO2Me)3,3′,5,5′-Me4dpa)Cl2 
(5) in DMSO-d6, 10 mM, 25 °C, shifts in ppm). Spectra at various times after dissolution of 5 
reveal its solvolysis to form [Pt(N(SO2Me)3,3',5,5'-Me4dpa)(DMSO)Cl]
+ (5sol, shown in line 





 This result further confirms that the new set of signals arises from [Pt(N(SO2Me)3,3',5,5'-
Me4dpa)(DMSO-d6)Cl]
+ (5sol). This conclusion is supported by the absence of the 5sol signals when 
solid 5 (10 mM) is dissolved in a DMSO-d6 solution containing 100 mM [Et4N]Cl (Solution 3). 
Other reported examples of mono-solvolysis in DMSO-d6 of Pt(II) dichloro complexes include 
complexes with a bidentate pyridyl ligand (Pt(bis(pyridine-2-yl)amine)Cl2),
43 a bidentate 
ethylenediamine (Pt(en)Cl2),
81 or a bidentate ligand bearing a deprotonated sulfonamide group 
(Pt(DNSH-dienH)Cl2).
10 
The changes over time in the species arising in solutions of 5 are revealing. In addition to 
the appearance of 5sol NMR signals in Solution 1 as just described, signals of the free 
N(SO2Me)3,3',5,5'-Me4dpa (1) ligand became detectable 4 h after 5 was dissolved in DMSO-d6 
(Figure 3.13). At 24 h, the ratio of 5:5sol:1 was 59:34:7 (Figure 3.14). At 9 d, the major species 
was 5sol (5:5sol:1 = 12:46:42); this is the equilibrium composition, as no further change in the ratio 
was detected even after 21 d. As discussed below, this finding indicates that the large chelate ring 
formed by ligand 1 in 5 leads to dissociation of the chelate even though the pyridyl rings interact 
favorably with Pt(II). 
 
Figure 3.14. Percent distribution of Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5, orange), 
[Pt(N(SO2Me)3,3',5,5'-Me4dpa)(DMSO)Cl]
+ (5sol, green), and free N(SO2Me)3,3',5,5'-Me4dpa (1, 
blue) in Solution 1 (10 mM solution of 5 in DMSO-d6) at 25 °C plotted versus time. Percent 





Solution 2, which was created from a one-day-old 10 mM solution of 5 in DMSO-d6 with 
NMR signals indicating 5:5sol:1 = 54:38:8, was also followed with time. When 10 molar equiv of 
[Et4N]Cl was added to this solution, the abundance of 5 increased (to 66%) and that of 5sol 
decreased (to 20%) during the first hour; thereafter the abundance of 5 began to decline 
(Supporting Information). By 24 h, almost no 5sol remained, while 42% of 5 remained. The 
decrease of 5 continued until the only NMR signals present were those for free 1 (~12 days). 
Solution 3 was made by dissolving 3.6 mg of solid 5 (10 mM) in a 100 mM [Et4N]Cl solution. At 
1 h, the amount of 5sol in Solution 3 was only 1%. For this solution, a maximum amount of 3% of 
5sol was detected in the spectrum recorded at 8 h, and by 24 h this amount had decreased again to 
1%. (In contrast, the abundance of 5sol reached 5% and 35% at 1 h and 24 h after the preparation 
of Solution 1 of 5, having no added [Et4N]Cl). In Solution 3, the 5sol peaks were no longer 
detectable by 3 d. Furthermore, 1H NMR peaks of free ligand 1 were first detected in the spectrum 
of Solution 3 recorded after 4 h, and these increased until 100% free 1 was present by ~12 days 
(Figure 3.15). Collectively this evidence indicates that the chloride ions facilitate ligand 1 
dissociation from 5 or 5sol.  
 
Figure 3.15. Percent distribution of Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5, orange), 
[Pt(N(SO2Me)3,3',5,5'-Me4dpa)(DMSO)Cl]
+ (5sol, green), and free N(SO2Me)3,3',5,5'-Me4dpa (1, 
blue) in Solution 3 [a mixture of 5 (3.6 mg, 1 molar equiv) added to a 100 mM solution of [Et4N]Cl 
in DMSO-d6] at 25 °C plotted versus time. Percent distribution values were calculated by using 





In another experiment, a freshly prepared 10 mM solution of ligand 1 was made by addition 
of 1.3 mg of 1 to 600 L of a cis-Pt(DMSO)2Cl2 (10 mM) and [Et4N]Cl (100 mM) solution in 
DMSO-d6. This "Solution 4" showed no NMR signals for 5 or 5sol even after 4 days, indicating 
that a high chloride ion concentration prevents 1 from coordinating to Pt(II). In contrast, when 
only ligand 1 and cis-Pt(DMSO)2Cl2 were mixed together in a 1:1 ratio (Solution 5, 10 mM) in 
DMSO-d6, NMR signals for 5sol were detectable in a spectrum recorded after 1 h. By 24 h after 
mixing, the 5:5sol:1 distribution was = 3:38:59, indicating that ligand 1 can coordinate to Pt(II) in 
the absence of an excess of competing chloride ions and that at 10 mM its affinity for Pt(II) is 
comparable to that of the DMSO-d6 solvent (the solvent molecule concentration is 14 M). 
NMR evidence for solvolysis and ligand dissociation over time as found for 5 in DMSO-
d6 solution was also observed for Pt(N(SO2Tol)3,3',5,5'-Me4dpa)Cl2 (6). Spectra recorded for a 
DMSO-d6 solution of 6 (10 mM) show signals for 6sol and 2 for the first time in 1 h and 4 h after 
dissolving, respectively. The equilibrated composition of this solution observed by 9 days (6:6sol:2 
= 17:51:32) is similar to the composition of 10 mM solution of 5, indicating that the dangling 
group has minimal influence on the robustness of these complexes. In contrast to the results in 
DMSO-d6, 5 and 6 show no sign of solvolysis or chelate ligand dissociation even after 7 d in DMF-
d7. Thus, 5 and 6 are rather robust in DMF-d7, although both are much less soluble in DMF-d7 than 
in DMSO-d6.  
Complexes 5 and 6, with a relatively large 8-membered chelate ring, exhibit low robustness 
in solution when compared to the known robust Pt(II) complexes of related ligands that have 5-
membered,26-28,57 6-membered33,43 or 7-membered55 chelate rings. However, the Pt−N−centroid 
angles of 5 are similar to the values of other bifunctional Pt(II) complexes of monodentate pyridyl 





These structural metrics as well as the greater downfield shifting of NMR signals noted above 
indicate that 5 has enthalpically favorable pyridyl-Pt bonding interactions; however, the 
unfavorable entropy component of an 8-membered chelate ring and possibly strain within the large 
chelate ring itself decrease the robustness of 5 and 6 in DMSO-d6. The relatively high robustness 
of 9 and 10 versus 5 and 6 can be attributed to a third bond, the Re−N(sulfonamide) bond, present 
in 9 and 10, which allows tridentate coordination to an octahedral face. 
The reactivity of Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5) with simple G derivatives, 9-MeG 
or Guo, was assessed at 25 °C. Because 5 is stable in DMF-d7, a 1:2.5 molar equiv mixture of 5 (5 
mM) and Guo in DMF-d7 (solution was cloudy because of poor solubility) was monitored by 
1H 
NMR spectroscopy. No reaction was detected even after 4 days. In DMSO-d6, 5 (10 mM) was 
treated with 2.5 molar equiv of 9-MeG or Guo. For both solutions, new 1H NMR peaks for 5sol and 
for free 1 were first detectable after ~1 h and ~4 h, respectively. These results are very similar to 
those observed in the absence of added 9-MeG or Guo.  Several new peaks consistent with the 
formation of G adducts were observed only at later times. However, even at 24 h the integration 
of these new peaks indicated a very low amount of G adduct formation as compared to reactions 
forming 5sol and free ligand 1. In addition, three reaction mixtures of 5 in DMSO-d6 solutions (10 
mM) with 2.5 molar equiv of ligands known to bind Pt(II) (1-methylimidazole, 5,5'-Me2bpy or 
Me4dt)
28,44,82
 were studied. During the first few hours, all three solutions exhibited new 
1H NMR 
peaks for 5sol and for free 1, which appeared over a time course similar to that found for solutions 
of 5. These results in DMF-d7 and DMSO-d6 indicate that G derivatives and other ligands do not 
promote chelate ring opening in 5. In contrast, 9-EtG (2.5 equiv) immediately promoted chelate 





D2O/DMSO-d6 mixture, pH ≈ 4, 25 °C).
57 The carrier ligand is bidentate in the adduct, 
[Pt(N(H)6,6'-Me2dpa)(9-EtG)2]
2+, indicating that 9-EtG facilitates chelate ring opening.57 
Solution Studies of 1H NMR Spectral Features and Robustness of Pt(II) and Re(I) 
Complexes of N(SO2R)6,6'-Me2dpa Ligands 3 and 4. All of the corresponding 1H NMR signals 
of ligands 3 and 4 are shifted downfield in [trans-Pt(DMSO)Cl2]2(N(SO2R)6,6'-Me2dpa) (7 and 8) 
and [Re(CO)3(N(SO2R)6,6'-Me2dpa)]PF6 (11 and 12) (Table 3.4). The 
1H NMR spectra of the 
complexes 7 and 11 of ligand 3 (having R = Me) are less complicated than those of 8 and 12 of 
ligand 4 (having R = Tol). Hence, the data for 7 and 11 are utilized here for comparison. 
As mentioned, [Re(CO)3(N(SO2R)3,3',5,5'-Me4dpa)]PF6 (9 and 10) are much more robust 
in DMSO-d6 than the Pt(II) complexes of the same ligands 1 and 2. However, a 
1H NMR spectrum 
of a 10 mM solution of [Re(CO)3(N(SO2Me)6,6'-Me2dpa)]PF6 (11) in DMSO-d6 recorded after 8 
d shows signals for free ligand 3 (9%, with no other signals except for the tridentately bound or 
free ligand signals). Similarly, a 12-days-old, 10 mM solution of [Re(CO)3(N(SO2Tol)6,6'-
Me2dpa)]PF6 (12) in DMSO-d6 also shows 16% of free ligand 4. Furthermore, the ~3-years-old 
solutions of 11 and 12 show signals for the corresponding free ligand only.  
Ligand dissociation from an octahedral Re(I) complex ordinarily occurs via a dissociative 
mechanism. In chelate complexes such as the [Re(CO)3(N(SO2R)Mendpa)]PF6 complexes, a 
terminal Re−N(sp2) bond is expected to be the first Re−N bond to start chelate ligand dissociation. 
This first step would be followed by solvent addition. Unlike the Re(I) complexes 11 and 12, 9 
and 10 do not show ligand dissociation, indicating that the carrier-ligand Re–N bonds are stronger 
in 9 and 10 than in 11 and 12. This conclusion is further supported by the normal Re−N bond 
distances observed for 9 (~2.18 Å; the typical Re−N(sp2) bond distance range is 2.14−2.18 





undergoes ligand dissociation, indicating that the Re−N bonds are weak and likely to break. A 
molecular structure of [Re(CO)3(N(H)6,6'-Me2dpa)]PF6 obtained by our group (unpublished) also 
shows relatively long terminal Re−N(sp2) bonds (2.23 Å). Furthermore, the molecular structures 
of [Re(CO)3(N(H)6,6'-Me2dpa)]PF6 and 12 overlap well when superimposed through Re and the 
three ligating N atoms, indicating that the structural features of the two complexes are similar. 
Also, the Re−N−centroid angles of the molecular structures of 9 (~174°) and 12 (~171°) are not 
very different from those angles for [Re(CO)3(N(H)6,6'-Me2dpa)]PF6 (169° and 173° for the two 
rings), indicating that the long terminal Re−N(sp2) bonds are not a result of the orientation of the 
pyridyl rings or the structural effects of the sulfonamide group. Therefore, we believe that the 
steric repulsion between the carbonyl ligands and the 6/6' Me groups in 3 and 4 weaken the 
Re−N(sp2) bonds, thereby facilitating the release of ligands 3 and 4 from complexes 11 and 12. 
The 1H NMR spectrum of a 1-day-old solution of [trans-Pt(DMSO)Cl2]2(N(SO2Tol)6,6'-
Me2dpa) (8) in DMSO-d6 (10 mM) shows new peaks corresponding to the mononuclear species 
[trans-Pt(DMSO)Cl2](N(SO2Tol)6,6'-Me2dpa) (8a). Peaks corresponding to the free ligand 4 were 
first observed after 5 days. The peaks of 8a and 4 grew with time; by 18 d, the composition of the 
8:8a:4 mixture was 37:56:7 (based on methylene signal integrations). Furthermore, a 1H NMR 
spectrum recorded for another ~3-year-old solution of 8 shows signals chiefly for the free ligand 
(~90%). Similarly, spectra recorded for a 10 mM solution of [trans-
Pt(DMSO)Cl2]2(N(SO2Me)6,6'-Me2dpa) (7) in DMSO-d6 also show that new peaks start 
appearing in 24 h. The chemical shifts of these new peaks (Table 3.4) indicate that they belong to 
the corresponding mononuclear species, 7a, as discussed above. In addition to the 7a signals, this 
10 mM solution of 7 showed signals of the free ligand 3 for the first time in a spectrum recorded 





of the solution of 7 with time was similar to observations for 8 (e.g., by 18 d, 7:7a:3 = 42:50:8 vs 
8:8a:4 = 37:56:7). Also, an ~3-year-old solution of 7 showed peaks for only free ligand 3.  
Under the same conditions, free ligand 1 or 2 appeared more quickly in DMSO-d6 solutions 
of Pt(II) complexes of these bidentate ligands than the free ligand 3 or 4 appeared from solutions 
of Pt(II) complexes of these monodentate ligands. As an example, by 9 d, the composition of the 
10 mM solution of 7, [trans-Pt(DMSO)Cl2]2(N(SO2Me)6,6'-Me2dpa), mentioned above was 
7:7a:3 = 60:37:3. In contrast, at a similar point in elapsed time (9 d), the 10 mM solution of 
Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5) in  DMSO-d6 exhibited a composition of 5:5sol:1 = 12:46:42. 
The ligand dissociation of the square planar Pt(II) complexes is initiated by the associative axial 
attack of a DMSO molecule. As shown in Figure 3.16, we believe that, in 7 and 8, a steric block 
created by the 6/6' methyl groups and the rest of the dangling ligand near the coordination sphere 
impedes the axial approach of the solvent molecule. In contrast, ligands 1 and 2 in complexes 5 
and 6 cannot move freely (bound bidentately) and do not contain any methyl groups near the axial 
attack site; thus, the solvent can approach the Pt(II) axial position more easily in 5 and 6 than in 7 
and 8. 
The partial (~40%) ligand release process for complexes 5 and 6 (bidentately bound ligand) 
reached completion in less time than the essentially complete (>90%) ligand release process for 7 
and 8 (monodentately bound ligand). This result indicates that the bidentate coordination of the 
ligands 1 and 2 leads to more thermodynamically stable complexes than does the monodentate 
coordination of ligands 3 and 4, as might be expected. However, the reasons for the slower release 
of ligands 3 and 4 are not so obvious. The Pt−N bond distances for 8 (2.062(9) and 2.066(8) Å) 
and for 8a (2.0757(9) Å) are not statistically different from these distances for 5 (2.023(2) and 





0.05 Å are not all statistically justified, there are enough consistent reports of Pt(II) structures to 
suggest that having a monodentate pyridine substituted at both the 2 and the 6 positions with groups 
having CH2Y (Y various groups such as OH) will increase the Pt−N bond distance by ~0.02 to 
~0.03 Å, and having a trans DMSO ligand will add a further ~0.01 to ~0.02 Å.83-86 Therefore, it is 
likely that the known trans influence of the DMSO ligand87-88 and the steric effect of the 2,6 
substituents weaken the Pt−N bond, leading to the more complete release of ligands 3 and 4, as 
compared to ligands 1 and 2. 
 
Figure 3.16. Possible role of the pyridine ring substituents in impeding axial solvent attack from 
the axial direction shown for Pt(N(SO2Tol)3,3',5,5'-Me4dpa)Cl2 (6), for [trans-
Pt(DMSO)Cl2]2(N(SO2Tol)6,6'-Me2dpa) (8), and for [trans-Pt(DMSO)Cl2](N(SO2Tol)6,6'-
Me2dpa) (8a). The axial attack (red arrow) is less sterically impeded for 6, with no substituents 
projecting toward the bottom axial approach pathway, as compared to axial attack (green double 
arrows) for 8 and 8a, both with substituents projecting toward the two axial approach pathways. 
One-half of the carrier ligand in 8 is removed for clarity. 
Possible Causes for the Absence of Bidentate Coordination to Pt(II) by N(SO2R)6,6'-
Me2dpa ligands (3 and 4). No evidence was found for bidentate coordination to the Pt(II)Cl2 core 
by N(SO2R)6,6'-Me2dpa ligands (3, R = Me and 4, R = Tol). In contrast, no direct evidence was 





and 2 (1, R = Me and 2, R = Tol). Because [trans-Pt(DMSO)Cl2](N(SO2Tol)6,6'-Me2dpa) (8a) 
was structurally characterized (Figure 3.7), we focus on studies with the N(SO2Tol)6,6'-Me2dpa 
ligand (4). Ligand 4 did not coordinate bidentately to Pt(II) but instead formed the binuclear 
compound (8) even under favorable conditions, such as longer reaction time of 4 with cis-
Pt(DMSO)Cl2 under reflux in MeOH or heating a dilute methanol solution of 8a (3.6 mg/5 ml, 1 
mM) at reflux overnight. Furthermore, a 5 mM solution of 8a in DMF-d7 was heated at 50 °C for 
several days, and the solution was monitored by 1H NMR spectroscopy at 24-h intervals. These 
spectra showed no change, indicating that the absence of bidentate coordination does not depend 
on the solvent. 
In the preceding section, we compared the release of all these bidentate ligands and 
monodentate ligands from Pt(II) in DMSO-d6 solution. It is noteworthy that we did not detect any 
buildup of monodentate intermediates as complexes 5 and 6 with bidentate ligands released free 
ligands 1 and 2, respectively. NMR spectra showed that ligands 1 and 2 were either free or 
coordinated in a bidentate mode. This finding means that the dangling pyridyl ring of the 
undetectably small amount of monodentate intermediates (5a and 6a), with only one pyridyl ring 
bound (the analogs of 7a and 8a) rapidly added to Pt(II), creating the 8-membered chelate ring 
present in 5 and 6.  
Solutions of 8a in DMSO-d6 gave no NMR spectral evidence for any bidentate chelate 
complex. If chelation were favorable, these DMSO-d6 conditions should have allowed such chelate 
ring closure because closure occurs readily in analogous intermediates having ligands 1 and 2. 
Factors that could inhibit or prevent ring closure in 7a and 8a most likely involve the 2,6-
substituents of the bound pyridyl ring. These 2,6-substituents might prevent this bound ring from 





Also, these substituents could offer a steric barrier to axial attack. Finally, the 2,6-substituents on 
the attacking dangling pyridyl ring itself would create very high steric hindrance to Pt–N bond 
formation. Only five structures of complexes containing two 2,6-substituted pyridyl ligands bound 
to the same Pt(II) center are in the CCDC data base, indicating that steric hindrance makes it 
difficult for two 2,6-substituted pyridyl ligands to coordinate to the same Pt(II).  Only one such 
complex has the two 2,6-substituted pyridyl ligands in cis positions, and in this case the pyridyl 
rings form part of a macrocycle.48 The 2,6-substituted pyridyl ligands in the other four complexes 
are in trans positions.89-90 In fact Kong et al. stated that it is almost impossible to form Pt(2,6-
lutidine)2Cl2 complexes.
91 
Furthermore, the two 2-methyl groups in cis-Pt(2-picoline)2Cl2 are anti to each other,
52 
minimizing the steric repulsion between the two syn 2-methyl groups. In contrast, if the 
N(SO2R)6,6'-Me2dpa ligands coordinated bidentately to Pt(II), as in 5 and 6, the 6/6' methyl groups 
would be syn; the resulting sterically unfavorable proximity of the 6/6' methyl groups would make 
bidentate coordination of 3 and 4 thermodynamically unlikely. Thus, we believe that both 
thermodynamic and kinetic factors make bidentate coordination of N(SO2R)6,6'-Me2dpa ligands 
to Pt(II) unfavorable. 
3.4 Conclusions 
 The N(SO2R)Mendpa ligands investigated here bind tridentately to the fac-[Re(I)(CO)3]
+ 
core in the [Re(CO)3(N(SO2R)Mendpa)]PF6 complexes but bind in diverse modes to the cis-
Pt(II)Cl2 core. The two types of ligands, N(SO2R)3,3',5,5'-Me4dpa and N(SO2R)6,6'-Me2dpa, bind 
bidentately and monodentately to Pt(II), respectively. We suggest that these differences in ligand 
binding modes arise mainly from electronic factors involving the central sulfonamide donor and 





Because of the steric preferences of the central tertiary sulfonamide donor, we propose that 
tridentate coordination by the new carrier ligands requires a facial rather than a meridional binding 
geometry.  Therefore, ligands 1 to 4 all bind readily and facially to Re(I) in fac-
[Re(CO)3(N(SO2R)Mendpa)]PF6 complexes. In cases we can find in which ligands having a 
tertiary sulfonamide donor bind meridionally, one of the adjacent chelate rings is 6-membered and 
one is 5-membered (see, for example, a Cu complex).72 Thus, we conclude that ligands such as 
N(SO2R)3,3',5,5'-Me4dpa (1 and 2), which would have two adjacent 5-membered chelate rings if 
bound tridentately, cannot bind tridentately to Pt(II) and must instead adopt the bidentate mode.  
The [Re(CO)3(N(SO2R)3,3',5,5'-Me4dpa)]PF6 complexes (9 and 10) formed by the two 
N(SO2R)3,3',5,5'-Me4dpa ligands, in which two protons are present at the 6/6' positions instead of 
the two methyl groups, are stable indefinitely in DMSO-d6. These complexes have relatively short 
Re–N bond lengths. In contrast, longer Re–N bond lengths to the pyridyl N are found for 
[Re(CO)3(N(SO2R)6,6'-Me2dpa)]PF6 complexes (11 and 12) and the analog, [Re(CO)3(N(H)6,6'-
Me2dpa)]PF6. The longer bonds are a result of the steric repulsion between the 6/6' methyl groups 
of coordinated tridentate ligands and the CO ligands in these complexes. However, only 11 and 12 
release tridentate ligand with time in DMSO-d6. Thus, both the steric repulsions involving the 6/6' 
methyl groups and the poor donor ability of the central sulfonamide of coordinated N(SO2R)6,6'-
Me2dpa tridentate ligands in 11 and 12 contribute to release of the tridentate ligand in DMSO-d6. 
The Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2 complexes (5 and 6) of the bidentately bound ligands 
(1 and 2)  have an unusually large 8-membered chelate ring. These complexes release free ligand, 
and eventually an equilibrium is established. The process occurs more rapidly than the release of 
free ligands from the [trans-Pt(DMSO)Cl2]2(N(SO2R)6,6'-Me2dpa) complexes (7 and 8) of 





hindrance of the 6/6' methyl groups in N(SO2R)6,6'-Me2dpa (3 and 4). However, the 6/6' methyl 
groups and the dangling part of the ligand act as barriers to the axial attack by solvent, accounting 
for the slower release of monodentately bound ligands 3 and 4 from 7 and 8 [trans-
(Pt(DMSO)Cl2]2(N(SO2R)6,6'-Me2dpa)) than release of the bidentately bound ligands 1 and 2 
from 5 and 6 (Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2). Because there is no buildup of the monodentate 
intermediate during the ligand release process, we do not know whether the trans ligand in the 
intermediate is chloride or DMSO. However, 7a and 8a have DMSO in the trans position, and 
DMSO has a larger trans effect than chloride.87-88 Thus, the slower release of ligands 3 and 4 from 
7a and 8a is clearly steric in nature; the steric effect undoubtedly involves the inhibition of axial 
attack of solvent DMSO. 
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CHAPTER 4. NNN-TRIDENTATE LIGANDS WITH TERMINAL IMIDAZOLYL RING 
AND CENTRAL SULFONAMIDE N-DONORS COORDINATED TO fac-[Re(I)(CO)3]+ 
AND Pt(II)Cl2 "CORES". DYNAMIC PROPERTIES OF THE 8-MEMBERED CHELATE 
RING IN THE PT(II) COMPLEXES AND IN THEIR ADDUCTS FORMED WITH 
MONODENTATE N-DONOR AROMATIC HETEROCYCLIC LIGANDS 
 
4.1 Introduction 
Identification of new linking strategies useful in modifying chelating ligands is crucial in 
developing new metal-mediated diagnostic or therapeutic drug molecules; new properties can be 
introduced to the drug molecules by linking groups such as fluorophores.1-15 A linear symmetrical 
tridentate ligand with an easily functionalizable central donor is a good framework to study and 
develop such new linking chemistries (Figure 4.1). Over the last few years our group was 
particularly interested in studying new bioconjugation possibilities involving a N−S linker within 
a similar framework (Figure 4.1). These studies have shown that N(SO2R)dpa
6,16 and 
N(SO2R)dien
7 type ligands in which the central N-donor atom is part of a tertiary sulfonamide 
group function as a new class of tridentate ligands; these ligands were derived from the parent 
ligands N(H)dpa (2-dipicolylamine) and dien (diethylenetriamine), respectively. 
 
Figure 4.1. Left: Schematic representation of a linear symmetrical tridentate carrier-ligand bound 
to a metal ion (M). Right: Sulfonamide group containing parent ligands studied by Marzilli Group 






Use of non-radioactive Re(I) complexes as models in developing new ligand systems for 
99mTc diagnostic agents and 186/188Re(I) therapeutic agents is common.17-21 Therefore, the 
N(SO2R)dpa and N(SO2R)dien ligands were utilized to synthesize a number of Re(I) complexes 
(fac-[Re(CO)3(N(SO2R)dpa)]
+ and fac-[Re(CO)3(N(SO2R)dien)]
+, R = Me, Tol, etc.) and their 
relevance to the development of 99mTc radiopharmaceutical agents was discussed.6-7 These 
complexes are the first examples to have a normal metal-to-N(sulfonamide) bond length when any 
metal is bound to a noncyclic linear tridentate ligand through a sulfonamide N-donor.6-7 
 Furthermore, in order to introduce the N−S linker in ligands employed in Pt chemistry, 
N(SO2R)Mendpa-type ligands (N(SO2R)dpa derivatives with methyl groups replacing some of the 
pyridyl ring protons; N(SO2R)3,3',5,5'-Me4dpa and N(SO2R)6,6'-Me2dpa, R = Me and Tol) were 
utilized to synthesize Pt(II) complexes.16 These ligands coordinated to Pt center either bidentately 
(to form Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2) or monodentately (to form [trans-
Pt(DMSO)Cl2]2(N(SO2R)6,6'-Me2dpa).
16 The sulfonamide nitrogen was not coordinated to the 
Pt(II) center in any of these complexes. Thus, the bidentate N(SO2R)3,3',5,5'-Me4dpa ligand forms 
an unusually large 8-membered chelate ring. The N(SO2R)6,6'-Me2dpa ligand binds 
monodentately because the 6,6'-methyl groups inhibit chelate ring formation.16 We concluded that 
the reason the tertiary sulfonamide N did not bind to Pt(II) was because such a donor group cannot 
anchor two adjacent 5-membered chelate rings in a meridional geometry. 
A key feature to be evaluated in Pt(II) complexes designed for biological applications is 
the ability to form adducts with biological molecules (such as guanine derivatives used to test 
propensity for reactivity toward G residues in DNA, a feature correlating with Pt drug anticancer 
activity). Unfortunately, none of the Pt complexes mentioned above were robust in DMSO-d6 and 





biomolecules such as guanine derivatives.16 Based on an extensive NMR and X-ray structural 
analysis, we hypothesized that the main reason for the low robustness and poor biomolecule 
reactivity of the Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2 complexes is the bulk of the 6-membered pyridyl 
donor groups of the carrier-ligands, N(SO2R)Mendpa. There was no evidence that the steric effect 
of this ring lacking a substituent in the Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2 complexes prevents the 
binding of the tertiary sulfonamide N, but this possibility cannot be ruled out. 
In this study, we designed N(SO2R)1,1'-Me2dma ligands (Figure 4.1) with smaller 5-
membered imidazolyl rings (compared to 6-membered pyridyl rings in N(SO2R)dpa and 
N(SO2R)Mendpa ligands); these new carrier ligands (R = Me and Tol, Figure 4.2) are derivatives 
of the parent ligand, N(H)1,1'-Me2dma (bis(1-methyl-2-methylimidazolyl)amine). As observed for 
the N(SO2R)3,3',5,5'-Me4dpa
 ligands, the N(SO2R)1,1'-Me2dma ligands coordinate tridentately in 
fac-[Re(CO)3(N(SO2R)1,1'-Me2dma)]ClO4 and bidentately in Pt(N(SO2R)1,1'-Me2dma)Cl2 
complexes (Figure 4.2). All of the fac-[Re(CO)3(chelate)]Y (Y = ClO4 or PF6) complexes 
discussed below have facial geometry, and thus from this point onward we omit the fac- 
designation when discussing specific compounds. 
 In addition to the characterization of the new carrier ligands and their metal complexes by 
1H NMR spectroscopy and single-crystal X-ray crystallography or mass spectrometry, we studied 
the dynamic properties of the Pt(N(SO2R)1,1'-Me2dma)Cl2 complexes. EXSY cross-peaks 
between the two 1H NMR signals of the methylene groups in DMF reveal that the 8-membered 
chelate ring undergoes dynamic motion involving rotation around the Pt–N bond. This process 
was not observed for the Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2 complexes, consistent with a steric 







Figure 4.2. General reaction route for forming N(SO2R)1,1'-Me2dma ligands:  N,N-di(1-methyl-2-
methylimidazolyl)methanesulfonamide, N(SO2Me)1,1'-Me2dma (1) and N,N-di(1-methyl-2-
methylimidazolyl)-p-tolylsulfonamide, N(SO2Tol)1,1'-Me2dma (2) and their 
[Re(CO)3(N(SO2R)1,1'-Me2dma)]ClO4 (3, R = Me and 4, R = Tol) and Pt(N(SO2R)1,1'-
Me2dma)Cl2 (5, R = Me and 6, R = Tol) complexes. The numbering scheme shown here is 
employed in the NMR discussion. Note that the p-tolyl group numbering is italicized to prevent 
confusion with the imidazolyl ring numbering.  
Finally, we describe the use of 1H NMR spectroscopy and in some cases X-ray 
crystallography to examine adducts formed by the Pt(N(SO2R)1,1'-Me2dma)Cl2 complexes with 
small N-donor ligands (such as 4-picoline) and guanine derivatives (G) such as guanosine and 9-
methylguanine. The substitution of the chloride ligands by biomolecules is important for biological 
applications of platinum(II) agents. In a previous study, we have shown that G readily form 
monoadducts in solutions with the monofunctional [Pt(N(R)1,1'-Me2dma)Cl]
+ cation in which the 
N(H)1,1'-Me2dma parent ligand and its methyl derivative, N(Me)1,1'-Me2dma, are bound 
tridentately to Pt(II).22 Furthermore, similar monofunctional platinum(II) complexes of N(H)dpa 






25 also form G monoadducts in solution. As mentioned, the Pt(N(SO2R)3,3',5,5'-
Me4dpa)Cl2 complexes did not exhibit useful reactivity towards guanine derivatives or other N-
donor ligands.16 In the current study, we find that the Pt(N(SO2R)1,1'-Me2dma)Cl2 complexes do 
form mono adducts ([Pt(N(SO2R)1,1'-Me2dma)GCl]
+) in the presence of an excess of G (G = 9-
MeG and Guo). Thus, reducing the size of the terminal rings does facilitate reaction. Indeed, the 
Pt(N(SO2R)1,1'-Me2dma)Cl2 complexes also form bis adducts with monodentate pyridyl ligands 
(4-picoline, 4-dimethylaminopyridine, and 3,5-lutidine). 1H NMR spectral and X-ray structural 
results of these bis complexes exhibit the existence of two bis conformers, Bis1 and Bis2 in which 
the SO2R group is projecting towards and away from the coordination sphere, respectively. 
Because the sulfonamide group is not coordinated to the Pt(II) center, the 8-membered ring of the 
Pt(N(SO2R)1,1'-Me2dma)Cl2 complexes and their adducts has a degree of dynamic freedom; the 
imidazolyl rings can rotate around the Pt–N bond and inversion can occur at the N(sulfonamide) 
atom. We believe that the observed monofunctional behavior of the Pt(N(SO2R)1,1'-Me2dma)Cl2 
complexes is due to a combination of the steric bulk of the chelate ligand and the guanine base, 
which is bulkier than the added monodentate pyridyl ligands. The monodentate pyridyl ligands are 
small enough to form bis adducts but the two bound cis monodentate pyridyl ligands decrease the 
dynamic motion of the 8-membered ring. 
4.2 Experimental Section 
Starting Materials. Methanesulfonamide (MeSO2NH2), p-tolylsulfonamide 
(TolSO2NH2), 1-methyl-2-imidazolecarboxaldehyde, tetraethylammonium chloride ([Et4N]Cl), 
guanosine (Guo), 9-methylguanine (9-MeG), 4-methylpyridine (4-pic), 3,5-lutidine (3,5-lut) and 







27 and 2-(chloromethyl)-1-methylimidazole hydrochloride28 were 
prepared by known methods. 
NMR Measurements. 1H NMR spectra were recorded on a 400 MHz or on an Avance-III 
Prodigy 500 MHz Bruker spectrometer. Peak positions are relative to TMS or solvent residual 
peak with TMS as reference. All NMR data were processed with TopSpin and MestReNova 
software. A presaturation pulse to suppress the water peak was employed when necessary. 
Mass Spectrometric Measurements. High resolution mass spectra were recorded on an 
Agilent 6210 ESI TOF LCMS mass spectrometer. 
X-ray Data Collection and Structure Determination. Diffraction data were collected on 
a Bruker Kappa Apex-II DUO CCD diffractometer with Mo K radiation (λ = 0.71073 Å), 
equipped with an Oxford Cryosystems Cryostream. All X-ray structures were determined by direct 
methods and difference Fourier techniques and refined by full-matrix least-squares by using 
SHELXL201429 with H-atoms in idealized positions. 
N(SO2Me)1,1'-Me2dma) (1). A solution of 2-(chloromethyl)-1-methylimidazole 
hydrochloride (1.00 g, 5.98 mmol), K2CO3 (~1.7 g, 12 mmol), and MeSO2NH2 (0.23 g, 2.4 mmol) 
in acetonitrile (95 mL) was heated at reflux under nitrogen for 18 h. The brown residue obtained 
after the removal of acetonitrile under reduced pressure was dissolved in water (45 mL) and the 
solution was extracted with CH2Cl2 (3 x 45 mL). The organic layers were combined, washed with 
saturated aqueous sodium chloride solution, dried over sodium sulfate, and taken to dryness under 
reduced pressure. The residue was dissolved in a solvent mixture of acetone:5.0 M NH4OH (90:10) 
and purified by chromatography on a silica column with the same eluent. Fractions were collected 
and spotted on TLC plates by using the same eluent. The cleanest fractions, as assessed by 1H 





N(SO2Me)1,1'-Me2dma as a pale yellow oil (0.55 g, 82% yield). 
1H NMR signals (ppm) in CDCl3: 
6.98 (2H, H5/5'), 6.86 (2H, H4/4'), 4.52 (s, 4H, CH2), 3.70 (s, 6H, CH3), 2.97 (s, 3H, CH3). 
1H 
NMR signals (ppm) in DMSO-d6: 7.12 (2H, H5/5'), 6.86 (2H, H4/4'), 4.40 (s, 4H, CH2), 3.61 (s, 
6H, CH3), 3.05 (s, 3H, CH3). ESI-MS (m/z): [M + H]
+ = 284.1171. Calcd for [M + H]+ = 284.1176. 
N(SO2Tol)1,1'-Me2dma) (2). A similar procedure as for ligand 1 with 2-(chloromethyl)-
1-methylimidazole hydrochloride (1.00 g, 5.98 mmol), K2CO3 (~1.7 g, 12 mmol), and TolSO2NH2 
(0.41 g, 2.4 mmol) afforded a brown residue, which was purified by using a solvent mixture of 
acetone:5.0 M NH4OH (90:10) to afford N(SO2Tol)1,1'-Me2dma as a white solid (0.15 g, 20% 
yield). 1H NMR signals (ppm) in CDCl3: 7.62 (d, J = 7.3 Hz, 2H, H2/6), 7.30 (d, J = 8.2 Hz, 2H, 
H3/5), 6.87 (2H, H5/5'), 6.75 (2H, H4/4'), 4.43 (s, 4H, CH2), 3.60 (s, 6H, CH3), 2.43 (s, 3H, CH3). 
1H NMR signals (ppm) in DMSO-d6: 7.56 (d, J = 8.3 Hz, 2H, H2/6), 7.34 (d, J = 8.1 Hz, 2H, 
H3/5), 7.01 (2H, H5/5'), 6.70 (2H, H4/4'), 4.30 (s, 4H, CH2), 3.54 (s, 6H, CH3), 2.38 (s, 3H, CH3). 
ESI-MS (m/z): [M + H]+ = 360.1499. Calcd for [M + H]+ = 360.1489. 
[Re(CO)3(N(SO2Me)1,1'-Me2dma)]ClO4 (3). A solution of N(SO2Me)1,1'-Me2dma (1, 
28 mg, 0.1 mmol) and [Re(CO)3(CH3CN)3]ClO4 (49 mg, 0.1 mmol) in acetonitrile (5 mL) was 
heated at reflux overnight (~16 h). The resultant clear pale-yellow solution was kept at room 
temperature to allow the solvent to evaporate slowly to produce white X-ray quality crystals 
overnight (34 mg, 52% yield). 1H NMR signals (ppm) in DMSO-d6: 7.34 (d, J = 1.5 Hz, 2H, H5/5'), 
7.13 (d, J = 1.5 Hz, 2H, H4/4'), 5.20 (d, J = 16.5 Hz, 2H, CH2), 4.98 (d, J = 16.4 Hz, 2H, CH2), 
3.85 (s, 3H, CH3), 3.66 (s, 6H, CH3).  
[Re(CO)3(N(SO2Tol)1,1'-Me2dma)]ClO4 (4). A solution of N(SO2Tol)1,1'-Me2dma (2, 





heated at reflux overnight (~16 h). The resultant clear pale-yellow solution was kept at room 
temperature to allow the solvent to evaporate slowly to produce white crystalline solid overnight 
(55 mg, 76% yield). 1H NMR signals (ppm) in DMSO-d6: 8.19 (d, J = 8.1 Hz, 2H, H2/6), 7.74 (d, 
J = 8.2 Hz, 2H, H3/5), 7.29 (s, 2H, H5/5'), 7.13 (s, 2H, H4/4'), 5.40 (d, J = 16.2 Hz, 2H, CH2), 
4.44 (d, J = 16.5 Hz, 2H, CH2), 3.54 (s, 6H, CH3), 2.56 (s, 3H, CH3). ESI-MS (m/z): [M]
+ = 
630.0825. Calcd for [M]+ = 630.0815. 
Pt(N(SO2Me)1,1'-Me2dma)Cl2 (5). A solution of N(SO2Me)1,1'-Me2dma (1, 28 mg, 0.1 
mmol) and cis-Pt(DMSO)2Cl2 (42 mg, 0.1 mmol) in methanol (5 mL) was heated at reflux 
overnight (~16 h) to afford a pale yellow solid, which was collected by filtration, washed with 
methanol and ether, and air-dried (17 mg, 36% yield). X-ray quality crystals were obtained by 
mixing equal volumes (1 mL) of cis-Pt(DMSO)2Cl2 (12.5 mM) and N(SO2Me)-1,1'-Me2dma (12.5 
mM) in acetonitrile and allowing the mixture to stand at room temperature. Yellow crystals 
collected within 2 days were characterized by single-crystal X-ray crystallography. The 1H NMR 
data for the solid and the crystals are identical. 1H NMR signals (ppm) in DMSO-d6: 7.20 (2H, 
H5/5'), 7.10 (2H, H4/4'), 5.25 (d, J = 17.6 Hz, 2H, CH2), 5.13 (d, J = 17.8 Hz, 2H, CH2), 3.72 (s, 
6H, CH3), 3.28 (s, 3H, CH3). 
1H NMR signals (ppm) in DMF-d7: 7.28 (2H, H5/5'), 7.18 (2H, 
H4/4'), 5.47 (d, J = 16.5 Hz, 2H, CH2), 5.29 (d, J = 16.3 Hz, 2H, CH2), 3.87 (s, 6H, CH3), 3.41 (s, 
3H, CH3).  
Pt(N(SO2Tol)1,1'-Me2dma)Cl2 (6). A similar procedure as for complex 5 with 
N(SO2Tol)1,1'-Me2dma (2, 36 mg, 0.1 mmol) and cis-Pt(DMSO)2Cl2 (42 mg, 0.1 mmol) afforded 
a pale yellow solid (20 mg, 32% yield). X-ray quality crystals were obtained by mixing equal 
volumes (1 mL) of cis-Pt(DMSO)2Cl2 (12.5 mM) and N(SO2Tol)-1,1'-Me2dma (12.5 mM) in 





4 days were characterized by single-crystal X-ray crystallography. The 1H NMR data for the solid 
and the crystals are identical. 1H NMR signals (ppm) in DMSO-d6: 7.97 (d, J = 7.9 Hz, 2H, H2/6), 
7.58 (d, J = 8.0 Hz, 2H, H3/5), 7.22 (s, 2H, H5/5'), 7.10 (s, 2H, H4/4'), 5.30 (d, J = 16.1 Hz, 2H, 
CH2), 4.77 (d, J = 15.7 Hz, 2H, CH2), 3.79 (s, 6H, CH3); the phenyl methyl signal is masked by 
the solvent peak. 1H NMR signals (ppm) in DMF-d7: 8.10 (d, J = 8.1 Hz, 2H, H2/6), 7.63 (d, J = 
8.1 Hz, 2H, H3/5), 7.31 (2H, H5/5'), 7.18 (2H, H4/4'), 5.40 (d, J = 15.7 Hz, 2H, CH2), 5.08 (d, J 
= 15.6 Hz, 2H, CH2), 3.97 (s, 6H, CH3), 2.52 (s, 3H, CH3). 
Reactions of Pt(N(SO2R)1,1'-Me2dma)Cl2 (5, R = Me and 6, R = Tol) with N-donor 
Monodentate Ligands (DMAP, 4-pic, and 3,5-lutidine). A 20 mM solution of DMAP in DMSO-
d6 (0.9 mg in 600 µl) was treated with 1.6 mg of 5 (5 mM) and the solutions were monitored by 
1H NMR spectroscopy. Another 1 day-old 5 mM solution of 5 in DMSO-d6 was treated with 4 
molar equiv of DMAP (0.9 mg, 20 mM) and the solution was monitored by 1H NMR spectroscopy. 
Further, a 20 mM solution of DMAP in DMSO-d6 was treated with 1.9 mg of Pt(N(SO2Tol)1,1'-
Me2dma)Cl2 (6, 5mM) and the solution was monitored by 
1H NMR spectroscopy. Isolation of 
[Pt(N(SO2R)1,1'-Me2dma)(N-donor)2](PF6)2-type solids/X-ray quality crystals (N-donor = 4-pic 
and 3,5-lut) was performed as follows. 
 Isolation of [Pt(N(SO2R)1,1'-Me2dma)(4-pic)2](PF6)2 Complexes (7, R = Me and 8, R 
= Tol). A suspension of 3 mg of 5 in 150 µl of 4-pic was heated at 60 °C and a clear pale-yellow 
solution was obtained overnight. Then the solution was treated with 3.7 mg of Na2PF6 (4 molar 
equiv) dissolved in 1 ml of H2O. The resultant milky white mixture was heated for ~5 min until 
became clear with two layers (a pale yellow 4-pic layer at the bottom and the aqueous layer at the 
top). X-ray quality white crystals of 7, [Pt(N(SO2Me)1,1'-Me2dma)(4-pic)2](PF6)2, were collected 





DMSO-d6 Bis1: 8.79 (d, J = 6.0 Hz, 4H, H2/64-pic), 7.44 (d, J = 6.0 Hz, 4H, H3/54-pic), 7.32 (s, 2H, 
H5/5'), 7.16 (s, 2H, H4/4'), 4.95 (s, 4H, CH2), 3.64 (s, 6H, CH3), 3.46 (s, 3H, CH3), 2.36 (s, 6H, 
CH3). Bis2: 8.93 (d, J = 5.9 Hz, 4H, H2/64-pic), 7.50 (d, J = 6.0 Hz, 4H, H3/54-pic), 7.32 (s, 2H, 
H5/5'), 7.37 (s, 2H, H4/4'), 5.54 (d, J = 16.4 Hz, 2H, CH2), 5.20 (d, J = 16.4 Hz, 2H, CH2), 3.73 
(s, 6H, CH3), 2.36 (s, 6H, CH3), the sulfonamide methyl signal is masked by the HOD peak. From 
a similar experiment performed using 6 produced pale-orange color X-ray quality crystals of 
[Pt(N(SO2Tol)1,1'-Me2dma)(4-pic)2](PF6)2.Me2CO (8) (One drop of acetone is added to the final 
solution to aid the crystallization). 1H NMR signals (ppm) in DMSO-d6 Bis1: 8.87 (d, J = 5.7 Hz, 
4H, H2/64-pic), 8.09 (d, J = 8.1 Hz, 2H, H2/6), 7.64 (m, 2H, H3/5), 7.49 (d, J = 6.0 Hz, 4H, H3/54-
pic), 7.33 (s, 2H, H5/5'), 7.21 (s, 2H, H4/4'), 4.84 (s, 4H, CH2), 3.60 (s, 6H, CH3), the phenyl methyl 
signal is masked by the solvent peak, 2.38 (s, 6H, CH3). Bis2: 8.87 (s, 4H, H2/64-pic), 8.03 (d, J = 
8.0 Hz, 2H, H2/6), 7.64 (m, 2H, H3/5), 7.45 (d, J = 6.3 Hz, 4H, H3/54-pic), 7.33 (s, 2H, H5/5'), 7.37 
(s, 2H, H4/4'), 5.35 (d, J = 16.3 Hz, 2H, CH2), 5.20 (d, J = 16.4 Hz, 2H, CH2), 3.84 (s, 6H, CH3), 
the phenyl methyl signal is masked by the solvent peak, 2.34 (s, 6H, CH3).  
Isolation of [Pt(N(SO2R)1,1'-Me2dma)(3,5-lut)2](PF6)2 Complexes (9, R = Me and 10, 
R = Tol). A suspension of 3 mg of 5 in 150 µl of 3,5-lutidine was heated at 80 °C. A white solid 
has deposited overnight, which was filtered and treated with 1 ml of aqueous solution of Na2PF6 
(4 molar equiv, 3.7 mg). Another 1 ml of acetone was added to the resultant milky white mixture. 
The resultant clear colorless solution was kept at room temperature to allow the solvent to 
evaporate slowly. A white crystalline solid of 9, [Pt(N(SO2Me)1,1'-Me2dma)(3,5-lut)2](PF6)2 was 
obtained overnight. 1H NMR signals (ppm) in DMSO-d6 Bis1: 8.77 (s, 4H, H2/63,5-lut), 7.67 (s, 2H, 
H43,5-lut), 7.32 (s, 2H, H5/5'), 7.15 (s, 2H, H4/4'), 4.95 (s, 4H, CH2), 3.64 (s, 6H, CH3), 3.49 (s, 3H, 





7.41 (s, 2H, H4/4'), 5.50 (d, J = 16.1 Hz, 2H, CH2), 5.23 (d, J = 16.1 Hz, 2H, CH2), 3.74 (s, 6H, 
CH3), 3.35 (s, 3H, CH3), 2.29 (s, 12H, CH3). ESI-MS (m/z): [M]
2+ = 346.1106. Calcd for [M]2+ = 
346.1105. A similar experiment performed using 6 produced white color X-ray quality crystals of 
[Pt(N(SO2Tol)1,1'-Me2dma)(3,5-lut)2](PF6)2.2Me2CO (10).
 1H NMR signals (ppm) in DMSO-d6 
Bis1: 8.87 (s, 4H, H2/63,5-lut), 8.13 (d, J = 7.8 Hz, 2H, H2/6), 7.71 (s, 2H, H43,5-lut), 7.66 (bs, 2H, 
H3/5), 7.32 (s, 2H, H5/5'), 7.20 (s, 2H, H4/4'), 4.76 (s, 4H, CH2), 3.59 (s, 6H, CH3), the phenyl 
methyl signal is masked by the solvent peak, 2.28 (s, 12H, CH3). Bis2: 8.83 (s, 4H, H2/63,5-lut), 
8.04 (d, J = 8.0 Hz, 2H, H2/6), 7.66 (bs, 2H, H3/5), 7.66 (bs, 2H, H43,5-lut), 7.33 (s, 2H, H5/5'), 
7.41 (s, 2H, H4/4'), 5.33 (d, J = 16.3 Hz, 2H, CH2), 5.21 (d, J = 16.4 Hz, 2H, CH2), 3.85 (s, 6H, 
CH3), the phenyl methyl signal is masked by the solvent peak, 2.24 (s, 12H, CH3).  
G Adduct Formation with Pt(N(SO2R)1,1'-Me2dma)Cl2 (5 and 6). Two 25 mM 
solutions of 9-MeG and Guo were treated separately with 1.6 mg of 5 in DMSO-d6 to make each 
solution 5 mM in complex 5. The solutions were maintained at 25 °C and monitored by 1H NMR 
spectroscopy until there was no change in the bound vs free H8 signal intensity. Another 50 mM 
solution of 9-MeG was treated with 1.6 mg of 5 (5 mM) in DMSO-d6. In another experiment, a 1-
day old 5 mM solution of 5 in DMSO-d6 was treated with 5 molar equiv of 9-MeG (2.5 mg, 25 
mM). Another 25 mM solution of 9-MeG was treated with 1.6 mg of 5 (5 mM) in DMF-d7. The 
solutions were maintained at 25 °C and monitored by 1H NMR spectroscopy. Two 25 mM 
solutions of 9-MeG and Guo) were treated with 1.9 mg of 6 in DMSO-d6 to make each solution 5 
mM in complex 6 and the solutions were monitored with time by 1H NMR spectroscopy. 
4.3 Results and Discussion 
Synthesis of N(SO2R)1,1'-Me2dma Derivatives and Their Re(I) and Pt(II) Complexes. 





sulfonamide compound with two equiv of 2-(chloromethyl)-1-methylimidazole under basic 
conditions (Figure 4.2), a similar synthetic route to that used in the synthesis of the analogous 
ligands containing pyridyl rings (N(SO2R)Mendpa).
16  However, the purification of the new ligands 
was more difficult and required more polar eluents (see Experimental Section) compared to the 
N(SO2R)Mendpa
16 ligands, perhaps owing to the higher hydrophilicity of the new ligands than the 
latter ligands. Using a slightly modified method reported in literature30 we obtained 
[Re(CO)3(N(SO2R)1,1'-Me2dma)]ClO4 complexes 3 and 4 by using [Re(CO)3(CH3CN)3]ClO4 as 
the metal precursor (Figure 4.2). The Pt(N(SO2R)1,1'-Me2dma)Cl2 complexes (5 and 6) were 
synthesized by employing a similar procedure as used in the synthesis of Pt(N(SO2R)Mendpa)Cl2 
complexes (using cis-Pt(DMSO)2Cl2 in methanol to react with the ligands at reflux), which 
produced the neutral Pt(II) complexes (5 and 6) in good yield. Even after several years, no evidence 
for chelate ligand dissociation was found in DMSO-d6 (complexes 3−6) or in DMF-d7 (complexes 
5 and 6) indicating that the ligands 1 and 2 can form robust [Re(CO)3(N(SO2R)1,1'-Me2dma)]ClO4 
and Pt(N(SO2R)1,1'-Me2dma)Cl2 complexes. 
Structural Results.  Crystal data and details of the structural refinement for all complexes 
are summarized in Table 4.1. Selected bond lengths and angles are reported in Tables 4.2 and 4.3. 
The ORTEP plots of 5 and 6 and cations of 3, 7, 8, and 10 (Figures 4.3 and 4.4) show the numbering 
system used to describe the solid-state data. 
The molecular structures of [Re(CO)3(N(SO2Me)1,1'-Me2dma)]
+ (3) and Pt(N(SO2R)1,1'-
Me2dma)Cl2 (5, R = Me and 6, R = Tol) complexes (Figure 4.3) confirm that the new imidazolyl 
ligands (1 and 2) coordinate tridentately to the fac-[Re(I)(CO)3]
+ core and bidentately to the 
Pt(II)Cl2 core. In [Re(CO)3(N(SO2Me)1,1'-Me2dma)]ClO4 (3), all three nitrogen atoms of the 
tridentate ligand occupy one face, and the three carbonyl ligands occupy the other face. In the Pt
111 
 
Table 4.1. Crystal Data and Structure Refinement for [Re(CO)3(N(SO2Me)1,1'-Me2dma)]ClO4 (3), Pt(N(SO2Me)1,1'-Me2dma)Cl2 (5), 
Pt(N(SO2Tol)1,1'-Me2dma)Cl2 (6), [Pt(N(SO2Me)1,1'-Me2dma)(4-pic)2](PF6)2 (7), [Pt(N(SO2Tol)1,1'-Me2dma)(4-pic)2](PF6)2 (8), and 
[Pt(N(SO2Tol)1,1'-Me2dma)(3,5-lut)2](PF6)2 (10) 













fw 653.03 549.34 625.44 954.64 1088.81 1174.93 
crystal system monoclinic orthorhombic triclinic triclinic triclinic monoclinic 
space group C2/c Pnma Pī Pī Pī P21/n 
a (Å) 18.9064(3) 9.1464(9) 9.2992(3) 10.5913(9) 10.4923(2) 9.8237(10) 
b (Å) 10.3460(2) 15.1789(17) 9.7727(4) 11.3539(9) 13.6072(4) 8.9302(9) 
c (Å) 22.1733(4) 12.055(1) 12.2223(6) 15.9287(14) 15.1738(4) 53.291(6) 
α (deg) 90 90 112.967(3) 71.804(6) 75.610(2) 90 
 (deg) 100.861(1) 90 91.062(3) 85.583(6) 89.200(2) 90.185(5) 
γ (deg) 90 90 94.381(3) 62.623(5) 77.032(5) 90 
V (Å3) 4259.53(13) 1673.6 (3) 1018.29(8) 1610.8 (2) 2042.88 (9) 4675.0(8) 
T (K) 105 90 90 90 90 150 
Z 8 4 2 2 2 4 
calc (g/m3) 2.037 2.180 2.040 1.968 1.770 1.669 





 3 5 6 7 8 10 
abs coeff (mm-1) 5.99 8.84 7.28 4.63 3.66 7.52 
2max () 95.2 51.4 54.2 61.2 66.6 136.8 
R[F2>2σ(F2)] 0.028 0.032 0.029 0.040 0.037 0.039 
Rw 0.057 0.062 0.101 0.080 0.086 0.090 
res. dens. (e Å-3) 3.37, -2.30 1.84, -1.00 2.95, -1.94 2.34, -1.47 2.50, -2.06 0.82, -1.22 
data/parameters 19874/283 1659/108 4005/256 9846/438 15504/567 32022/663 
a R = (||F| - |Fc||)/|F|. 
b Rw = [[w(F2 - Fc
















complexes 5 and 6, two cis coordination positions are occupied by the imidazolyl nitrogen atoms 
creating a large 8-membered chelate ring. The remaining coordination positions are occupied by 
two Cl atoms. As discussed in our previous work of the analogous ligands containing pyridyl rings, 
N(SO2R)Mendpa,
16 we believe that the different coordination modes exhibited by the new ligands 
in Pt(N(SO2R)1,1'-Me2dma)Cl2 and [Re(CO)3(N(SO2R)1,1'-Me2dma)]ClO4 complexes could be 
mainly due to steric restraints as a tertiary sulfonamide N with two adjacent 5-membered chelate 
rings must anchor a facially coordinated rather than a meridionally coordinated ligand. 
Table 4.2. Selected Bond Distances (Å) and Angles (deg) for [Re(CO)3(N(SO2Me)1,1'-
Me2dma)]ClO4 (3) 
Bonds Angles 
Re–N1 2.1493(11) N1–Re–N2 75.29(4) 
Re–N2 2.3706(10) N1–Re–N3 83.59(4) 
Re–N3 2.1536(10) N2–Re–N3 75.45(4) 
Re–C1 1.9040(14) S1–N2–C9 108.16(7) 
Re–C2 1.9233(13) S1–N2–C10 108.69(7) 
Re–C3 1.9274(13) C9–N2–C10 111.39(9) 
S1–O4 1.4315(10) Re–N2–S1 110.62(5) 
S1–O5 1.4328(11) Re–N2–C9 109.45(8) 
N2–S1 1.7477(10) Re–N2–C10 108.54(7) 
N1−N3a 2.868(2) N1–Re–C2 95.11(5) 
  N1–Re–C3 93.51(5) 
  N3–Re–C2 97.76(5) 
  N3–Re–C1 93.93(5) 
  dihedral angleb 87.67, 82.29 
  Re−N−centroid 170.65, 171.28 
aNon-bonded distance between the two atoms. bAngle between the coordination plane (defined by 
the Re, N1, N3, O1 and O3 atoms) and the pyridyl ring planes. 
114 
 
Table 4.3. Selected Bond Distances (Å) and Angles (deg) for Pt(N(SO2Me)1,1'-Me2dma)Cl2 (5), Pt(N(SO2Tol)1,1'-Me2dma)Cl2 (6), 
[Pt(N(SO2Me)1,1'-Me2dma)(4-pic)2](PF6)2 (7), [Pt(N(SO2Tol)1,1'-Me2dma)(4-pic)2](PF6)2 (8) and [Pt(N(SO2Tol)1,1'-Me2dma)(3,5-
lut)2](PF6)2 (10) 
 5 6 7 8 10 
Pt–N1 2.004(5) 2.020(6) 2.002(3) 2.011(3) 2.015(4) 
N2−Pta 3.912 3.765(5) 3.050(4) 3.083(3) 3.0840(4) 
Pt–N3 2.004(5) 2.027(6) 2.004(3) 2.023(2) 2.016(4) 
Pt–Cl1/N6 2.3051(15) 2.313(2) 2.018(3) 2.022(2) 2.017(4) 
Pt–Cl2/N7 2.3051(15) 2.2925(16) 2.021(3) 2.014(3) 2.017(4) 
S1–O1 1.425(5) 1.434(6) 1.424(3) 1.423(3) 1.428(4) 
S1–O2 1.425(5) 1.433(6) 1.436(3) 1.428(3) 1.430(4) 
N2–S1 1.641(7) 1.641(7) 1.626(3) 1.641(3) 1.649(4) 
S1−Pta 5.532 5.343(2) 3.726(1) 3.7266(8) 3.877(2) 
N1–Pt–N3 88.8 (3) 93.2 (2) 90.60 (13) 91.49(10) 89.00(14) 
S1–N2–C4 116.3 (4) 116.9 (4) 119.6 (3) 118.0(2) 117.3(3) 
S1–N2–C5 116.3 (4) 119.3 (5) 117.3 (3) 118.4(2) 117.0(3) 





      
 5 6 7 8 10 
C4–N2–C5 114.7 (7) 118.5 (6) 118.8 (3) 117.8(3) 117.1(4) 
N1–Pt–Cl2/N7 177.87 (15) 176.52 (19) 176.98 (14) 176.62(10) 177.86(16) 
N1−Pt−Cl1/N6 89.56(14) 88.3(2) 90.75(13) 88.83(11) 91.61(14) 
N3–Pt–Cl1/N6 177.87 (15) 178.36 (15) 178.23 (14) 178.48(10) 178.44(16) 
N3−Pt−Cl2/N7 89.56(14) 87.31(15) 91.58(14) 89.63(11) 91.59(15) 
Cl1/N6–Pt–Cl2/N7 92.07 (8) 91.10 (7) 87.11 (14) 89.97(11) 87.75(15) 
dihedral angleb 74.85 66.61, 71.56 84.96, 54.19 72.39, 57.69 84.99, 57.88 
Pt− N−centroid 176.87 167.81, 173.67 176.66, 176.82 175.44, 174.19 177.72, 175.63 
N1−N3a 2.805(6) 2.941(8) 2.847(5) 2.890(3) 2.825(5) 
aNon-bonded distance between the two atoms. bAngle between the coordination plane (defined by the Pt, N1, N3, and two Cl atoms) 









The length of the Re−N(sulfonamide) bond (Table 4.2) in 3 (2.3706(10) Å) is longer than 
the typical range (2.23−2.29 Å) reported for Re−N(sp3) bonds,31-32 while the Re−N1 and Re−N3 
bond distances of 3 (2.1493(11) and 2.1536(10) Å) are in the typical range (2.14−2.18 Å) for 




16 the structural features such as the angles around the 
sulfonamide N and the N−S bond lengths of the Pt(N(SO2R)1,1'-Me2dma)Cl2 complexes (5 and 6) 
are consistent with the uncoordinated tertiary sulfonamide group, while these structural features 
of 3 ([Re(CO)3(N(SO2Me)1,1'-Me2dma)]ClO4) are consistent with the coordinated NSO2Me group 
(Tables 4.2 and 4.3). Similarly, the structural metrics of the molecular structures of 7 = 
[Pt(N(SO2Me)1,1'-Me2dma)(4-pic)2](PF6)2, 8 = [Pt(N(SO2Tol)1,1'-Me2dma)(4-pic)2](PF6)2, and 
10 = [Pt(N(SO2Tol)1,1'-Me2dma)(3,5-lut)2](PF6)2 are also consistent with the uncoordinated 
sulfonamide group (Table 4.3). 
 
Figure 4.3. ORTEP plots of complexes [Re(CO)3(N(SO2Me)1,1'-Me2dma)]ClO4 (3), 
Pt(N(SO2Me)1,1'-Me2dma)Cl2 (5), and Pt(N(SO2Me)1,1'-Me2dma)Cl2 (6). Thermal ellipsoids are 





The Pt−N(1) and Pt−N(3) bond lengths (Table 4.3) in all the Pt complexes (5, 6, 7, 8, and 
10) are in the range typically reported for Pt−N(sp2) bonds (1.99−2.08 Å).16,22,24-25,35 The 
N1−Pt−N3 bite angles (~90°, Table 4.3) of these complexes are comparable to the angles of the 
reported platinum complexes containing relatively large uncommon 8-membered chelate rings 
(average 89.5°).16,36-38 The dihedral angles (defined as the angle between the coordination plane 
and the imidazolyl ring planes) of 5 and 6  (67-75°, Table 4.3) are not as large as the dihedral 
angles of the reported platinum complexes containing 8-membered chelate rings (average value 
~83°),16,36-38 but significantly larger than the values reported for complexes of smaller chelating 
ligands (<65° for platinum(II) complexes of 5-, 6- and 7-membered chelate rings).16 In order to 
understand the special structural features of relatively rare square planar Pt(II) complexes 
containing 8-membered chelate rings, in a previous work we have analyzed more than fifty 
molecular structures of cis Pt(II) complexes containing two aromatic ring nitrogens 
(pyridyl/imidazolyl) and two halides as the ligating atoms (data obtained from the CCDC data 
base).16 The study indicated that the certain structural features such as the dihedral angles and the 
N1−Pt−N3 bite angles of the complexes differ based on the chelate ring size; the dihedral angles 
of the studied complexes increase almost linearly with the increasing chelate ring size. Also, the 
N1−Pt−N3 bite angles increase with the increasing ring size. These structural features in 5 and 6 
follow the trends we found in our previous analysis of structural features of chelate in platinum 
complexes, including the few containing relatively large 8-membered chelate rings.16  
[Pt(N(SO2R)1,1'-Me2dma)(N-donor)2](PF6)2 crystalline solids (7 = [Pt(N(SO2Me)1,1'-
Me2dma)(4-pic)2](PF6)2, 8 = [Pt(N(SO2Tol)1,1'-Me2dma)(4-pic)2](PF6)2, and 10 = 
[Pt(N(SO2Tol)1,1'-Me2dma)(3,5-lut)2](PF6)2) were isolated by treating 5 and 6 (Pt(N(SO2R)1,1'-





that the chelate ligand in 5 and 6 are not displaced by the high temperature conditions (60 °C or 
80 °C). In contrast, 40% of the bound chelate ligand dissociated within 9 days when 
Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2 complexes were dissolved in DMSO-d6 at room temperature.
16  
 
Figure 4.4. ORTEP plots of complexes [Pt(N(SO2Me)1,1'-Me2dma)(4-pic)2](PF6)2 (7), 
[Pt(N(SO2Tol)1,1'-Me2dma)(4-pic)2](PF6)2.Me2CO (8), and [Pt(N(SO2Tol)1,1'-Me2dma)(3,5-
lut)2](PF6)2.2Me2CO (10). Thermal ellipsoids are drawn with 50% probability. 
The location of the sulfonamide group is the main structural difference between the chelate 
ligands in the dichloro complexes, 5 and 6, and the chelate ligands in [Pt(N(SO2R)1,1'-
Me2dma)(N-donor)2](PF6)2 (7, 8 and 10, Figure 4.4). In order to explain the difference in location 
of the sulfonamide group in the two types of complexes, a new plane (plane A) is defined as 
follows: Plane A is perpendicular to the coordination plane and goes through the two N atoms of 
the imidazolyl rings of the carrier ligand (Figure 4.5). In 5 and 6 and in the previously reported 
Pt(N(SO2R)Mendpa)Cl2 complexes (R = Me or Tol), the sulfonamide group and the rest of the 
carrier ligand are almost completely on the same side of Plane A as the sulfonamide group, which 
projects out from the coordination sphere (chelate ligand conformation SO2R-out). In contrast, in 





which projects toward the coordination sphere (chelate ligand conformation SO2R-in). 
Furthermore, the reported molecular structures of fac-[Re(CO)3(chelate)]Y complexes of the 
similar sulfonamide-incorporated tridentate ligands6-7,16 and of [Re(CO)3(N(SO2Me)1,1'-
Me2dma)]ClO4 (3, Figure 4.3) show that the chelate ligand conformation is “SO2R-in” to allow 
formation of the Re–N(sulfonamide bond). The observation of the sulfonamide group in two 
different locations in different molecular structures of Pt(II) complexes indicates that a bidentate 
chelate ligand with the sulfonamide group uncoordinated to Pt(II) center has enough dynamic 
freedom to exchange between SO2R-in and SO2R-out conformations. 
1H NMR data discussed 
below also provide evidence for the inversion of the SO2R group at the N(sulfonamide) atom 
and/or the rotation around the Pt–N bond in the Pt(II) complexes studied here.  
 
Figure 4.5. Line drawings of Pt(N(SO2Me)1,1'-Me2dma)Cl2 (5, left) and [Pt(N(SO2Me)1,1'-
Me2dma)(4-pic)2](PF6)2  (7, right) showing the location of the sulfonamide group in each complex. 
Plane A is indicated as an orange broken-line. The 1/1′-Me groups, hydrogen atoms in 5 and 7 and 
4-pic rings in 7 are hidden for clarity. 
NMR Spectroscopy. The ligands, 1 and 2 (in CDCl3 and DMSO-d6) and their Re and Pt 
complexes, 3−10 (in DMSO-d6 and/or in DMF-d7) reported here were characterized by 
1H NMR 





the complexes by analyzing the chemical shift, splitting pattern, integration and data from 1H-1H 
ROESY NMR experiments as discussed below. 1H NMR data and assignments are presented in 
the Experimental Section; see also Tables 4.4 and 4.5. 
1H NMR Assignments of [Re(CO)3(N(SO2R)1,1'-Me2dma)]ClO4 Complexes (3, R = 
Me and 4, R = Tol) and Pt(N(SO2R)1,1'-Me2dma)Cl2 (5, R = Me and 6, R = Tol). The 1H NMR 
spectra recorded in DMSO-d6 (and also in DMF-d7 for 5 and 6) show that all the aromatic signals 
of the free ligands 1 and 2 upon metal coordination to form 3−6 were shifted downfield, a result 
caused by the inductive effect of the Pt(II) or Re(I) metal center (Figure 4.6). The 
[Re(CO)3(N(SO2R)1,1'-Me2dma)]ClO4 complexes (3 and 4) in DMSO-d6 do not show any change 
in the spectra with time. The 1H NMR assignments of 3 and 4 were based on their ROESY spectra 
recorded in DMSO-d6 (a selected region of the ROESY spectrum of 3 is presented in Supporting 




6 complexes.  
 
Figure 4.6. Selected region of 1H NMR spectra in DMSO-d6 at 25 °C (shifts in ppm) of 
N(SO2Me)1,1'-Me2dma (1), [Re(CO)3(N(SO2Me)1,1'-Me2dma)]ClO4 (3), Pt(N(SO2Me)1,1'-




Table 4.4. Selected 1H NMR Chemical Shifts for the N(SO2R)1,1'-Me2dma Free Ligands (1 and 2) and for Their Re(I) (3 and 4) and 
Pt(II) (5 and 6) Complexes (ppm, DMSO-d6, 25 °C). 
1H NMR Chemical Shifts of the Platinum Complexes in DMF-d7 also Presented 
within Brackets 
 H5/5′ H4/4′ CH2 1/1′-Me SO2Me SO2Tol 
      H2/6 H3/5 Me 
1 7.12 6.86 4.40 3.61 3.05 - - - 
3 7.34 7.13 5.20a, 4.98b 3.85 3.66 - - - 
5 7.20 (7.28) 7.10 (7.18) 5.25 (5.47)a, 5.13 (5.29)b 3.72 (3.87) 3.28 (3.41) - - - 
       
2 7.01 6.70 4.30 3.54 - 7.56 7.34 2.38 
4 7.29 7.13 5.40a, 4.44b 3.54 - 8.19 7.74 2.56 
6 7.22 (7.31) 7.10 (7.18) 5.30 (5.40)a, 4.77 (5.08)b 3.79 (3.97) - 7.97 (8.10) 7.58 (7.63) 2.50c (2.52) 
 




















Table 4.5. Selected 1H NMR Chemical Shifts for the [Pt(N(SO2R)1,1'-Me2dma)(N-donor)2]
2+
 Adducts or Complexes (R = Me or Tol, N-
Donor = DMAP, 4-pic or 3,5-lut) (ppm, DMSO-d6, 25 °C) 
 N-donor SO2R H2/6DMAP/4-pic/3,5-lut H5/5′ H4/4′ CH2 1/1′-Me Bis1:Bis2 
   Bis1 Bis2 Bis1 Bis2 Bis1 Bis2 Bis1 Bis2 Bis1 Bis2  
              
 DMAPa Me 8.23 8.52 7.31 7.28 7.13 7.42 4.91 5.80, 5.17 3.65 3.75 2.19:1 
 DMAPa Tol 8.33 8.40 7.33 7.31 7.19 7.44 4.82 5.46, 5.18 3.62 3.84 1.38:1 
              
7 4-pic Me 8.79 8.93 7.32 7.32 7.16 7.37 4.95 5.54, 5.20 3.64 3.73 2.54:1 
8 4-pic Tol 8.87 8.87 7.33 7.33 7.21 7.37 4.84b 5.35, 5.20 3.60 3.84 1.23:1 
              
9 3,5-lut Me 8.77 8.87 7.32 7.32 7.15 7.41 4.95b 5.50, 5.23 3.64 3.74 2.55:1 
10 3,5-lut Tol 8.87 8.83 7.32 7.33 7.20 7.41 4.76b 5.33, 5.21 3.59 3.85 1.27:1 






Our experience is that PtLCl2 complexes in DMSO-d6 change and also form adducts with 
added ligands but PtLCl2 complexes usually do not change or from adducts in DMF-d7. The 
1H 
NMR spectra recorded for freshly prepared DMSO-d6 solutions of X-ray quality crystals of 5 and 
6 are consistent with symmetrical Pt(N(SO2R)1,1'-Me2dma)Cl2 complexes, as found in the solid. 
However, within the first 10 min of dissolution of 5 or 6 in DMSO-d6, a new set of minor signals 
(denoted as 5m or 6m, discussed later) start to appear. In contrast, the spectra recorded for 5 or 6 in 
DMF-d7 do not change or produce new signals with time but are similar to the major set of 5 or 6 
signals, respectively, in DMSO-d6.  
NMR spectra recorded in DMF-d7 were used in assigning the signals of 5 (R = Me) and 6 
(R = Tol). Both complexes have two apparent 1H NMR singlets in the aromatic region, as expected 
for the H4/4' and H5/5' protons. As discussed previously for [Pt(N(R)1,1'-Me2dma)Cl]Cl 
complexes (R = H and Me),22 owing to the nearby quadrupolar nitrogens, these signals appear as 
singlets rather than doublets. In the 1H-1H ROESY spectrum of 5 (Figure 4.7), a strong NOE cross-
peak from the 1/1′-Me signal at 3.87 ppm (assigned based on integration) to the more downfield 
(7.28 ppm) of two aromatic singlets allows the signal to be assigned to H5/5'. The other aromatic 
peak (7.18 ppm) thus can be assigned to H4/4', an assignment supported by the absence of any 
NOE cross-peaks from this signal to any other peaks except to the H5/5' signal. The methylene 
protons of 5 show an AB pattern in the 1H NMR spectrum, an observation reported for many 
similar compounds and extensively discussed in our previous work.22-25 The inequivalent 
methylene protons in the complex 5 (also in 6) project toward and away from the Cl ligands and 
are designated as endo-CH and exo-CH protons, respectively (Figure 4.8). In the ROESY spectrum 
of 5, the more upfield AB signal (5.29 ppm) showed a strong cross-peak to the 1/1′-Me signal, thus 





closer to the exo-CH protons (2.97 Å) than the endo-CH protons (4.23 Å). The downfield AB peak 
(5.47 ppm) is thus assigned to the endo-CH. 
 
Figure 4.7. 1H-1H ROESY spectrum (selected region) of Pt(N(SO2Me)1,1′-Me2dma)Cl2 (5) (25 
°C, 10 mM, DMF-d7, shifts in ppm). 
The carrier-ligand signals including the methylene signals (two doublets instead of an AB 
signal) of the complex 6 were assigned in a similar manner as for 5 except for the Tol (p-tolyl) 
signals (8.10, 7.63 and 2.52 ppm). Between the two aromatic doublets corresponding to the Tol 
group, the more upfield doublet (8.10 ppm) was assigned to H3/5 because it showed an NOE cross-
peak to the tolyl methyl signal at 2.52 ppm in a ROESY spectrum of 6 in DMF-d7 (Supporting 
Information). Therefore, the other doublet at 8.10 ppm was assigned to the H2/6 protons. 
Furthermore, the ROESY spectra of 5 and 6 in DMF-d7 recorded at RT (25 °C), have EXSY 
cross-peaks between the endo and exo-CH signals (Figure 4.7 and Supporting Information). These 
cross-peaks indicate that the endo- and exo-CH protons are made magnetically equivalent by a 





dynamic process becomes faster at high T. We suggest that a similar dynamic process as observed 
within Bis1 conformer (see below) in the [Pt(N(SO2R)1,1'-Me2dma)(N-donor)2]
2+-type complexes 
takes place in the symmetrical Pt(N(SO2R)1,1'-Me2dma)Cl2 dichloro complexes, 5 and 6. In 
contrast, the ROESY spectrum of the [Re(CO)3(N(SO2Me)1,1'-Me2dma)]ClO4 (3, Supporting 
Information) or of other reported  Pt(II) complexes of analogous ligands such as [Pt(N(R)1,1'-
Me2dma)Cl]Cl,
22 [Pt(N(H)dpa)Cl]Cl,23 [Pt(N(H)6-Medpa)Cl]Cl,24 and [Pt(N(H)6,6′-
Me2dpa)]Cl,
25 do not show any EXSY cross-peaks (but show NOE cross-peaks) between the 
methylene doublets. In these complexes, the ligands are bound tridentately. Therefore, the 
inversion of the central N atom and also the rotation of the pyridyl/imidazoyl rings are restricted; 
thus, a dynamic process making the endo- and exo-CH protons magnetically equivalent is unlikely 
to occur. However, the Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2 (R = Me or Tol) complexes in which the 
ligands are bound bidentately also do not show any EXSY cross-peaks (but show NOE cross-
peaks) between the methylene doublets, indicating that a process in which a methylene proton's 
position changes between the endo- and exo-CH positions is not fast enough to give cross-peaks.   
 
Figure 4.8. Designation of the endo-CH and exo-CH methylene protons illustrated for the structure 
of Pt(N(SO2Me)1,1′-Me2dma)Cl2 (5). 
The Pt(N(SO2R)1,1'-Me2dma)Cl2 complexes (5 and 6) dissolved in DMSO-d6 (10 mM) do 
not show any free ligand signals even in years-old solutions (~3 years), indicating that the 





complexes, Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2 (R = Me or Tol), in DMSO-d6 eventually (within a 9 
d period) released the free ligand until only 60% of the ligand remained bound.16 The relatively 
high robustness of the chelate in Pt(N(SO2R)1,1'-Me2dma)Cl2 (5 and 6) compared to 
Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2 could be explained by the less steric hindrance in the 
coordination sphere of 5 and 6 as imidazole rings are smaller than the pyridyl rings and also by the 
higher basicity of the imidazolyl N donors (pKa (DMSO) = 6.26) than the pyridyl N donors (pKa 
(DMSO) = 3.4).39 
After 5 (Pt(N(SO2Me)1,1'-Me2dma)Cl2, 10 mM) was dissolved in DMSO-d6, the new 
signals, 5m, gradually increased for ~7 h. The results for a 10 mM solution of 6 (Pt(N(SO2Tol)1,1'-
Me2dma)Cl2) in DMSO-d6 were similar. Interestingly, the formation of these species (5m or 6m) 
giving the initial minor set of signals did not affect the yield of products in the adduct formation 
reactions; the solutions of 5 and 6 in DMSO-d6 readily react with different G derivatives (9-MeG 
and Guo) and with other N-donor ligands (DMAP, 4-pic and 3,5-lut) to produce expected mono 
or bis products (confirmed based on the NMR and X-ray structural data). Thus, the species, 5m or 
6m, will not be further discussed.  
Reactions of Pt(N(SO2R)1,1'-Me2dma)Cl2 Complexes (5 and 6) with DMAP, 4-pic, 
and 3,5-lut. A spectrum of the reaction mixture of Pt(N(SO2Me)1,1'-Me2dma)Cl2 (5, 5 mM) and 
4 molar equiv of DMAP (20 mM) in DMSO-d6 recorded about 1 h after mixing contained a new 
set of peaks for the mono adduct, [Pt(N(SO2Me)1,1'-Me2dma)(DMAP)Cl]
+, in addition to the 5 
and 5m peaks (Figure 4.9). A spectrum recorded about 7 h after mixing had peaks for a mono 
adduct (deduced from the integration of the bound DMAP signals and the carrier-ligand aromatic 
signals) along with another two new sets of peaks (in 2 to 1 ratio), but no peaks for 5m or 5. The 





abundance ratio (Figure 4.9). Each of these two sets of peaks are consistent with a symmetric 
compound and have integrations between the bound DMAP signals and the carrier-ligand aromatic 
signals indicating that each is a bis adduct, [Pt(N(SO2Me)1,1'-Me2dma)(DMAP)2]
2+. These two 
sets of peaks are denoted as Bis1 (more abundant species) and Bis2 (Figure 4.9). (Very similar 
results were obtained when a 1 day-old 5 mM solution of 5 containing more 5m than fresh solutions 
was treated with 4 molar equiv of DMAP). Similarly, a solution of Pt(N(SO2Tol)1,1'-Me2dma)Cl2 
(6, 5mM) and DMAP (20 mM) in DMSO-d6 at ~9 d gave similar results as found for 5 but with a 
slightly different final Bis1:Bis2 ratio of a ~1.4:1 (Table 4.5 and Supporting Information).  
 
Figure 4.9. Selected region of 1H NMR spectra showing the formation of mono (red) and bis 
adducts (Bis1-purple and Bis2-green) of 5 with DMAP at various time points after 1.6 mg of 
Pt(N(SO2Me)1,1′-Me2dma)Cl2 (5, blue) was dissolved in a 20 mM solution of DMAP in DMSO-





A ROESY spectrum of the final solution of the reaction between 5 and DMAP (in DMSO-
d6 at 25 °C) shows EXSY peaks between Bis1 and Bis2, indicating that the two sets of peaks are 
for two conformers of the same bis adduct (Figure 4.10). This finding prompted us to prepare and 
isolate crystals of such a bis adduct. As described in the Experimental Section, we used liquid N-
donor ligands (4-pic and 3,5-lut; this method is not suitable to use with DMAP because it is a solid 
at RT) to prepare [Pt(N(SO2R)1,1'-Me2dma)(N-donor)2](PF6)2. The molecular structures of the 
resultant X-ray quality crystals (7, 8, and 10) show cis configuration in each bis complex (Figure 
4.4) and 1H NMR spectra of each isolated complex 7−9 (solid or crystals) recorded immediately 
after dissolving in DMSO-d6 show two sets of peaks similar to what is observed for the bis adducts 
of 5 and 6 with DMAP (Figure 4.11). Furthermore, as observed for the [Pt(N(SO2Me)1,1'-
Me2dma)(DMAP)2]
2+ adduct, ROESY spectra recorded at 25 °C for all the isolated bis complexes 
(in DMSO-d6 or DMF-d7) show EXSY cross-peaks between Bis1 and Bis2. The 
1H NMR shifts 
of the corresponding signals of 7−9 are similar and are listed in Table 4.5 (selected regions of the 
ROESY spectra of the complexes are presented in Supporting Information).  
Structural and Spectral Assignment Strategy for [Pt(N(SO2R)1,1'-Me2dma)(N-
donor)2]2+ Conformers. As mentioned in the Structural Section, the location of the sulfonamide 
group with respect to Plane A in the molecular structures of the [Pt(N(SO2R)1,1'-Me2dma)(N-
donor)2]
2+ complexes 7, 8, and 10 (SO2R-in, Pt−S distance is <3.8 Å) is different from the location 
of the sulfonamide group in the molecular structures of the dichloro Pt(N(SO2R)1,1'-Me2dma)Cl2 
complexes 5 and 6 (SO2R-out, Pt−S distance is >5.3 Å) (Figure 4.5). This observation suggests 
that dynamic motion of the chelate ring occurs such that there is interchange between the SO2R-in 
and SO2R-out conformers in Pt(N(SO2R)1,1'-Me2dma)Cl2 and [Pt(N(SO2R)1,1'-Me2dma)(N-
donor)2]





two sets of peaks can be observed corresponding to the two conformers, which is the case for the 
[Pt(N(SO2R)1,1'-Me2dma)(N-donor)2]
2+complexes/adducts analyzed in this study. Therefore, we 
suggest that the two conformers (Bis1 and Bis2) detected in the 1H NMR studies for 
[Pt(N(SO2R)1,1'-Me2dma)(N-donor)2]
2+ are likely to be to the two conformers, SO2R-in and 
SO2R-out. Below, we use 2D NMR data to assign the two sets of 
1H NMR signals to each 
conformer. 
 
Figure 4.10. 1H-1H ROESY spectrum (selected region) of the [Pt(N(SO2Me)1,1′-
Me2dma)(DMAP)2]
2+ bis adducts, Bis1 (purple) and Bis2 (green) at 25 °C in DMSO-d6 (shifts in 
ppm). *Indicates the free DMAP signals. 
NOE cross-peaks from the SO2R group signals to signals of the carrier-ligand or the bound 
N-donor can be analyzed to indicate whether the location of the sulfonamide group for a given set 





SO2Me adducts because SO2Me signals appear near the HOD peak. However, the SO2Me singlet 
of Bis1 (3.49 ppm) of [Pt(N(SO2Me)1,1'-Me2dma)(3,5-lut)2](PF6)2 (9) is well resolved from the 
HOD peak and has an NOE cross-peak to the H2/63,5-lut singlet (8.77 ppm) of the Bis1 conformer 
(Figure C.4). No such NOE cross-peak is observed for the Bis2 conformer. This information 
indicates that Bis1 has the SO2R-in conformation, because the SO2Me group is closer to the bound 
3,5-lut ligands in the SO2R-in conformer than in the SO2R-out conformer (Figure 4.5). Therefore, 
Bis2 can be assign to the SO2R-out conformer. Furthermore, in the ROESY spectra of 
[Pt(N(SO2Tol)1,1'-Me2dma)(N-donor)2](PF6)2 (8 and 10), the H2/6 doublets of the Tol group of 
Bis1 are connected to the H2/6 signals of the N-donor (4-pic and 3,5-lut) through NOE cross-peaks 
(Figures C.5 and C.6). In contrast, the Bis2 signals do not show such NOE cross-peaks. In order 
to relate this information with structural data, we superimposed the molecular structure of 
[Pt(N(SO2Tol)1,1'-Me2dma)Cl2 (6) with its corresponding bis complexes [Pt(N(SO2Tol)1,1'-
Me2dma)(N-donor)2](PF6)2 (8 and 10) through Pt, N1, and N2 atoms and then the non-bonded 
distances between the H2/6 protons of the Tol group and the H2/6 protons of the N-donor were 
measured (Figures C.7). In both cases, the shortest non-bonded distances between the H2/6 protons 
of the Tol group and the H2/6 protons of the N-donor measured (Figures C.7) in the SO2R-in 
conformer (~ 4.0 Å) is shorter than these distances in the SO2R-out conformer (~ 6.6 Å), supporting 
the above conclusion. 
The 1H NMR signals for the methylene protons of the Bis2 conformer in all of the 
[Pt(N(SO2R)1,1'-Me2dma)(N-donor)2]
2+complexes/adducts are sharp doublets which are 
connected to each other through NOE cross-peaks. The more upfield methylene doublet of each 
complex is assigned to exo-CH, as this doublet exhibited an NOE cross-peak to the 1/1′-Me singlet 





in each complex is assigned to endo-CH; no or relatively very weak NOE cross-peak can be 
observed between this doublet and the 1/1′-Me singlet. In the ROESY spectra of all the 
[Pt(N(SO2R)1,1'-Me2dma)(N-donor)2]
2+complexes/adducts, the endo-CH signal of the Bis2 
conformer is connected to the H2/6 doublet of the N-donor (DMAP, 4-pic, and 3,5-lut) through a 
sharp NOE cross-peak. 
 
Figure 4.11. Selected region of 1H NMR spectra in DMSO-d6 at 25 °C (shifts in ppm) of the 
[Pt(N(SO2R)1,1'-Me2dma)(N-donor)2](PF6)2 bis complexes (Bis1-purple and Bis2-green), 
[Pt(N(SO2Me)1,1'-Me2dma)(4-pic)2](PF6)2 (7), [Pt(N(SO2Tol)1,1'-Me2dma)(4-pic)2](PF6)2 (8), 
[Pt(N(SO2Me)1,1'-Me2dma)(3,5-lut)2](PF6)2 (9), and [Pt(N(SO2Tol)1,1'-Me2dma)( 3,5-
lut)2](PF6)2 (10). *Free 4-pic as an impurity. 
In contrast, no such NOE cross-peak is observed between the broad Bis1 methylene signal 
and the N-donor H2/6. This observation indicates that the endo-CH protons in the Bis2 conformer 
is relatively closer to the N-donor aromatic ring than the endo-CH protons of the Bis1 conformer. 
In superimposed molecular structures of [Pt(N(SO2R)1,1'-Me2dma)Cl2 (5 or 6) with their 
corresponding bis complexes [Pt(N(SO2R)1,1'-Me2dma)(N-donor)2](PF6)2 (7, 8, or 10) through Pt, 





donor were measured; the overlay of [Pt(N(SO2Tol)1,1'-Me2dma)Cl2 (6) and [Pt(N(SO2Tol)1,1'-
Me2dma)(4-pic)2](PF6)2 (8) along with the measured non-bonded distances are shown in Figure 
4.12. In all the cases, the non-bonded distances between the endo-CH and the H2/6 protons in the 
SO2R-out conformer are shorter by at least 0.1 Å than these distances in the SO2R-in conformer, 
supporting the above conclusion that made through NMR data stating that the endo-CH protons in 
the Bis2 conformer is relatively closer to the N-donor aromatic ring than the endo-CH protons of 
the Bis1 conformer.  
 
Figure 4.12. Overlap of the stick drawings of [Pt(N(SO2Tol)1,1'-Me2dma)Cl2 (6, green) and 
[Pt(N(SO2Tol)1,1'-Me2dma)(4-pic)2]
2+ (8, purple) by superimposing the Pt, N1, and N2 atoms. 
The non-bonded distances between the endo-CH and the H2/64-pic protons were measured by using 
Mercury CSD 3.10.1 software. For clarity, some of the hydrogens, methyl groups and the SO2Tol 
group of the sulfonamides are hidden. 
 
For all the bis complexes/adducts, the chemical shifts of H4/4′ signals of Bis1 are relatively 
upfield by ~0.2 ppm than the chemical shifts of the H4/4′ signals of Bis2 (Table 4.5). Whereas, the 
chemical shifts of the H5/5′ signals are similar for both conformers. As an example, the H4/4′ 





respectively, while the H5/5′ shift for both conformers is 7.32 ppm. This observation suggests that 
the H4/4′ protons might be affected differently by the anisotropic aromatic rings of the 
monodentate N-donors in each conformer resulting in different shifts as mentioned above; in the 
Bis1 conformer, the N-donor aromatic ring anisotropy experienced by the H4/4′ protons could be 
higher relative to the anisotropic effect experienced by the H4/4′ protons in the Bis2 conformer. 
All the molecular structures containing SO2R-in conformation (3, 7, 8, and 10), the carrier-ligand 
is distorted when compared to the molecular structures of the SO2R-out conformation (5 and 6). 
In the former complexes, one of the imidazolyl rings (dihedral angle ~55°) is significantly more 
canted than the other ring (72-85°), whereas in 5 and 6, the molecular structures are relatively more 
symmetrical and both imidazolyl rings have similar dihedral angles (67-75°, Table 4.3). Because 
of the low dihedral angle, the H4/4′ protons of the highly canted imidazolyl ring in each of 7, 8 
and 10 complexes are closer to the nearby bound N-donor group (H4/4′ −N4-pic/3,5-lut non-bonded 
distance ~3.1 Å) than the H4/4′ protons in the less canted imidazolyl ring in the same complex 
(H4/4′ −N4-pic/3,5-lut non-bonded distance ~3.5 Å). Therefore, we suggest that due to the distorted 
carrier-ligand in Bis1 (SO2R-in), the H4/4′ protons could be projecting towards the N-donor 
aromatic rings, thus the H4/4′ signals of Bis1 could have upfield chemical shifts compared to the 
H4/4′ signals of Bis2 (SO2R-out).  
The conformational interchanging processes are greatly affected by temperature. Thus, to 
further understand the processes involved in the conformer interchange in [Pt(N(SO2R)1,1'-
Me2dma)(N-donor)2]
2+-type complexes, we collected NMR data at different temperatures by 
utilizing a solution of [Pt(N(SO2Me)1,1'-Me2dma)(4-pic)2](PF6)2 (7) in DMF-d7 (freezing point -
60 °C). At RT, the two methylene doublets observed for Bis2 are connected through NOE cross-





at high T such as 50 °C and low T such as -13 °C, these peaks remain sharp doublets (Figure C.9), 
showing there are no dynamic processes involved within the Bis2 conformer (in contrast, NMR 
data discussed below suggest that there is another dynamic process involved within Bis1 other 
than the Bis1-Bis2 interchange). Each of the methylene doublets of Bis2 has EXSY peaks with the 
broad methylene peak of Bis1 at RT, indicating the Bis1 and Bis2 methylene protons interchange 
with each other through a relatively fast process on the NMR time scale. However, in the ROESY 
spectrum recorded at low temperature (-13 °C, Figure C.10), no EXSY peaks were observed 
between the methylene signals of Bis1 and Bis2, indicating that at this T, the interchange between 
Bis1 and Bis2 is relatively very slow or does not occur. 
The broadness of the methylene signal of Bis1 conformer [Pt(N(SO2Me)1,1'-Me2dma)(4-
pic)2](PF6)2 (7) in DMF-d7 at RT (5.33 ppm) suggests that all four methylene signals of Bis1 either 
have similar chemical shifts or they interchange with each other very rapidly on the NMR time 
scale. At high T such as 50 °C, we observed that the methylene signal for Bis1 become sharper 
than the peak at RT (Supporting Information). However, in the 1H NMR spectra recorded at low 
T (0 and -13 °C), the Bis1 methylene signal eventually resolve in to two signals (at -13 °C, Bis1 
methylene protons produce two broad peaks at 5.04 and 5.62 ppm, Supporting Information). The 
ROESY spectrum of this solution at -13 °C shows EXSY cross-peaks between these two peaks. 
All these data indicate that within the Bis1 conformer, another rapid methylene proton interchange 
process takes place. This interchange is a faster-dynamic process relative to the Bis1-Bis2 
conversion process at RT, but this process slows down at low T to produce two peaks connected 
through EXSY peaks (Supporting Information). The distortion of the carrier-ligand in SO2R-in 
conformer shown in 7, 8, and 10 suggests that this fast interchange process within the Bis1 





As discussed in the structural section, the central sulfonamide N is not bound, hence the 
imidazolyl groups have freedom to rotate around the Pt−N bonds and the sulfonamide group has 
some degree of freedom to invert at the N(sulfonamide) atom. Therefore, it is conceivable that the 
observation of two different conformers for the [Pt(N(SO2R)1,1'-Me2dma)(DMAP)2]
2+ adduct is a 
result of a combination of the rotation of the imidazolyl rings and the inversion at N of the central 
sulfonamide group. 
Formation of the [Pt(N(SO2R)1,1'-Me2dma)(N-donor)2]
2+-type complexes through the 
reaction of 5 and 6 with simple N-donors indicates that the Pt(N(SO2R)1,1'-Me2dma)Cl2 
complexes are capable of acting as bifunctional platinum agents to form bis adducts with N-donors, 
an important functionality relevant to biological applications because platinum anticancer agents 
form adducts with guanine bases in DNA. As a preliminary step of evaluating the reactivity of the 
Pt(N(SO2R)1,1'-Me2dma)Cl2 complexes towards biological molecules, we treated 5 and 6 with two 
different guanine derivatives, 9-MeG and Guo. 
Reactions of Pt(N(SO2Me)1,1'-Me2dma)Cl2 (5) with G (G = 9-MeG and Guo). A 1H 
NMR spectra of the reaction mixture of Pt(N(SO2Me)1,1'-Me2dma)Cl2 (5, 5 mM) and 2.5 molar 
equiv of 9-MeG in DMSO-d6 lead to growth of a new set of signals with time until the reaction 
was completed at 19 h (Figure 4.13). The new signals remained unchanged even after 14 d, 
indicating that the adduct formed is stable. 
In the 1H NMR spectrum of the adduct solution has a new broad H8 singlet at 8.60 ppm 
characteristic of Pt(II)-bound 9-MeG40 because it is shifted downfield from the free H8 signal at 
7.62 ppm (Table 4.6). Also, a new NH peak (11.35 ppm), which is shifted downfield from the free 
NH signal by 0.8 ppm, is observed. A new NH2 peak detected at 7.01 ppm is downfield shifted by 





the aromatic region; these should be signals of the carrier-ligand protons of the new G adduct 
because they are the only other aromatic protons in the formed adduct (Figure 4.13). The 
integration values of the four doublets and the bound H8 signal are roughly the same, which 
indicates that the reaction produced a mono G adduct, [Pt(N(SO2Me)1,1'-Me2dma)(9-MeG)Cl]
+. 
 
Figure 4.13. Line drawings of [Pt(N(SO2Me)1,1′-Me2dma)(9-MeG)Cl]
+ and 9-MeG (top) and 
selected region of the 1H NMR spectra (bottom, 25 °C, DMSO-d6, shifts in ppm) of the reaction 
mixture forming the adduct recorded 5 min, 1 h, 2 h, 4 h, 19 h, and 14 d after addition of 1.6 mg 
of solid 5 in to a 25 mM solution of 9-MeG. 
In order to conveniently assign the proton signals of the [Pt(N(SO2Me)1,1'-Me2dma)(9-
MeG)Cl]+ adduct, the 9-MeG and the imidazolyl ring with non-prime numbers are drawn on the 
same side of the coordination plane, as shown in Figure 4.13. In a ROESY spectrum of the final 
reaction mixture (Figure 4.14), an NOE cross-peak between the bound H8 signal and the most 
downfield-shifted doublet (7.37 ppm) allows the signal to be assigned to the H4 proton (Table 4.7). 





assigned to H5. Two imidazolyl Me signals can be seen at 3.79 and 3.68 ppm (identified by 
integration); the more upfield singlet at 3.68 ppm has an NOE cross-peak with the H5 signal and 
thus can be assigned to 1-Me. The other aliphatic Me singlet at 3.79 ppm has an NOE cross-peak 
with another aromatic doublet at 7.28 ppm, therefore each signal can be assigned to 1-Me' and H5'. 
The remaining doublet is assigned to H4' (7.09 ppm), which is further supported by an NOE cross 
peak between this peak and the H5' signal.  
Table 4.6. Selected 1H NMR Data (ppm) for the G Ligand in [Pt(N(SO2R)1,1'-Me2dma)GCl]
+ 
Adducts (ppm, DMSO-d6, 25 °C). Non-prime Numbering Signals are for the Protons of the 
Imidazolyl Ring Closest to the Bound G (See Figure 4.10) 
R  H8 NH2 NH 
  free adduct free adduct free adduct 
        
Me 9-MeG 7.62 8.60 6.47 7.01 10.56 11.35 
Me Guo 7.93 8.92, 8.90 6.49 7.01 10.66 11.39 
        
Tol 9-MeG 7.61 8.59 6.41 6.93 10.50 11.19 
Tol Guo 7.90 8.91, 8.88 6.44 6.95 10.62 11.25 
 
Observing only one H8 signal for the [Pt(N(SO2Me)1,1'-Me2dma)(9-MeG)Cl]
+ adduct 
indicates that the rotation of the guanine derivative is not highly impeded in the new adduct. As 
discussed in our previous papers, the metal-bound-G molecules can rotate around the Pt−N7(G) 
bond.22-23 If the in plane bulk of the carrier-ligand is high enough to restrict this rotation of the 
bound G base on the NMR time scale, two or more H8 signals should be observed corresponding 
to different rotamers of the adduct.22-23 However, the broadness of the H8 peak (instead of the 
expected sharp peak for H8) of the [Pt(N(SO2Me)1,1'-Me2dma)(9-MeG)Cl]
+ adduct suggests that 
possibly the chemical shifts of the resulting rotamers perhaps have similar chemical shifts. The 
adduct formation of the Pt(N(SO2Me)1,1'-Me2dma)Cl2 (5) complex is significantly faster (∼19 h 





completion time with 9-EtG is 10 d).22 The less steric hindrance created by the low canted aromatic 
rings (dihedral angle ~75°) in the bifunctional coordination sphere of the new complex compared 
to the monofunctional coordination sphere of the [Pt(N(Me)1,1'-Me2dma)Cl]Cl complex (dihedral 
angle ~12°)22 might be the reason for the significantly different reaction times. 
 
Figure 4.14. 1H-1H ROESY spectrum (selected region) of the [Pt(N(SO2Me)1,1′-Me2dma)(9-
MeG)Cl]+ adduct (25 °C, DMSO-d6, shifts in ppm). 
Similar results were obtained when a 12.5 mM solution of Guo (2.5 molar equiv) in 
DMSO-d6 was treated with 1.6 mg of Pt(N(SO2Me)1,1'-Me2dma)Cl2 (5, 5 mM). An 
1H NMR 
spectrum taken 10 min after the mixing showed signals of 5m (Figure 4.15). In a spectrum recorded 
about 5 h after mixing showed clearly detectable peaks for the new adduct, [Pt(N(SO2Me)1,1'-
Me2dma)(Guo)Cl]
+ (in addition to 5m peaks). The reaction was completed during the first 24 h 
period as indicated by the ratio between the adduct peaks and the 5m peaks being constant (4:1, 
calculated based on the integrations of carrier-ligand aromatic protons). The proton signals of the 
[Pt(N(SO2Me)1,1'-Me2dma)(Guo)Cl]
+ adduct were assigned in a similar way as for the 9-MeG 





Information). Among the four doublets corresponding to the imidazolyl aromatic protons, the two 
peaks of H4 (7.40 ppm) and H5 (7.24 ppm) are broad, which may be because of quadrupolar N 
atoms in the nearby guanine base. In contrast, the H4' (7.08 ppm) and H5' (7.30 ppm) peaks 
corresponding to the carrier ligand side close to the bound chloride ion were sharp doublets. In 
contrast to the broad one H8 peak observed for the 9-MeG adduct ([Pt(N(SO2Me)1,1'-Me2dma)(9-
MeG)Cl]+), the Guo adduct of 5 shows two closely associated signals at 8.92 and 8.90 ppm as the 
adduct now contain a chiral center (Figure 4.12 and Table 4.6). In order to investigate if the 
reaction would consume all of the complex (5 or 5m) molecules with the presence of a high 
concentration of G, another experiment was performed by mixing Guo (100 mM) and 5 (10 mM) 
in a 10:1 ratio (in DMSO-d6). The reaction was completed during the first 24 h and the integration 
shows the same ratio of adduct:5m = ~4:1 as of the reaction mentioned above with a reaction 
mixture of 2.5:1 (12.5 mM Guo and 5 mM 5). 
Table 4.7. Selected 1H NMR Data (ppm) for the N(SO2R)1,1'-Me2dma Carrier Ligands in 
[Pt(N(SO2R)1,1'-Me2dma)GCl]
+ and in Pt(N(SO2R)1,1'-Me2dma)Cl2 (ppm, DMSO-d6, 25 °C). 
Non-prime Numbering Signals are for the Protons of the Imidazolyl Ring Closest to the Bound G 
(See Figure 4.10) 
  H4/4' H5/5' 1/1′-Me SO2Me 
R  H4 H4' H5 H5' 1-Me 1′-Me  
         
Me Cla 7.10 7.20 3.72 3.28 
Me 9-MeG 7.37 7.09 7.21 7.28 3.68 3.79 3.31c 
Me Clb 7.10 7.19 3.72 3.28 
Me Guo 7.40 7.08 7.25 7.30 3.68 3.79 3.31c 
         
Tol Cla 7.10 7.21 3.79 - 
Tol 9-MeG 7.38 7.10 7.23 7.31 3.75 3.88 - 
Tol Clb 7.09 7.20 3.79 - 
Tol Guo 7.41 7.10 7.27 7.32 3.64 3.76 - 
aSignals are recorded for a solution with excess of 9-MeG. bSignals are recorded for a solution 





The results for the reactions of Pt(N(SO2Me)1,1'-Me2dma)Cl2 (5) with 9-MeG and Guo 
reveal a contrastingly high reactivity compared to its dpa analog, Pt(N(SO2Me)3,3',5,5'-
Me4dpa)Cl2.
16 The Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 complex, does not show any prominent 
reaction with either 9-MeG or Guo.16 Instead, the complex get attacked by the solvent (DMSO) to 
produce a monosolvolysis product and eventually 40% of the chelate ligand get dissociated. The 
relative high robustness of 5 than of its analogous dpa complexes, Pt(N(SO2R)3,3',5,5'-
Me4dpa)Cl2,
16 could be due to the less steric hindrance in the coordination sphere due to the small 
size and the high basicity of the imidazolyl rings relative to the pyridyl rings. 
 
Figure 4.15. Selected region of the 1H NMR spectra (bottom, 25 °C, DMSO-d6, shifts in ppm) of 
the reaction mixture forming the [Pt(N(SO2Me)1,1′-Me2dma)(Guo)Cl]
+ adduct recorded 10 min, 
1 h, 5 h, 24 h, and 8 d after addition of 1.6 mg of solid 5 in to a 25 mM solution of Guo. 
Reactions of Pt(N(SO2Tol)1,1'-Me2dma)Cl2 (6) with G (G = 9-MeG and Guo). As 
observed for Pt(N(SO2Me)1,1'-Me2dma)Cl2 (5), the Pt(N(SO2Tol)1,1'-Me2dma)Cl2 (6, 5 mM) 
complex also produces mono G adducts, [Pt(N(SO2Tol)1,1'-Me2dma)GCl]
+, when treated with 2.5 
molar equiv of G in DMSO-d6 (Supporting Information). The adduct yields and the reaction 
completion times of the formation of each G adduct (G = 9-MeG and Guo) of 6 is similar to the 
corresponding adduct formed with 5; the reactions between 6 and 9-MeG and Guo were finished 





the carrier ligand and the G in each [Pt(N(SO2Tol)1,1'-Me2dma)GCl]
+ mono adduct is similar to 
its corresponding [Pt(N(SO2Me)1,1'-Me2dma)GCl]
+ adduct (Tables 4.6 and 4.7), indicating that 
the effect of the dangling R group on the chemical properties of the G adducts is minimal. 
4.4 Conclusions 
 The N(SO2R)Mendpa ligands investigated here bind tridentately to the fac-[Re(I)(CO)3]
+ 
core in the [Re(CO)3(N(Even though the N(R)1,1′-Me2dma type ligands (R = H or Me) bind 
tridentately to Pt(II), the N(SO2R)1,1'-Me2dma ligands show bidentate coordination. In contrast, 
N(SO2R)1,1'-Me2dma ligands coordinate tridentately to fac-[Re(CO)3]
+ core. The different 
binding modes exhibited by the N(SO2R)1,1'-Me2dma ligands with Pt(II) and Re(I) can be 
attributed to the steric factors of the terminal imidazolyl rings and the electronic factors of the 
central sulfonamide donor. Regardless of the different binding modes, both Pt(N(SO2R)1,1'-
Me2dma)Cl2 and [Re(CO)3(N(SO2R)1,1'-Me2dma)]ClO4 complexes are robust and do not show 
any ligand dissociation in solution (DMSO-d6), indicating that the sulfonamide-incorporated 
imidazolyl ligands, N(SO2R)1,1'-Me2dma, are better N-donor ligands than their dpa analogs, 
N(SO2R)3,3',5,5'-Me4dpa. Chloride ligands of the Pt(N(SO2R)1,1'-Me2dma)Cl2 complexes were 
easily replaced by simple N-donor ligands such as DMAP, 4-picoline, and 3,5-lutidine to produce 
bis adducts. Furthermore, Pt(N(SO2R)1,1'-Me2dma)Cl2 react with G to form stable mono adducts, 
[Pt(N(SO2R)1,1'-Me2dma)(G)Cl]
+ (G = 9-MeG and Guo) in DMSO-d6, indicating that the new 
imidazolyl based complexes are robust and reactive enough to employ in further studies to evaluate 
if they possess any actual anticancer properties. Furthermore, NMR spectral data for the 
Pt(N(SO2R)1,1'-Me2dma)Cl2 and [Pt(N(SO2R)1,1'-Me2dma)(N-donor)2]
2+-type complexes 
provide evidence for dynamic motion involving the 8-membered chelate ring. From the X-ray 





imidazolyl rings around the Pt–N bond and the inversion of the SO2R group at the sulfonamide N 
atom leading to SO2R-in and SO2R-out conformations evident in solid-state structures. 
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CHAPTER 5. CONCLUSIONS 
 This dissertation research contributes to the understanding of fundamental chemistry of 
Pt(II) and Re(I) complexes of linear tridentate ligands terminated with aromatic N-donor groups; 
this chemistry is relevant to biological/biomedical applications. A series of new ligands terminated 
with either two pyridyl rings or two imidazolyl rings were utilized in preparing the new Pt(II) and 
Re(I) complexes.  Furthermore, the basic ligand framework of the tridentate ligands terminated by 
aromatic rings was utilized to explore new bioconjugation possibilities with a N−S linker by 
making the central nitrogen atom part of a tertiary sulfonamide group. 
The [Pt(N(R)1,1′-Me2dma)Cl]Cl complexes were used to prepare several Pt(N(R)1,1′-
Me2dma)G mono adducts (G = unlinked guanine or hypoxanthine derivatives), which were 
analyzed by using NMR spectroscopy to evaluate the chemical properties of the adducts relevant 
to anticancer activity. The observation of two sharp G H8 NMR signals (corresponding to a 
syn/anti rotamer mixture) indicates that these carrier-ligands are bulky enough to impede the free 
rotation of the bound G molecules. Anticancer-active monofunctional platinum(II) complexes 
have bulky carrier-ligands that cause DNA adducts to be distorted. Therefore, the [Pt(N(R)1,1′-
Me2dma)Cl]Cl complexes could be a good starting point to further analyze the relationship 
between the ligand steric bulk and the anticancer properties of the monofunctional Pt(II) 
complexes.  
The N(SO2R)1,1′-Me2dma and N(SO2R)Mendpa ligands were utilized to develop a new 
conjugation approach through a N−S link. Such new linking strategies are useful in introducing 
biological properties (such as enhanced targeting ability, fluorescence, and high anticancer 
activity) to metal complexes. The new N(SO2R)1,1′-Me2dma and N(SO2R)Mendpa ligand 





isomerically pure highly robust fac-Re[(CO)3L]
+ type complexes.  These new complexes provide 
useful insights in the development of 99mTc and 187Re radiopharmaceuticals. 
The N(SO2R)1,1′-Me2dma and N(SO2R)Mendpa ligands were also utilized to investigate 
whether the normally highly favorable Pt−N bond could also be formed by a sulfonamide N-donor 
present in a tridentate ligand terminated by aromatic rings. This study shows that the sulfonamide 
N atom in the N(SO2R)1,1′-Me2dma and N(SO2R)Mendpa ligands does not coordinate to the Pt(II) 
center; as a consequence the ligands usually form Pt(N(SO2R)1,1′-Me2dma)Cl2 or 
Pt(N(SO2R)Mendpa)Cl2 complexes with a bidentate coordination mode and an unusually large 8-
membered chelate ring; these complexes are the very first examples of Pt(II) complexes of 
sulfonamide-incorporated linear ligands having 8-membered chelate rings. Both Pt(N(SO2R)1,1′-
Me2dma)Cl2 and Pt(N(SO2R)Mendpa)Cl2 type complexes exhibit interesting and unusual chemical 


















APPENDIX A. SUPPLEMENTARY MATERIAL FOR CHAPTER 2 
 
Figure A.1. Tilting of the imidazolyl rings in the [Pt(N(R)1,1′-Me2dma)Cl]BF4 cations (overlay of 
3b (R = H, pink) and 4b (R = Me, green) by superimposing the Pt, N2, and N3 atoms (left) and Pt, 
N2, and N1 atoms (right) viewed along the coordination plane. In order to display the tilting 
clearly, only parts of one chelate ring are shown in each half of the figure, and the N-Me group on 
each imidazolyl ring is hidden. The figure shows that the methylene groups are farther on the other 
side of the coordination plane from the NH or NMe group in the R = Me cation. 
 
Figure A.2. Overlay of the [Pt(N(R)1,1′-Me2dma)Cl]BF4 cations, 3b (R = H, pink) and 4b (R = 
Me, green) by superimposing the Pt, Cl, N1, N2, and N3 atoms, viewed from the top (top) and 
along the coordination plane (bottom), where the endo-CH and the exo-CH protons are designated. 







Figure A.3. Models of the anti (left) and syn (right) rotamers of the Pt(N(H)1,1′-Me2dma)(3'-GMP) 
adduct based on the molecular structure of 5 as described in the main text. The ribose and 
phosphate groups are hidden in order to display the models clearly. 
 
Structural Features of the 3′-GMPH Ligand. Bond lengths and angles for the guanine 
rings are in the normal range found for nucleotides, e.g., 5′-GMP70-71 and 3'-GMP.64 The nucleotide 
conformation in 5 is anti, i.e., antiperiplanar (the C12─N6─C1'─O2 torsion angle around the 
N6─C1' glycosidic bond is ‒164.9°).178 The 5'-GMP has the anti conformation in all of the 
structurally characterized bis adducts of 5′-GMP69-72 referred to in the main text discussion. The 
pucker of the ribose sugar group in 5 is C2'-endo (S pucker), as indicated by the 0.157 Å 
displacement in the C5' direction of the C2' atom from the plane defined by the C1', C4' and O2 
atoms and by the pseudo-rotation phase angle P ~177°.179 The ribose S puckering is retained in 
solution, as indicated by the H1' and H2' coupling constant of 4.8 Hz.180-181 Most of the platinum 
G adducts described in the literature have ribose groups with similar S puckering.66,70,181 Two of 
the terminal P─O bonds in 5 have lengths (P─O5, 1.492(9) Å, and P─O7, 1.471(8) Å) that are 
shorter than the P─O6 bond (1.574(9) Å), which is comparable in length to the P─OH bonds 
(1.536(1)–1.598(5) Å) of the bis complexes of 5′-GMP referenced above.69-72 Thus, O6 in 5 is 









Figure A.4. 1H-1H ROESY spectrum (selected region) of Pt(N(H)1,1′-Me2dma)Cl]Cl (3a) (25 °C, 
D2O, pH 6, shifts in ppm). 
 
 
Figure A.5. 1H-13C HSQC spectrum (aromatic region) of the [Pt(N(H)1,1′-Me2dma)Cl]Cl (3a) 






 NMR Assignments for [Pt(N(Me)1,1′-Me2dma)Cl]Cl (4a). As discussed in the main 
text, 4a has downfield 1H NMR signals for the H4/4' and H5/5' aromatic protons. In the ROESY 
spectrum in D2O for 4a (Figure A.6), a strong NOE cross-peak from the 1/1′-Me signal at 3.78 
ppm assigns the most downfield signal (7.19 ppm) to H5/5'. The other aromatic peak (7.05 ppm) 
can thus be assigned to H4/4', an assignment supported by the NOE cross-peak to the H5/5' signal 
and by the absence of any other cross-peak. By the reasoning used in the main text, the upfield and 
downfield methylene signals of 4a were assigned to the exo-CH and endo-CH signals, respectively. 
Assignments of the 13C NMR signals for 4a were made through an HSQC experiment (Figure 
A.7). 13C NMR signals for the C4/4', C5/5', and C1/1' were assigned with the aid of cross-peaks 
(in ppm) involving the H4/4' (7.05−124.3), H5/5' (7.20−122.6), Me-1/1' (3.78−34.7) and N-Me 
(3.14−52.73) signals, respectively. Cross-peaks from the endo-CH and exo-CH signals assign the 
13C NMR signal at 61.95 ppm to C6/6'. The signal at 152.87 ppm, the only 13C NMR signal with 
no HSQC cross-peak, is assigned to C2/2'. 
 
 
Figure A.6. 1H-1H ROESY spectrum (selected region) of Pt(N(Me)1,1′-Me2dma)Cl]Cl (4a) (25 







Figure A.7. Selected region of a 1H-13C HSQC spectrum of [Pt(N(Me)1,1′-Me2dma)Cl]Cl (4a) (25 
°C, D2O, pH 6, shifts in ppm). 
 
 
Figure A.8. 1H NMR spectra of a 10 mM solution (600 µL) of [Pt(N(H)1,1′-Me2dma)Cl]Cl (3a) 
(25 °C, D2O, shifts in ppm) at pH 7 before (bottom), and after adding 10 µL of concentrated HCl 







Figure A.9. Aromatic and H1′ region of the 1H NMR spectra of [Pt(N(H)1,1′-Me2dma)Cl]
+ (10 
mM, bottom) and of the reaction mixture with 5'-GTP (1:2.5 molar ratio, 25 C, D2O, pH 4.0, 




Figure A.10. Aromatic and H1' region of the 1H NMR spectra of [Pt(N(H)1,1′-Me2dma)Cl]
+ (10 
mM, bottom) and of the reaction mixture with 3′-GMP (1:2.5 molar ratio, 25 C, D2O, pH 4.0, 







Figure A.11. Aromatic and H1' region of the 1H NMR spectra of [Pt(N(H)1,1′-Me2dma)Cl]
+ (10 





Figure A.12. Aromatic and H1' region of the 1H NMR spectra of [Pt(N(H)1,1′-Me2dma)Cl]
+ (10 
mM, bottom) and of the reaction mixture with 1-MeGuo (1:2.5 molar ratio, 25 C, D2O, pH 4.0, 







Figure A.13. Aromatic and H1' region of the 1H NMR spectra of [Pt(N(H)1,1′-Me2dma)Cl]
+ (10 
mM, bottom) and of the reaction mixture with 9-EtG (1:2.5 molar ratio, 25 C, D2O, pH 4.0, shifts 
in ppm). Note that 9-EtG is only partially soluble in D2O. 
 
 
Figure A.14. Aromatic and H1' region of the 1H NMR spectra (25 °C, D2O, pH 4) of [Pt(N(Me)1,1′-
Me2dma)Cl]
+(10 mM, bottom) and of the reaction mixture forming Pt(N(Me)1,1′-Me2dma)(5'-








Figure A.15. Aromatic and H1' region of the 1H NMR spectra of [Pt(N(Me)1,1′-Me2dma)Cl]
+ (10 
mM, bottom) and of the reaction mixture with 5'-GTP (1:2.5 molar ratio, 25 C, D2O, pH 4.0, shifts 




Figure A.16. Aromatic and H1' region of the 1H NMR spectra of [Pt(N(Me)1,1′-Me2dma)Cl]
+ (10 
mM, bottom) and of the reaction mixture with 3'-GMP (1:2.5 molar ratio, 25 C, D2O, pH 4.0, 







Figure A.17. Aromatic and H1' region of the 1H NMR spectra of [Pt(N(Me)1,1′-Me2dma)Cl]
+ (10 




Figure A.18. 1,1′-Me-to-H5/5′ NOE cross-peak (traced in green) in the 1H-1H ROESY spectrum 






Figure A.19. 1H-13C HSQC spectrum (aromatic region) of the Pt(N(H)1,1′-Me2dma)(5'-GMP) 




Figure A.20. 1H-13C HSQC spectrum (selected region) of the Pt(N(H)1,1′-Me2dma)(5'-GMP) 






Figure A.21. A selected region of the 1H-1H ROESY spectrum of the Pt(N(Me)1,1′-Me2dma)(5'-


























Table A.1. 1H NMR Shifts (ppm) for the N(H)1,1'-Me2dma Carrier Ligands in Pt(N(H)1,1'-
Me2dma)G Adducts and in [Pt(N(H)1,1'-Me2dma)Cl]Cl in 65:35 D2O:DMSO-d6 (pH 4.0) at 25 
°C. (Data5 for [Pt(N(H)dpa)(Cl)]Cl and Pt(N(H)dpa)G Are Included for Comparison.) 
Complex       H4/4' or H6/6' H5/5' Me-1/1' N(Me) 
  syn         anti      
[Pt(N(H)1,1'-Me2dma)Cl]Cla 6.80 7.02 3.56 - 
Pt(N(H)1,1'-Me2dma)(5'-GMP)a 6.41, 6.39 6.44 6.96b 3.57 - 
Pt(N(H)1,1'-Me2dma)(5'-GTP)a 6.39, 6.37 6.42 6.97b 3.57 - 
[Pt(N(H)dpa)(Cl)]Cl 8.61 7.34 - - 
Pt(N(H)dpa)(5'-GMP) 7.51, 7.44 7.57 7.21 - - 
Pt(N(H)dpa)(5'-GTP) 7.49, 7.43 7.57 7.23 - - 
aendo and exo-H6/6' are masked by the solvent peak. bsyn and anti signals are overlapped.  
 
Table A.2. Selected 1H NMR Shifts (ppm) for G in Pt(N(H)1,1′-Me2dma)G Adducts 65:35 
D2O:DMSO-d6 (pH 4.0) at 25 °C. (Data for Pt(N(H)dpa)G
















Pt(N(H)1,1′-Me2dma)(5'-GMP) 7.95 8.57 8.86 5.71 5.85 5.89 1.08:1 0.29  
Pt(N(H)1,1′-Me2dma)(5'-GTP) 7.98 8.61 8.91 5.71 5.85 5.90 0.95:1 0.30  
Pt(N(H)dpa)(5'-GMP)  7.96 8.72 9.08 5.71 5.91 5.98 1.14:1 0.36  
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Figure B.1. Relationship between the average Pt−N−aromatic ring centroid angle and the chelate 
ring size of bifunctional Pt(II) complexes of linear ligands terminated by pyridyl or imidazolyl 
rings (with the remaining coordination sites occupied by halide). Plot is based on reported 
molecular structures (Cambridge Crystallographic Data Centre, ConQuest 1.19); of the 108 
structures available for complexes with a 5-membered chelate ring, data from 26 randomly 
selected structures were used to prepare the plot. Data for bifunctional Pt(II) complexes of 
monodentately bound pyridyl or imidazolyl rings are also included for comparison. 
 
 
Figure B.2. 1H-1H ROESY spectrum (selected region) of Pt(N(SO2Me)3,3′,5,5′-Me4dpa)Cl2 (5) 







Figure B.3. 1H-1H ROESY spectrum (selected region) of Pt(N(SO2Tol)3,3′,5,5′-Me4dpa)Cl2 (6) 
(25 °C, 10 mM, DMSO-d6, shifts in ppm). 
 
 
Figure B.4. Stack plot of 1H NMR spectra (selected region) of Pt(N(SO2Tol)3,3′,5,5′-Me4dpa)Cl2 







Figure B.5. 1H-1H ROESY spectrum (selected region) of Pt(N(SO2Tol)3,3′,5,5′-Me4dpa)Cl2 (6) 
(75 °C, 10 mM, DMSO-d6, shifts in ppm). *Solvolysis peaks. 
 
Figure B.6. 1H-1H ROESY spectrum (selected region) of [trans-Pt(DMSO)Cl2]2(N(SO2Me)6,6′-






Figure B.7. 1H-1H ROESY spectrum (selected region) of [trans-Pt(DMSO)Cl2]2(N(SO2Tol)6,6′-
Me2dpa) (8) (25 °C, 10 mM, DMSO-d6, shifts in ppm). 
 
 
Figure B.8. 1H-1H ROESY spectrum (selected region) of [trans-Pt(DMSO)Cl2](N(SO2Tol)6,6′-






Figure B.9. 1H-1H ROESY spectrum (selected region) of fac-[Re(CO)3(N(SO2Me)3,3',5,5'-
Me4dpa)]PF6 (9) (25 C, 10 mM, DMSO-d6, shifts in ppm).  
 
 
Figure B.10. 1H-1H ROESY spectrum (selected region) of fac-[Re(CO)3(N(SO2Tol)6,6'-
Me2dpa)]PF6 (12) (25 C, 10 mM, DMSO-d6, shifts in ppm). The green line indicates the NOE 
cross-peak between the H3/5 signal and the p-tolyl methyl signal, which is diminished when the 






Figure B.11. Selected region of 1H NMR spectra in DMSO-d6 at 25 °C (shifts in ppm) of (a) 
[Re(CO)3(N(SO2Me)6,6'-Me2dpa)]PF6 (11) and (b) Re(CO)3(N(SO2Tol)6,6'-Me2dpa)]PF6 (12). 
1H NMR Assignments of Methylene Signals. In the ROESY Spectrum of 5 (Figure B.2), 
the 3/3'-Me signal has a very intense NOE cross-peak with the more upfield methylene doublet 
(5.37 ppm). The cross-peak allows us to assign the doublet to the exo-CH, owing to the spatial 
proximity of the exo-CH protons to the 3/3'-Me group (the non-bonded distances range from 
2.22−2.31 Å). Therefore, the more downfield doublet (5.99 ppm) can confidently be assigned to 
the endo-CH (the non-bonded distances between the endo-CH and the 3/3'-Me groups range from 
3.66−3.71 Å). This conclusion is further supported by a relatively stronger exo-CH to SO2Me NOE 
cross-peak compared to the endo-CH to SO2Me NOE cross-peak. In the molecular structure, the 
non-bonded distances between this methyl group and the exo-CH (2.59−2.62 Å) are smaller than 
the distances to the endo-CH (2.78−2.86 Å). This reasoning applies also to fac-
[Re(CO)3(N(SO2R)Mendpa)]PF6 complexes (9−12), and the ROESY spectra for 9 and 12 are 
shown in Figures S9 and S10. 
The ROESY spectrum of 6 taken at 25 °C (Figure B.3) has strong NOE cross-peaks 
between the methylene AB signals and the 3/3'-Me and H2/6 protons. However, it is difficult to 





shifts (separated by 0.08 ppm). Therefore, to assign the methylene signals of 6, the temperature 
dependence of the shift of the methylene signals was investigated (Figure B.4). With increasing 
temperature, the more downfield AB signal (5.55 ppm at 25 °C) moved upfield and the other signal 
moved downfield (the two signals crossed between 40-50 °C). In the ROESY spectrum of 6 at 75 
°C (Figure B.5), the 3/3'-Me signal has an intense NOE cross-peak with the more upfield 
methylene signal (5.50 ppm), a finding allowing assignment of the 5.50 ppm signal to the exo-CH. 
Therefore, the more downfield signal (5.60 ppm) can confidently be assigned to the endo-CH. The 
more upfield AB signal at 75 °C and the more downfield AB signal at 25 °C can be assigned to 
the exo-CH. Similarly, the more upfield AB signal at 25 °C can be assigned to the endo-CH. 
 
Figure B.12. Selected region of 1H NMR spectra showing the reduction of 5sol peaks in a 1-day-
old solution of Pt(N(SO2Me)3,3′,5,5′-Me4dpa)Cl2 (5) in DMSO-d6 (10 mM, bottom spectrum) 
when 10 mg (10 molar equiv) of solid [Et4N]Cl was added (Solution 2). Spectra recorded 5 min, 








Figure B.13. Percent distribution of Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5, orange), 
[Pt(N(SO2Me)3,3',5,5'-Me4dpa)(DMSO)Cl]
+ (5sol, green), and free N(SO2Me)3,3',5,5'-Me4dpa (1, 
blue) in Solution 2 [a mixture of [Et4N]Cl (10 mg, 10 molar equiv) added to a 1-day-old solution 
of 5 (10 mM) in DMSO-d6] at 25 °C plotted versus time. Percent distribution values were 
calculated by using integrations of H4/4' signals of each species. 
 
Table B.1. Selected 1H NMR Chemical Shifts for N(SO2Me)3,3',5,5'-Me4dpa (1) and 
N(SO2Tol)3,3',5,5'-Me4dpa (2) and for Their Pt(II) Complexes (ppm, DMSO-d6, 25 °C) 
 H6/6′ H4/4′ CH2 5/5′-Me 3/3′-Me SO2Me SO2Tol 
              H2/6 H3/5 Me 
1 8.17 7.33 4.45 2.12 2.23 3.13 - - - 
5  8.98 7.56 5.99, 5.37 2.23 2.37 3.35 - - - 
5a  9.04 7.61 6.25, 5.50 2.29 2.48 3.46 - - - 
  
      
 
  
2 7.94 7.21 4.41 2.13 2.16 - 7.62 7.32 2.39 
6  8.9 7.56 5.55, 5.47 2.21 2.45 - 8.03 7.60 2.50b 
6a  8.97 7.63 5.77, 5.66 2.28 2.59 - 8.12  7.65 2.52 
aShifts in DMF-d7, reference peak at 8.03 ppm. 













Figure C.1. 1H-1H ROESY spectrum (selected region) of fac-[Re(CO)3(N(SO2Me)1,1'-
Me2dma)]ClO4 (3) (25 C, 10 mM, DMSO-d6, shifts in ppm).  
 
 
Figure C.2. 1H-1H ROESY spectrum (selected region) of Pt(N(SO2Tol)1,1′-Me2dma)Cl2 (6) (25 






Figure C.3. Selected region of 1H NMR spectra showing the formation of mono (red) and bis 
adducts (Bis1-purple and Bis2-green) of 6 with DMAP at various time points after 1.9 mg of 
Pt(N(SO2Tol)1,1′-Me2dma)Cl2 (6, blue)  was dissolved in a 20 mM solution of DMAP in DMSO-
d6 (25 °C, shifts in ppm). 
 
 
Figure C.4. 1H-1H ROESY spectrum (selected region) of [Pt(N(SO2Me)1,1'-Me2dma)(3,5-
lut)2](PF6)2  (9) (25 °C, 10 mM, DMSO-d6, shifts in ppm). *SO2Me group of Bis2 is suppressed 






Figure C.5. 1H NMR spectra (selected region) of [Pt(N(SO2Tol)1,1'-Me2dma)(4-pic)2](PF6)2  (8) 
(25 °C, 10 mM, DMSO-d6, shifts in ppm). 
 
 
Figure C.6. 1H-1H ROESY spectrum (selected region) of [Pt(N(SO2Tol)1,1'-Me2dma)(3,5-






Figure C.7. Overlap of the stick drawings of [Pt(N(SO2Tol)1,1'-Me2dma)Cl2 (6, green) and 
[Pt(N(SO2Tol)1,1'-Me2dma)(4-pic)2]
2+ (8, purple) by superimposing the Pt, N1, and N2 atoms. 
The non-bonded distances (Å) between the H2/6 protons of the Tol group and the H2/64-pic protons 
were measured by using Mercury CSD 3.10.1 software. For clarity, some of the hydrogen atoms, 
oxygen atoms, and methyl groups are hidden.  
 
 
Figure C.8. 1H-1H ROESY spectrum (selected region) of [Pt(N(SO2Me)1,1'-Me2dma)(4-






Figure C.9. 1H NMR spectrum (selected region) of [Pt(N(SO2Me)1,1'-Me2dma)(4-pic)2](PF6)2  (7, 
10 mM, DMF-d6, shifts in ppm) recorded at different temperatures, 50, 25, 0, and -13 °C. 
 
 
Figure C.10. 1H-1H ROESY spectrum (selected region) of [Pt(N(SO2Me)1,1'-Me2dma)(4-






Figure C.11. 1H-1H ROESY spectrum (selected region) of the [Pt(N(SO2Me)1,1′-
Me2dma)(Guo)Cl]
+ adduct (25 °C, DMSO-d6, shifts in ppm). 
 
 
Figure C.12. Selected region of the 1H NMR spectra of the reaction mixture forming 
[Pt(N(SO2Tol)1,1′-Me2dma)(9-MeG)Cl]
+ adduct recorded 5 min, 1 h, 2 h, 19 h, 24 h, and 8 d after 






Figure C.13. Selected region of the 1H NMR spectra of the reaction mixture forming 
[Pt(N(SO2Tol)1,1′-Me2dma)(Guo)Cl]
+ adduct recorded 5 min, 1 h, 12 h, and 24 h after addition of 
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